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Abstract 
 Trichloroacetimidates are known to be excellent alkylating agents when activated by a 
catalytic amount of a Brønsted or Lewis acid. Work described herein involved taking advantage 
of the favorable reactivity of trichloroacetimidates to establish several different synthetic 
protocols, including the application of these reagents in the synthesis of pyrroloindoline based 
natural products, 3,3'-disubstituted indolenines and benzylic trichloroacetamides. 
Initial investigations on the utilization of the reactivity of trichloroacetimidates found that 
diphenylmethyl trichloroacetimidate, which is a precursor to a highly stabilized carbocation, 
undergoes facile displacement with carboxylic acids providing the ester product without the need 
of any exogenous catalyst. Both hindered and unhindered carboxylic acids were esterified with 
high yields, with no preference for aromatic or aliphatic carboxylic acids. Carboxylic acids with 
unprotected hydroxyl groups or β-lactam rings were esterified efficiently. Substrates that are 
highly prone to elimination or retro-aldol were also esterified in high yields. Carboxylic acids 
with highly enolizable α-stereocenters were esterified without any racemization. Mechanistic 
studies indicate that the carboxylic acid substrate itself is acidic enough to be effective at 
promoting the esterification reaction. 
 During our studies on esterification with imidates it was found that these imidates also 
showed a tendency to undergo rearrangement to the corresponding trichloroacetamides. Two 
different sets of conditions, thermal and Lewis acid catalyzed, were established which provided 
these rearranged products with high yields. Various benzylic trichloroacetimidates were shown 
to undergo these transformations under the established conditions. Based on the observations 
discussed in this work a cationic mechanism is proposed. 
 After the preliminary studies on alkylation of benzylic trichloroacetimidate with different 
nucleophiles, this chemistry was applied towards the synthesis of natural products and their 
analogs. The pyrroloindoline ring system is found in many alkaloids and cyclic peptides which 
mainly differ in the substitution at the C3a position. To provide rapid access to these natural 
products a diversity-oriented strategy was established via displacement of C3a-
trichloroacetimidate pyrroloindoline. Carbon, oxygen, sulfur and nitrogen nucleophiles were all 
shown to undergo substitution reactions with these trichloroacetimidates in the presence of a 
Lewis acid catalyst. In order to demonstrate the utility of this new method it was applied towards 
the synthesis of arundinine and a formal synthesis of psychotriasine. Current investigations 
involve the application of this method towards the synthesis of a complex pyrroloindoline natural 
product kapakahine C and the progress made therein has been discussed. 
 The reactivity of trichloroacetimidates was also investigated for the selective C3-
alkylation of 2,3-disubstituted indoles to provide indolenines. Indolenines serve as useful 
intermediates in the synthesis of many complex alkaloids. Different benzylic and allylic 
trichloroacetimidates were shown to provide 3,3’-disubstituted indolenines with high yields in 
the presence of catalytic amounts of Lewis acids. Various substituted indoles were evaluated 
under these reaction conditions. This methodology was also applied towards the synthesis of the 
core tetracyclic ring system found in communesin natural products. 
In addition to the above work, synthesis of small molecule inhibitors of Src Homology 2 
Domain-Containing Inositol Phosphatase (SHIP) has also been described. Aberrations in the 
phosphoinositide 3-kinase (PI3K) cellular signaling pathway can lead to diseased cellular states 
like cancer. Herein we have reported stereoselective synthesis of two quinoline based small 
molecule SHIP inhibitors. The lead compounds and their analogs were tested for their activities 
against SHIP by Malachite green assay and the discoveries made therein are discussed. In 
addition to this synthesis of a tryptamine based SHIP inhibitor has also been reported. 
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Chapter 1 – Trichloroacetimidates: Versatile Tools in Organic Synthesis 
 
Abstract 
Trichloroacetimidates are excellent electrophiles when activated by a catalytic amount of 
Lewis or Brønsted acids. The mild conditions that activate trichloroacetimidates allow for their 
application in highly complex systems. One common application of trichloroacetimidates is in 
the formation of glycosidic bonds in carbohydrate chemistry. Trichloroacetimidates have also 
been utilized for installing protecting groups on carboxylic acids and alcohols. Rearrangement of 
allylic trichloroacetimidates to their corresponding allylic trichloroacetamides has also been 
widely studied, as the rearrangement provides facile access to protected amines. Chiral transition 
metal catalysts have now been developed to render many of these transformations 
enantioselective. More recently chiral Brønsted acids have been employed to perform 
asymmetric transformations using achiral trichloroacetimidate starting materials. Herein an 
overview of the most common applications of trichloroacetimidates and recent advances in 
asymmetric transformations are discussed. 
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1.1 Introduction 
Trichloroacetimidates (1.2 in Scheme 1.1, also known as imidates) are structurally 
characterized by the presence of an oxygen atom substituted with a vicinal imine decorated with 
a trichloromethyl group at the imine carbon. Steinkopf and Malinowski first reported synthesis of 
trichloroacetimidates from their corresponding alcohols using inexpensive trichloroacetonitrile 
and an alkoxide as a base (Scheme 1.1).1 Later modifications by Cramer involve the use of a 
catalytic amount of metal hydrides as a base for the synthesis of trichloroacetimidates.2-3 In 
subsequent years the use of a milder base, DBU was first reported by Bernet as an alternative to 
metal alkoxides and hydrides.4 Imidates provide an excellent alternative to other electrophilic 
sources like halides that often generate stoichiometric quantities of metal salts or other inorganic 
waste by-products.5-7 
Scheme 1.1. Synthesis of Trichloroacetimidates 
 
Trichloroacetimidates possess a basic nitrogen as part of the imine that allows for ready 
activation by acid catalysts. When activated with catalytic amount of Lewis or Brønsted acids, 
imidates serve as excellent electrophiles or as cation precursors. This reactivity is enhanced by 
the isomerization of the imidate to the corresponding amide, which is thermodynamically 
favored by ~14 kcal/mol due to the greater strength of the carbon oxygen double bond.8-9 
Trichloroacetimidates are best known for their application towards the synthesis of allylic amines 
(the Overman rearrangement),10-12 formation of glycosidic bonds (the Schmidt glycosylation),13-
17 and in the installation of protecting groups on alcohols and carboxylic acids.18-21 Imidates have 
been also used for Friedel-Crafts type alkylations of aromatic systems.22-23 In the following 
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sections we will highlight common uses for trichloroacetimidates in organic synthesis, reviewing 
important examples from the literature.  
1.1.1 Rearrangement of Allylic Trichloroacetimidates for the Synthesis of Allylic Amines 
Allylic amines are widely distributed in natural products, pharmaceuticals and bioactive 
molecules making them attractive intermediates and targets for synthesis.24-29 Additionally 
oxidative cleavage of the alkene provides ready access to unnatural amino acids, which are often 
in high demand. Several strategies to install amine motifs in allylic systems have been 
investigated, including the Gabriel synthesis,30-31 the Mitsunobu reaction32-34 and reductive 
amination.35-36 The aza-Claisen rearrangement of allylic trichloroacetimidates like 1.3 to provide 
allylic trichloroacetamides 1.4, a protected variant of the amine, has also become a widely 
utilized method for accessing complex allylic amines (Scheme 1.2). These transformations 
(commonly referred to as the Overman rearrangement, after Overman, who pioneered this 
chemistry) provide rapid access to allylic amines from readily available allylic alcohols. 
Scheme 1.2. The Overman Rearrangement 
 
The initial discovery from Overman’s group reported that allylic trichloroacetimidates, 
when refluxed in a high boiling solvent like m-xylene, underwent rearrangement to afford the 
allylic trichloroacetamide.10-11 Mechanistically these thermal transformations were proposed to 
proceed through a concerted [3,3]-sigmatropic rearrangement pathway (Scheme 1.3, eq. 1). The 
resulting trichloroacetamide can be transformed into the corresponding amine by treatment with 
aqueous 3M sodium hydroxide. Alternatively, it was found that addition of a catalytic amount 
(10-20 mol %) of mercuric trifluoroacetate to the allylic trichloroacetimidates resulted in 
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spontaneous rearrangement to the allylic trichloroacetamides at room temperature. These 
transformations were proposed to proceed via a two step iminomercuration-deoxymercuration 
pathway (Scheme 1.3, eq. 2).10 The first step involves the activation of the alkene by the 
mercury, followed by attack of the basic imidate nitrogen to form the organomercurial 1.5. This 
intermediate then collapses to provide the product trichloroacetamide 1.4. The formation of the 
product 1.4 is more favored than the reverse reaction (which leads to starting material) due to the 
thermodynamic driving force provided by rearrangement of the imidate. 
Scheme 1.3. Proposed Mechanisms for Thermal and Catalytic Rearrangement 
 
Later investigations involved palladium catalysts, which offer several advantages over 
mercury. Importantly palladium is less toxic and chiral palladium complexes may also be used to 
develop asymmetric variants of these transformations. The earliest asymmetric systems 
documented the Pd(II) catalyzed rearrangement of allylic N-arylimidates to the corresponding 
allylic N-arylamides.12, 37-39 Drawing on some of these preliminary observations, Overman 
developed conditions for the first asymmetric rearrangement of the allylic N-phenylbenzimidate 
1.6 to the corresponding amide 1.7 using the chiral Pd(II) complex 1.8 (Scheme 1.4), which 
contained a diamine ligand.40 
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Scheme 1.4. Asymmetric Rearrangement of N-phenylbenzimidate with a Chiral Pd 
Catalyst 
 
Transformations using these diamine ligands provided products with moderate enantio-
enrichment. More ligand screening led to the development of palladium catalysts with 
ferrocenyl-oxazoline ligands which provided the rearranged product with high enantioselectivity 
(up to 96% ee).41 Even though these methods provided an exceptional strategy to access chiral 
allylic amines from achiral precursors, cleavage of these benzamides proved to be difficult, 
providing the free amines in moderate yields.41-44 Hence the reactivity had to be generalized to 
imidates that would provide amides that were more susceptible to hydrolysis. Aiming for such 
substrates Overman found that cobalt oxazoline palladium 1.11 (COP-Cl) catalyzed the 
rearrangement of allylic trichloroacetimidates like 1.9 to the corresponding trichloroacetamides 
like 1.10 with high yields and excellent enantioselectivity (Scheme 1.5).43, 45 The trichloroacetyl 
group could be removed under acidic, basic or reducing conditions providing facile access to the 
free amine.10-11, 46-50 These COP catalysts were however found to provide high yields with only 
E-allylic trichloroacetimidates, with the Z-isomers providing significantly lower conversion (< 
20%).45 
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Scheme 1.5. Asymmetric Rearrangement using the COP Catalyst 
 
The palladium-catalyzed rearrangement is proposed to occur via a cyclization-induced 
rearrangement (CIR) mechanism (Figure 1.1).8 This pathway involves the displacement of a 
chloride ion from the palladium by the allyl imidate 1.12 to provide the π–complex 1.13. 
Intramolecular addition of the nitrogen to this activated alkene leads to the formation of the 
cyclic intermediate 1.14. The cyclized intermediate then disintegrates to afford the rearranged 
intermediate 1.15 which, upon chloride ion displacement, regenerates the catalyst resulting in the 
formation of the product 1.16. 
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Figure 1.1. Cyclization Induced Rearrangement Mechanism using the COP Catalyst 
The COP-Cl (1.11) catalyst was found to be less soluble in solvents other than DCM, 
therefore further modifications were explored. These studies have resulted in the development of 
the COP-acac catalyst (1.19) that has higher solubility in less polar solvents, but still efficiently 
catalyzes the rearrangement.43, 51 
 
Figure 1.2. Overman’s Chiral Palladium Catalysts 
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The rearrangement approach to chiral allylic amines has been employed in the synthesis 
several of biologically relevant molecules. For example, the γ-aminobutyric acid (GABA) 
aminotransaminase inhibitor vigabatrin (1.22) was synthesized using this rearrangement 
approach.52 Overman also demonstrated an enantioselective synthesis of vigabatrin using COP-
Cl (1.11), by the rearrangement of allylic imidate 1.20 to obtain the amide 1.21 with 73% yield 
and 95% ee (Scheme 1.6).44-45 The amide 1.21 was then converted into the target by deprotection 
under acidic conditions. 
Scheme 1.6. Synthesis of (S)-Vigabatrin 
 
 
1.1.2 Glycosylation with Trichloroacetimidates 
Trichloroacetimidates are also commonly utilized for glycosidic bond formation. These 
transformations were popularized by Schmidt in the early 1980s and since then have been 
adopted as an exceptional method for stereoselective glycosidic bond formation in carbohydrate 
chemistry.16, 53 This methodology is often utilized to join protected glycoside monomers together 
to form more complex polysaccharides. Trichloroacetimidates provide several advantages over 
the traditional glycosidic bond formation reactions, which involved the displacement of unstable 
anomeric halides like chloride or bromide with a nucleophilic glycosyl bond acceptor (typically 
an alcohol).5-7, 54-56 These reactions usually required stoichiometric amounts of base or heavy 
metals,6, 57-59 that limits their application in sensitive substrates and to large scale application, and 
also suffered in terms of stereoselective bond formation. Trichloroacetimidates provide a useful 
alternative wherein the anomeric hydroxyl group can be activated as the imidate using a catalytic 
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amount of a base and trichloroacetonitrile. The imidate may then be displaced readily using a 
Lewis acid catalyst. The control of anomeric stereochemistry from these reactions is dependent 
on both the anomeric configuration of the trichloroacetimidate and the structure of the 
substituted pyran ring.53 Depending on the selection of the base, conditions have been 
established to provide the desired anomeric configuration of the trichloroacetimidate. Weak 
bases like potassium carbonate provide the β-anomer selectively while strong bases like sodium 
hydride provide the α-anomer selectively.60-61 The key glycosidic bond forming reactions are 
often dependent on the stereochemistry of the starting trichloroacetimidate, so the ability to 
control the configuration is critical to many of these transformations. Apart from the 
stereochemistry of the glycosyl bond donors, the resulting stereochemistry of the glycosidic bond 
is also determined by other factors like steric effects,16, 62 neighboring group effects,63-67 and 
solvent effects68 (Scheme 1.7).  
Scheme 1.7. Glycosidic Bond Formation and its Stereocontrol 
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Advances in new promoters for trichloroacetimidate glycosylations is still an active area 
of investigation. For example, Nguyen has developed conditions for stereoselective glycosylation 
reactions using catalytic amounts of palladium complexes (Scheme 1.8).64, 69 Here the cationic 
Pd(CH3CN)(BF4)2 complex acts as a Lewis acid because of its vacant coordination site. This 
Pd(II) complex is air and moisture stable providing advantages over other Lewis acid catalysts 
for glycosylation.  
Scheme 1.8. Stereoselective Formation of Glycosidic Bonds using a Pd(II) Catalyst 
 
A possible explanation for the selectivity observed with the cationic Pd(II) catalyst was 
provided with the mechanism below (Figure 1.3). The imidate 1.26 is proposed to undergo an 
SN1-type displacement with the alcohol wherein the Pd catalyst coordinates with the imidate 
nitrogen to form the complex 1.26a that then ionizes to form the oxocarbenium intermediate 
1.26b. The acceptor prefers to add to the intermediate 1.26b axially (from the bottom face) to 
avoid steric interactions with the vicinal OBn group, resulting in product 1.27. In addition this 
axial attack allows the half-chair 1.26b to directly access the preferred chair conformation, 
avoiding the higher energy twist-boat conformation, as is typically invoked by the Fürst-Plattner 
rule. In the case of the imidate 1.28, an SN2 displacement with the alcohol was suggested which 
involves a seven membered chelated intermediate 1.28a where the C-2 -OBn group is datively 
bound to the cationic palladium. This intermediate directs the selective β addition of the glycosyl 
acceptor through an SN2 mechanism leading to the product 1.29.  
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Figure 1.3. Proposed Explanation for Stereocontrol 
Trichloroacetimidate glycosylation chemistry has been widely utilized in the synthesis of 
glycolipids, glycosyl amino acids, glycosaminoglycans, cell wall constituents and complex 
bioactive molecules.53 One example is the synthesis of the glycopeptide antibiotic vancomycin 
by Nicolaou’s group (Scheme 1.9).70-73 This synthesis involved a late stage glycosylation of the 
phenol 1.32 with the carbohydrate trichloroacetimidate 1.33. The glycosylation proceeded with 
excellent stereoselectivity and in high yield to provide the target vancomycin (1.35), 
demonstrating the generality of these transformations in the synthesis of complex systems. 
Analogs of vancomycin were also synthesized using similar glycosylation reactions.74 
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Scheme 1.9. Glycosylation in the Synthesis of Vancomycin 
 
Another application of trichloroacetimidates in accessing complex molecules may be 
found in the synthesis of the structurally sensitive neocarzinostatin chromophore (Scheme 
1.10).75 The enediyne motif in 1.36 is quite sensitive to acidic and basic conditions, which can 
trigger a Bergman cyclization of the substrate leading to aromatic products. The sensitive alcohol 
1.36 was glycosylated with the imidate 1.37 to afford the intermediate 1.38 with good selectivity 
in moderate yield. This intermediate was then converted into the target (+)-neocarzinostatin 
chromophore (1.39). 
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Scheme 1.10. Synthesis of (+)-Neocarzinostatin Chromophore 
 
1.1.3 Trichloroacetimidates for Protecting Group Installation 
Alcohols are commonly protected as benzyl ethers in complex molecule synthesis, as 
these groups may be cleaved under mild conditions and ethers are more compatible than alcohols 
with many carbon-carbon bond forming reactions.76-77 The most commonly used protocols for 
etherification of alcohols involve the Williamson ether synthesis, dehydration under strongly 
acidic conditions78-83 or the use of heavy metals like tungsten,84  palladium85-87 or gold88 
catalysts. These reactions may also be facilitated through the use of ionic liquids.89 The 
Williamson conditions depend on the use of a metal alkoxide as the nucleophile and alkyl halide 
as the electrophile.90-102 The strongly basic nature of the alkoxide limits its application in base 
sensitive substrates. In addition, these methods also generate large quantities of waste by-
products. Alternatively, typical dehydration conditions utilize strong acid catalysts and the 
reactions are usually carried out at elevated temperatures, again limiting the use of these methods 
in sensitive substrates. The heavy metal catalyzed conditions provide useful alternatives since 
these reactions proceed under much milder conditions, although they require the use of 
expensive metal catalysts.  
Due to the extensive distribution of hydroxyl groups in complex molecules, there still 
remains a need for the development of mild and efficient conditions for etherification that are 
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compatible with complex molecules. Discoveries on glycosylation led to the exploration on the 
use of trichloroacetimidates for protecting free alcohols as their corresponding ethers. Benzylic 
trichloroacetimidates were found to be activated easily with a catalytic amount of Lewis acids to 
provide the etherified product in high yields. Based on these conditions, free alcohols have been 
protected as their tert-butyl, p-methoxybenzyl and diphenylmethyl ethers using 
trichloroacetimidate precursors (Scheme 1.11). 18, 20-21 These conditions are extremely mild and 
the only side product obtained from the reaction is the inert trichloroacetamide (1.42). Recently it 
has been reported that free alcohols can be protected as their diphenylmethyl ethers (like 1.45) 
under neutral conditions by simply refluxing the alcohols (like 1.44) with diphenylmethyl 
trichloroacetimidate (1.43, Scheme 1.11).103 Imidates are particularly useful for the protection of 
-hydroxy esters like 1.44, which undergo retroaldol reactions when attempts are made to protect 
them under basic conditions. Other than trichloroacetimidates, similar trifluoroacetimidate and 
phosphinimidate reagents have also been used for protection of free alcohols.104-105 Thiols, which 
are in many ways analogous to alcohols, have also been shown to be etherified by 
trichloroacetimidates under thermal conditions (THF, reflux) without the need of an exogenous 
catalyst.106  
Scheme 1.11. Etherification using Trichloroacetimidates 
 
Carboxylic acids are also typically required to be protected as their corresponding esters 
to avoid complications from their acidity and allow crucial transformations to access complex 
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molecules. Benzyl or allyl esters are commonly employed in complex molecule synthesis, as 
these groups can be removed under a variety of conditions, which is often advantageous. 
Commonly esters are formed by alkylation of carboxylic acids with alkyl halides under basic 
conditions or by dehydration under acidic conditions. These conditions function well for simple 
esters, but are incompatible with complex substrates. This has led to alternate conditions that 
involve the activation of the carboxylic acid followed by the coupling with the alcohol.107-110 
However these alternatives utilize expensive reagents that generate significant waste. 
Alternatively the carboxylic acid can be esterified using diazomethane derivatives, although 
these reagents are often unstable, toxic and energetic.111-113  
Trichloroacetimidates have also been used to protect carboxylic acids. These reactions 
were first demonstrated by esterification of carboxylic acids as their benzyl and allyl ester using 
the respective trichloroacetimidates in the presence of catalytic amount of Lewis acids (Scheme 
1.12, eq. 1).19 Following the initial report, Thierry and co-workers reported esterification of N-
protected amino acids as their tert-butyl esters 1.53 and 2-phenylisopropyl esters 1.51 using the 
corresponding trichloroacetimidates.114 These reactions were found to provide the esters without 
the need of any catalyst. Such spontaneous esterification was reasoned to proceed due to the 
highly stable cation formed from these trichloroacetimidates. These discoveries have resulted in 
the use of trichloroacetimidates for protecting carboxylic acids that are intermediates in the 
synthesis of complex small molecules. One such example was the use of PMB-imidate (1.54) for 
esterification of carboxylic acid 1.55 to form 1.56, an intermediate that was then converted into a 
small molecule that inhibits the interleukin-1β converting enzyme (Scheme 1.12).115-116 
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Scheme 1.12. Esterification using Trichloroacetimidates 
 
1.1.4 Trichloroacetimidates in Friedel-Crafts Alkylations 
 Friedel-Crafts alkylation of aromatic rings providing alkyl substituted aromatic systems is 
one of the most widely used methods for C-C bond formation in aromatic systems.117-119 
Typically, these reactions are performed with an alkyl halide donor, an electron rich aromatic 
ring as an acceptor and a stoichiometric amount of a powerful Lewis acid promoter, like 
aluminum trichloride. The transformation does have some limitations with respect to the 
substrate scope, however, as typically only precursors to stable carbocations may be utilized as 
electrophiles and only electron rich aromatic systems participate. In addition, the generation of a 
stoichiometric amount of hydrogen halide under the reaction conditions and the disposal of waste 
products generated from the use of stoichiometric amount of Lewis acids during the workup of 
these reactions imposes further limitations. This has led to several modified protocols, like using 
activated metals salts of indium as promoters120 and the direct coupling of alcohols with aromatic 
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systems using Sc(OTf)3.
121 Transition metal catalyzed C-H activation methods122-124 also provide 
a useful alternative to traditional Friedel-Crafts reactions. Activation of the aromatic nucleophile 
as an aryl zinc reagent has also been successfully employed to access Friedel-Crafts products in 
recalcitrant systems.125  
Despite these advances there still remains a need to develop more efficient and milder 
conditions that are applicable to wide range of substrates. Bode and Schäfer utilized benzyl 
hydroxamates for such alkylation reactions,126 while Dudley and Albiniak employed benzyl 
pyridinium triflate salts.127 Both these reagents are structurally analogous to 
trichloroacetimidates, and indeed Schmidt has utilized benzylic imidate 1.57 and 
phthalimidomethyl trichloroacetimidate (1.60) for Friedel-Crafts alkylation type transformations 
(Scheme 1.13).23, 128 Interestingly, these reactions even proceeded with electron-poor 
nucleophiles like dinitrobenzene 1.58. These reactions afforded the coupled product with high 
yields over a wide range of substrates and required only a catalytic amount of TMSOTf for 
activation. In addition, Schmidt also utilized trichloroacetimidates for the synthesis of C-
glycosides.22, 129 This transformation involved the alkylation of aromatic system with anomeric 
glycosyl trichloroacetimidates. 
Scheme 1.13. Friedel-Crafts Alkylation using Trichloroacetimidates 
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A more recent application of a trichloroacetimidate-based Friedel-Crafts reaction in the 
synthesis of a complex molecule involves the synthesis of dictyodendrin E (1.67, Scheme 
1.14).130 Dictyodendrin’s are alkaloids that show inhibitory activities against telomerase enzymes 
(100% inhibition at 50 µg/mL). A key intermediate towards the synthesis of dictyodendrin E is 
indole 1.65. Initial investigations on the synthesis of 1.65 involved the alkylation of 1.64 with 
PMB-Cl. No product formation was observed with the chloride 1.63 under various Lewis acid 
catalyzed conditions. Using the PMB-imidate (1.54) and a catalytic amount of the Lewis acid 
Yb(OTf)3, the desired alkylated product 1.65 was obtained in addition to the over alkylated 
product 1.66. This example clearly demonstrates the superiority of trichloroacetimidates as 
electrophiles in comparison to halides. Also the excellent conversion obtained from this reaction 
demonstrates the applicability of this methodology in sensitive and complex substrates. 
Intermediate 1.65 was then converted into the desired target dictyodendrin E. 
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Scheme 1.14. Application of PMB-imidate Towards Synthesis of Dictyodendrin E 
 
1.1.5 Recent Advances in the use of Trichloroacetimidates for Asymmetric 
Transformations 
Since trichloroacetimidates provide an efficient alternative for the formation or C-O and 
C-C bonds in a variety of settings, a number of asymmetric versions of these transformations 
have been developed. Typically these transformations take advantage of the ease of activation 
that the imidate provides and utilize chiral catalysts to achieve enantioselectivity. Several of the 
most recent and well known asymmetric transformations are detailed below. 
With the advent of the chiral COP catalysts, Overman’s group also investigated the 
application of these catalysts towards enantioselective esterification and etherification of allylic 
trichloroacetimidates (Scheme 1.15).131-134 Chiral allylic alcohols and their derivatives serve as 
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essential building blocks for the synthesis of several biologically important molecules, and so 
enantiomerically enriched versions of these systems became targets of this research. Z-Allylic 
trichloroacetimidates were found to undergo COP catalyzed substitution reactions with phenols 
and carboxylic acids43, 45 with very high yields and enantioselectivity. The Z-allylic imidates 
were very slow to undergo rearrangement to the corresponding trichloroacetamide, so instead the 
enantioselective substitution occurred. 
Scheme 1.15. Enantioselective Etherification and Esterification of Z-allylic 
Trichloroacetimidates 
 
Brønsted acid catalysts and thiourea catalysts have also been developed for asymmetric 
transformations utilizing trichloroacetimidate starting materials. One such application involves 
the use of a benzylic trichloroacetimidate as a leaving group for the formation of a meso-
episulfonium ion followed by asymmetric ring opening (Scheme 1.16).135 The racemic imidate 
1.72 gets activated by the BINOL catalyst 1.73 resulting in the formation of the tight ion pair 
1.73a involving the episulfonium cation and the chiral phosphate anion. Asymmetric 
nucleophilic addition of different alcohols (like 1.74) to the ion pair 1.73a results in the 
formation of the enantioenriched sulfide 1.75. Similar asymmetric transformation have been 
explored by Jacobsen’s group using thiourea catalysts and indole derivatives as nucleophiles.136 
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Scheme 1.16. Asymmetric Ring Opening of Episulfonium Ions 
 
Jacobsen and co-workers also utilized trichloroacetimidates for intramolecular 
asymmetric cyclizations in the presence of NIS and the chiral thiourea catalyst 1.77 to synthesize 
chiral β-iodoamines (Scheme 1.17).137 The thiourea catalyst is proposed to complex to the NIS, 
activating the iodination agent and controlling the face of the alkene that reacts to form a chiral 
iodonium ion. The alkenyl trichloroacetimidate 1.76 adds to the chiral iodonium leading to the 
formation of the product 1.78. The utility of this transformation was demonstrated by 
derivatizing the resulting product. Deprotection of the trichloroacetamide group of compound 
1.78 using acid in the presence of water afforded the β-iodo-1,3-aminoalcohol 1.80. Under 
anhydrous conditions treatment with acid afforded the β-iodo-1,3-aminochloride 1.79. Reaction 
of the compound 1.78 with sodium cyanide did not result in the direct displacement of the 
primary iodine instead resulted in the addition of cyanide at the imine carbon followed by the 
iodide displacement to provide the aziridine N,O-acetal 1.81 as a single diastereomer. 
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Scheme 1.17. Iodocyclization of Trichloroacetimidates using Chiral Urea Catalyst 
 
Recently, Kuroda and co-workers also showed that allylic trichloroacetimidates, like 
1.82, underwent asymmetric intramolecular SN2’ reactions to provide substituted pyrrolidines 
like 1.84 (Scheme 1.18).138 These reactions were catalyzed by BINOL phosphoric acid 1.83, with 
the enantioselectivities largely being dependent on the amine protecting group. Recent examples 
from the Chisholm group involving the alkylation of sulfonamides with benzylic 
trichloroacetimidates under thermal conditions show that imidates can alkylate sulfonamides 
without the need of any external catalyst.139  
23 
 
Scheme 1.18. BINOL Catalyzed Intramolecular Asymmetric SN2’ Reaction 
 
Kuroda's group also utilized trichloroacetimidates for the kinetic resolution of 1,2-
aminoalcohols (Scheme 1.19).140 The racemic alcohol 1.85 attacked PMB-imidate (1.54) in the 
presence of the BINOL phosphoric acid catalyst 1.86 resulting in a kinetic resolution to provide 
enantioenriched ether product. The hydroxyl group of other enantiomer remains unetherified 
thereby resolving the two enantiomers. The etherified PMB-ether 1.87 can also be readily 
cleaved to provide the free alcohol. The vicinal protected amine was required to be protected by 
the Foc group and the bulky 6,6’-bisnitro substituted BINOL catalyst was essential to the success 
of the transformation. Mechanistic studies revealed that the BINOL PMB phosphate was the 
intermediate in this reaction, which was formed by displacement of the imidate by the 
phosphoric acid catalyst. The hydrogen bonding model 1.86a was suggested to explain the 
selectivity for the observed kinetic resolution during the etherification.  
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Scheme 1.19. BINOL Catalyzed Kinetic Resolution of 1,2-Aminoalcohols using 
Trichloroacetimidates 
 
 
1.2 Conclusions 
Trichloroacetimidates have found wide use in organic synthesis. Allylic 
trichloroacetimidates have been commonly utilized for the synthesis of allylic amines. Different 
chiral COP catalysts have been developed to catalyze the rearrangements of allylic 
trichloroacetimidate to their corresponding chiral trichloroacetamides. Glycosyl 
trichloroacetimidates have been explored in carbohydrate chemistry for the formation of glycosyl 
bonds. Trichloroacetimidates have also been found to be excellent electrophiles and have been 
alkylated with free alcohols, carboxylic acids and carbon nucleophiles under very mild to neutral 
conditions. These methods are now frequently employed to install protecting groups on alcohols 
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and carboxylic acids. More recent advances have utilized trichloroacetimidates for asymmetric 
transformations using BINOL based phosphoric acid catalysts and thiourea catalysts. The 
excellent reactivity of trichloroacetimidates led to the hypothesis that several other imidates 
could be utilized as alkylating agents for the protection of carboxylic acids and that imidates may 
be useful for the selective alkylation of indoles to provide highly functionalized intermediates. 
We also hypothesized that since a wide range of nucleophiles could be used to displace the 
imidates, these reagents may be employed in the development of a diversity oriented strategy 
towards the synthesis of pyrroloindoline based natural products and their analogs. Subsequent 
chapters discuss the exploration of the above hypotheses and the discoveries made therein.  
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Chapter 2 – Esterification of Carboxylic Acids Using Diphenylmethyl Trichloroacetimidate 
 
Abstract 
 Carboxylic acids are among the most common functional groups in organic molecules. 
Quite often carboxylic acids must be protected as their corresponding esters, which are more 
compatible with conditions for carbon-carbon bond-forming reactions. The diphenylmethyl ester 
is a popular choice among protecting groups for carboxylic acids due to the facile removal of this 
group under several disparate sets of conditions. A wide range of reagents have been developed 
for the formation of diphenylmethyl esters, however most common methods require harsh 
conditions posing limitations on the substrate scope. Mild conditions for the formation of 
diphenylmethyl esters from diphenylmethyl trichloroacetimidate have been developed. These 
reactions occur at room temperature by simply stirring the carboxylic acids with the 
diphenylmethyl trichloroacetimidate, and do not require any promoter or catalyst. A number of 
carboxylic acids containing a variety of sensitive functional groups were esterified with very 
high yields under these new conditions. Carboxylic acid substrates with a highly enolizable α-
stereocenter were also esterified without detectable racemization. 
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2.1 Introduction 
 
2.1.1 Common Methods for Esterification 
Carboxylic acids are common functional groups in complex molecules. Multistep organic 
synthesis usually requires that carboxylic acids be protected, as the low pKa of the acid precludes 
the use of many reagents that are necessary for carbon-carbon bond formation and functional 
group interconversions. Many methods have been developed for the formation of esters from 
carboxylic acids. The most common esterification technique involves the dehydration reaction of 
a carboxylic acid and alcohol in the presence of an catalytic amount of strong acid, also known 
as the Fischer esterification.1 Another common method is the displacement of an alkyl halide by 
the carboxylate ion, which is facilitated by the addition of base.2-9 Both the above methods 
require the use of strong acids or bases that limits their utility in terms of applicability to 
sensitive substrates. Therefore several more modern methods have been developed for protection 
of sensitive carboxylic acids. The most common of these alternatives involves activation of 
carboxylic acids using coupling agents like DCC and DMAP10 or methyl imidazole carbamate 
(Scheme 2.1).11 The use of a coupling agent for esterification of carboxylic acids in N-protected 
amino acids may result in the erosion of the enantiopurity of the chirality center next to the ester 
unless precautions are taken (Scheme 2.1, eq. 1). In addition, electron rich substrates like 4-
methoxybenzoic acid are often unreactive under these conditions, providing the anhydride as the 
only product. Milder uronium based coupling agents have been developed which avoid the issues 
with racemization and possess a broader substrate scope.12 Alternatively, methods to activate 
alcohols and then have them react with carboxylic acids have also been successfully applied to 
the formation of esters. The best known example of this type of procedure is the Mitsunobu 
reaction (Scheme 2.1, eq. 2).13-15 While this procedure occurs rapidly under mild conditions, it 
45 
 
only provides good yields with unhindered alcohols and produces significant amounts of high 
molecular weight waste byproducts that must typically be removed by chromatography. Diazo 
compounds are also often employed for esterification of sensitive substrates, although the 
energetic and sometimes toxic nature of these compounds makes them unattractive.16-18 
Scheme 2.1. Esterification Via Carboxylic Acid Activation 
 
In cases of complex sensitive molecules there still remains a need to develop mild and 
more efficient methods to protect carboxylic acids with simple reagents that minimize waste and 
tolerate sensitive functional groups. Many groups have disclosed reagents in an attempt to meet 
this challenge. For example, Sarpong has popularized the use of methyl imidazole carbamate 
(MImc, 2.8) to protect the carboxylic acids as their methyl esters (Scheme 2.2, eq. 1).11 In the 
case of the protected amino acid 2.7 extensive racemization of the resulting ester 2.9 was 
reported, however. In addition, Dudley has developed the pyridinium based reagent 2.11 for the 
installation of benzyl esters (Scheme 2.2, eq. 2).19-21 Another example is the isourea based 
reagents 2.13 which are capable of forming esters under mild conditions, with the caveat that the 
urea side product must typically be removed chromatographically (Scheme 2.2, eq. 3).22 
 
 
46 
 
Scheme 2.2. Mild Reagents for Esterification 
 
In examining the above methods, most focus on introducing the methyl or benzyl ester, 
yet in complex molecule synthesis the ability to remove a protecting group under orthogonal 
conditions is a real advantage. This allows for the use of alternate conditions should the planned 
deprotection procedure disturb other functionality in the complex molecule. In surveying ester 
protecting groups, the diphenylmethyl (DPM) group seems to meet these requirements. The 
DPM group can be removed easily by treatment with dilute acids, aqueous base, or by 
hydrogenation.23 Hence the DPM group has been widely used as a protecting group in the 
synthesis of complex natural products,24-32 β-lactam antibiotics,33-34 and peptides.35-36 The DPM 
group also does not install a new stereocenter and hence does not complicate NMR spectra with 
diastereomers in chiral systems. Typically DPM systems can be formed from inexpensive 
starting materials like diphenylmethanol. With these factors in mind we decided to investigate 
the use of trichloroacetimidates to introduce this ester to a carboxylic acid under mild reaction 
conditions. 
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2.1.2 The Diphenylmethyl Ester as a Protecting Group for Carboxylic Acids 
 
The installation of the DPM ester in simple carboxylic acid systems has often been 
effected using acid catalysts and diphenylmethanol (Scheme 2.3, eq. 1).37 Displacement of 
diphenylmethyl chloride by the silver salt of a carboxylic acid has also been reported.38 
However, these conditions can result in undesirable side reactions in substrates with sensitive 
functionality. In an attempt to develop milder conditions the DPM group has been installed using 
diphenyldiazomethane (Scheme 2.3, eq. 2)33, 39 but the unstable and toxic nature of this reagent 
limits its applications.17-18 This has resulted in a number of modifications like protection of 
carboxylic acids by in situ formation of diphenyldiazomethane from diphenylmethyl hydrazone. 
Unfortunately these conditions require the use of metal salts or strong oxidizing reagents.36, 39-41 
DPM protection using diphenylmethyl phosphates has also been reported but requires catalytic 
amount of strong acids (Scheme 2.3, eq. 3).42-43 
Scheme 2.3. Common Methods for DPM Protection of Carboxylic Acids 
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 As discussed earlier (chapter 1, section 1.1.3) trichloroacetimidates have been applied in 
the esterification of carboxylic acids in the presence of a catalytic amount of Lewis acid.44 Some 
trichloroacetimidates that are precursors to stable carbocations like tert-butyl,45 2-
phenylisopropyl,46 or para-methoxybenzyl46-47 have been able to esterify carboxylic acids under 
neutral conditions without the need of any exogenous catalyst. Diphenylmethyl 
trichloroacetimidate (DPM-imidate) has been used for protection of free alcohols utilizing a 
Lewis acid catalyst,48 however the reactivity of DPM-imidate with carboxylic acids has not been 
reported. Based on previous spontaneous esterification examples we hypothesized that DPM-
imidate, which is also a precursor to a stabilized carbocation, should undergo spontaneous 
esterification with carboxylic acids without the need for a Lewis or Brønsted acid catalyst. 
 
2.2 Results and Discussion 
2.2.1 Development of Esterification Conditions 
 
The DPM-imidate (2.20) was synthesized from benzhydrol (2.15) according to the 
procedure reported by Schmidt.48 The imidate 2.20 was obtained as a white solid in high yields 
(92%) and the reaction could be readily scaled to 20 grams. The imidate 2.20 was found to 
exhibit remarkable stability when stored below 0 °C, showing no decomposition under these 
storage conditions. This stands in contrast to the para-methoxybenzyl trichloroacetimidate and 
dimethylphenyl trichloroacetimidate which are oils and more prone to hydrolysis. However it 
was noted that improper storage of DPM-imidate at room temperature over several weeks led to 
its contamination with the amide 2.23. Upon further investigation it was found that refluxing the 
imidate 2.20 in toluene for 18 hours resulted in the rearrangement of the imidate to the amide 
2.23 in 46% isolated yield, so storage at room temperature was not recommended. 
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Initially esterification of lauric acid (2.21) was attempted using imidate 2.20 (1.3 equiv.) 
by simply stirring the two reactants together in anhydrous dichloromethane at room temperature 
for 18 hours. Even though the reaction proceeded with complete consumption of the carboxylic 
acid, isolation of the desired ester 2.22 by column chromatography provided only impure 
product. The impurities were shown to be the ether 2.24 and the rearranged imidate product 2.23 
arising from the excess of imidate 2.20 used. These side products were formed due to the 
exposure of the unreacted imidate 2.20 to silica gel during purification by column 
chromatography and while making slurry (charge) for the column. It was soon determined that 
buffering the eluent for column purification with 1% triethylamine and addition of triethylamine 
to silica gel while making slurry stopped the imidate 2.20 from disintegrating into 2.23 and 2.24. 
Using the modified isolation conditions the ester 2.22 was isolated in pure form in 84% yield. 
Scheme 2.4. Initial Challenges with Esterification 
 
2.2.2 Esterification of Simple Carboxylic Acids 
After overcoming the initial challenges, the scope of simple carboxylic acid reactants 
towards esterification with DPM-imidate 2.20 was explored (Table 2.1). Aliphatic carboxylic 
acids with linear chains provided good yields of the corresponding ester. Sterically encumbered 
carboxylic acids provided more moderate yields (Table 2.1, entries 5 and 6). Unsaturated 
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carboxylic acids and substrates with unprotected terminal alkynes also provided esters with high 
yields (Table 2.1, entries 7-11). Simple aromatic carboxylic acids were also converted into their 
corresponding DPM-esters with high yields. The presence of ortho-substituents did not seem to 
affect the yields of these transformations, as both an ortho bromide and an ortho methoxy acid 
were esterified in good yield using these conditions. 
Table 2.1: Esterification of Carboxylic Acids with Imidate 2.20 
 
              All reactions were run at 0.25 M concentration 
2.2.3 Esterification of More Complex Substrates 
 Next we explored some more complex carboxylic acids with sensitive functional groups 
in order to demonstrate the utility of this transformation (Table 2.2). Vinyl acetic acid, which is 
susceptible to isomerization to provide the more stable α,β-unsaturated system, was converted 
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into the corresponding ester 2.37 with high yields and only a trace amount of the isomerized 
product (< 3%, as determined in the crude 1H NMR). Carboxylic acids with α-bromides such as 
2.38 were also esterified with high yields and no elimination of the bromide was observed. The 
penicillin derivative was esterified to provide 2.39 in moderate yield, but no opening of the β-
lactam ring or epimerization of the ester was observed (Table 2.2, entry 3). The lower yield was 
attributed to the steric bulk of the nearby quaternary carbon. Esterification of this substrate 
clearly demonstrates the applicability of this methodology to complex carboxylic acids. We also 
chose (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid as a substrate, as this acid has a highly 
enolizable stereocenter (Table 2.2, entry 4). The esterification provided the product 2.40 in very 
high yield. In addition, no racemization of the stereocenter was observed when the product was 
analyzed by chiral HPLC analysis. Likewise the amino acid boc-protected D-alanine 2.41 was 
esterified with high yields, and no racemization was observed by chiral HPLC. In these cases 
racemic product was used for comparison, and was prepared by heating the chiral ester with 
DBU to facilitate the epimerization. Attempts to esterify the unprotected amino acids failed, 
which was attributed to the lack of solubility of the zwitterionic amino acid in dichloromethane. 
When the reaction was carried out in polar aprotic solvents like acetonitrile, no esterification was 
observed; whereas in case of polar protic solvents like isopropanol, the alcohol reacted with the 
imidate providing the isopropyl DPM ether as the major product. Hence the method was found to 
be restricted to N-protected amino acids. The base sensitive acetate functionality was also well 
tolerated, providing the ester 2.42 in high yield. Unprotected alcohols were well tolerated under 
the reaction conditions and no etherification product was observed, selectively affording the 
esters 2.43 and 2.44 in high yields. A high yield in case of the ester 2.44 was gratifying since the 
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β-hydroxy system can easily undergo β-elimination or retroaldol reactions. Heteroaromatic 
systems like 2.45 and 2.46 were also well tolerated under these conditions. 
Table 2.2. Esterification of Complex Carboxylic Acids with Imidate 2.20 
 
         All reactions were run at 0.25 M concentration 
The more acidic phenols did lead to mixtures of products, as demonstrated by the 
esterification of salicylic acid (Scheme 2.5). In addition to the desired ester 2.48 that was 
obtained with a high yield (77%), the greater reactivity of the phenolic hydroxyl group resulted 
in etherified products 2.49 and 2.50 which were not observed with other free hydroxyl groups in 
2.43 and 2.44. This may be attributed to the greater acidity of the phenol of salicylic acid, which 
is accentuated by the electron withdrawing effects of the nearby carbonyl. 
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Scheme 2.5. Esterification of Salicylic Acid 
 
 Removal of the DPM ester was also investigated. Ester 2.40 was chosen as the substrate 
for deprotection to determine if deprotection would disturb the nearby stereocenter. Subjecting 
the ester 2.40 to hydrogenation conditions provided the acid 2.51 in very high yield and no 
racemization of the stereocenter was observed by chiral HPLC analysis. 
Scheme 2.6. Deprotection of the DPM Ester without Racemization 
 
2.2.4 Mechanistic Discussions 
As diphenylmethyl imidate is a precursor to the highly stabilized diphenylmethyl cation, 
the mechanism of the esterification was initially thought to proceed through an SN1 pathway. The 
acidic proton from the carboxylic acid must be acidic enough to protonate the imidate thereby 
activating it. To further confirm the role of the acidic proton from the carboxylic acid, the 
carboxylic acids were stirred with an excess of triethylamine in DCM for approximately 15 
minutes (Figure 2.1). The imidate 2.20 was then added to the reaction mixture and after 18 hours 
analysis of the crude mixture showed completely unreacted imidate 2.20, affirming that indeed 
the proton from carboxylic acid is self catalyzing the activation of the imidate. Mechanistically 
we propose that once the imidate is activated by the acidic proton from carboxylic acid, the 
activated complex 2.20a then undergoes dissociation, which is facilitated by rearrangement of 
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the imidate to the acetamide, to provide the cation 2.20b. Addition of the carboxylate ion to this 
cation results in the formation of the product 2.20c. Based on the observations made from the 
substrate scope and studies with addition of base to the reaction mixture some postulations were 
made on the required pKa’s of carboxylic acids for esterification. Since addition of triethylamine 
did not yield any esterified product, the pka of the initiating acidic proton must be lower than that 
of triethylammonium salt (pKa = 10.75). Also since picolinic acid (2.45 precursor) underwent 
esterification successfully the pKa of initiating acid can be higher than that of the pyridinium salt 
(pKa = 5.39). 
 
Figure 2.1. Mechanistic Studies 
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2.3 Conclusions 
 A new method for the protection of carboxylic acids as their corresponding DPM esters 
employing DPM-imidate 2.20 has been demonstrated. The DPM-imidate reagent is isolated as a 
white solid which makes handling very convenient. This reagent may be synthesized very easily 
on a scale of at least 20 grams at a time. The imidate was also found to be quite stable when 
stored below 0 °C. This strategy provides a facile alternative to methods relying on the use of 
highly energetic compounds or harsh conditions. A wide range of carboxylic acids differing in 
sterics and electronics were esterified successfully. Systems prone to isomerization of a double 
bond, elimination or retro-aldol were all esterified using DPM-imidate with very high yields with 
trace (< 3%) to no side reactions. Substrates with unprotected alcohols, heteroaromatic rings, a 
sensitive β-lactam ring and highly enolizable stereocenters were also well tolerated under these 
conditions. The DPM group was removed under hydrogenation conditions without affecting any 
stereocenters in the molecule. This methodology provides an inexpensive, safe and convenient 
strategy for protection of sensitive carboxylic acids as DPM esters in complex systems. 
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2.4 Experimental 
Representative procedure with diphenylmethyl imidate and cinnamic acid: 
Cinnamic acid (0.20 g, 1.35 mmol) and diphenylmethyl trichloroacetimidate 2.20 (0.58 g, 1.76 
mmol) were added to a flame dried round bottom flask. Anhydrous dichloromethane (5.4 mL) 
was then added and the reaction stirred under argon for 18 h. After triethylamine (0.5 mL) was 
added, the reaction mixture was preadsorbed on silica gel and purified by silica gel 
chromatography using 1% triethylamine/5% ethyl acetate/94% hexanes to give 0.39 g (93%) of 
the diphenylmethyl cinnamate 2.31 as a white solid. 
Procedures for Purification of Esters: 
Method A. Triethylamine was added and the reaction mixture was preadsorbed on silica gel and 
purified by silica gel chromatography using the listed solvent system.  
Method B. The reaction mixture was preadsorbed on silica gel and purified by silica gel 
chromatography using the listed solvent system.  
Method C. After the stirring the reaction mixture for 18 h, methanol (~5 mL) was added to the 
reaction and the mixture was stirred for 2 h. The reaction mixture was then preadsorbed on silica 
gel and purified by silica gel chromatography using the listed solvent system. 
 
 
Purified by method B using silica gel chromatography (1% ethyl acetate/99% hexanes). 
Benzhydryl dodecanoate (2.22). White solid (0.37 g, 84%); mp = 60-62 oC; TLC Rf = 0.91 
(10% ethyl acetate/90% hexanes); IR (KBr) 2845, 2837, 1694, 1240, 900 cm-1; 1H NMR (300 
MHz, CDCl3), δ 7.36-7.26 (m, 10H), 6.91 (s, 1H), 2.43 (t, J = 7.5 Hz, 2H), 1.70-1.65 (m, 2H), 
1.26 (br s, 16H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3), δ 173.0, 140.6, 128.7, 
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128.1, 127.3, 76.8, 34.8, 32.2, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 25.2, 22.9, 14.4; Anal. Calcd for 
C25H34O2: C, 81.92; H, 9.35. Found: C, 82.25; H, 9.12. 
 
Purified by method B using silica gel chromatography (1% ethyl acetate/99% hexanes).  
Benzhydryl 3,3-dimethylbutanoate (2.25). Clear colorless oil (0.67 g, 92%); TLC Rf = 0.79 
(10% ethyl acetate/90% hexanes); IR (thin film) 3033, 2959, 2870, 1734, 1227, 1127 cm-1;  1H 
NMR (300 MHz, CDCl3), δ 7.37-7.26 (m, 10H), 6.90 (s, 1H), 2.32 (s, 2H), 0.99 (s, 9H);  
13C 
NMR (75 MHz, CDCl3), δ 171.4, 140.6, 128.6, 127.9, 127.4, 76.7, 48.2, 31.1, 29.8. Anal. Calcd 
for C19H22O2: C, 80.82; H, 7.85.  Found: C, 81.11; H, 8.03. 
 
Purified by method A using silica gel chromatography (1% triethylamine/5% ethyl acetate/94% 
hexanes). 
Benzhydryl cyclopropanecarboxylate (2.26). Clear colorless oil (0.52 g, 89%); TLC Rf = 0.25 
(5% ethyl acetate/95% hexanes); IR (thin film) 3064, 3032, 2939, 1729, 1391, 1260, 1164 cm-1; 
1H NMR (300 MHz, CDCl3), δ 7.35-7.26 (m, 10H), 6.89 (s, 1H), 1.80-1.71 (m, 1H), 1.08-1.03 
(m, 2H), 0.93-0.86 (m, 2H); 13C NMR (75 MHz, CDCl3), δ 174.1, 140.6, 128.8, 128.1, 127.3, 
77.0, 13.5, 8.9. Anal. Calcd for C17H16O2: C, 80.93; H, 6.39. Found: C, 81.34; H, 6.47.   
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/94% hexanes). 
Benzhydryl 2,2-diphenylacetate (2.27). White solid (0.27 g, 76% ); mp = 107-108 °C; TLC Rf 
= 0.50 (10% ethyl acetate/90% hexanes); IR (KBr) 3061, 3086, 3030, 2950, 1715, 1120, cm-1; 1H 
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NMR (300 MHz, CDCl3), 7.32-7.19 (m, 20H), 6.92 (s, 1H), 5.16 (s, 1H); 
13C NMR (75 MHz, 
CDCl3), δ 171.5, 140.1, 138.6, 129.0, 128.7, 128.6, 128.1, 127.5, 127.3, 77.9, 57.5. Anal. Calcd 
for C27H22O2: C, 85.69; H, 5.86. Found: C, 86.06; H, 5.66.   
 
Benzhydryl adamantane-1-carboxylate (2.28) 
Purified by method B using flash column chromatography (5% ethyl acetate/95% hexanes). 
White solid (0.34 g, 59%); mp = 131-134 oC; TLC Rf = 0.64 (10% ethyl acetate/90% hexanes); 
IR (KBr) 3032, 2907, 2852, 1728, 1226, 1071 cm-1; 1H NMR (300 MHz, CDCl3), δ 7.35-7.25 
(m, 10H), 6.84 (s, 1H), 2.04 (br s, 3H), 1.96 (br s, 6H), 1.73 (br s, 6H);  13C NMR (75 MHz, 
CDCl3), δ 176.5, 140.8, 128.6, 128.5, 127.9, 127.4, 127.1, 76.3, 41.0, 38.9, 36.6, 28.1. Anal. 
Calcd for C24H26O2: C, 83.20; H, 7.56. Found: C, 83.17; H, 7.85. 
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/94% hexanes). 
(S)-benzhydryl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (2.29). Clear colorless oil 
(0.46 g, 59%); [α]20 D = +13.9 (c = 1.00, CHCl3); TLC Rf = 0.50 (10% ethyl acetate/90% 
hexanes); IR (thin film) 3066, 3034, 2950, 2849, 1749, 1246, 1122 cm-1; 1H NMR (300 MHz, 
CDCl3), 7.40-7.21 (m, 15H), 7.09 (s, 1H), 3.49 (d, J = 1.2 Hz, 3H); 
13C NMR (75 MHz, CDCl3), 
δ 165.9, 140.2, 139.4, 139.3, 132.6, 129.9, 129.6, 129.0, 128.8, 128.7, 128.6, 128.5, 128.4, 128.1, 
128.0, 127.8, 127.6, 127.3, 123.9 (q, J = 286.8 Hz), 85.0 (q, J = 27.5 Hz), 79.4, 55.84, 55.83; 
Anal. Calcd for C23H19F3O3: C, 68.99; H, 4.78. Found: C, 68.61; H, 4.40.   
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Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/94% hexanes). 
(E)-Benzhydryl but-2-enoate (2.30). Clear colorless oil (0.85 g, 79%); TLC Rf = 0.50 (10% 
ethyl acetate/90% hexanes); IR (thin film) 3089, 3064, 3033, 2973, 2943, 2851, 2254, 1953, 
1700, 1656, 1254, 1173, 867, 700 cm-1; 1H NMR (300 MHz, CDCl3), 7.38-7.24 (m, 10H), 7.03 
(qd, J = 6.9, 15.6 Hz, 1H), 6.94 (s, 1H), 6.01-5.94 (m, 1H), 1.90 (dd, J = 1.8, 6.9 Hz, 3H); 13C 
NMR (75 MHz, CDCl3), δ 165.6, 145.8, 140.8, 128.9, 128.2, 127.5, 123.0, 76.9, 18.3. Anal. 
Calcd for C17H16O2: C, 80.93; H, 6.39. Found: C, 80.72; H, 6.60.   
 
Purified by method A using flash column chromatography (1% triethylamine/10% ethyl 
acetate/89% hexanes). 
Lit. ref. for characterization data: Magens, S.; Plietker, B. J. Org. Chem. 2010, 75, 3715. 
(E)-Benzhydryl cinnamate (2.31). White solid (0.40 g, 93%); mp = 74-77 °C; TLC Rf = 0.57 
(10% ethyl acetate/90% hexanes); 1H NMR (300 MHz, CDCl3), δ 7.78 (d, J = 16.2 Hz, 1H), 
7.57-7.54 (m, 2H), 7.44-7.26 (m, 13H), 7.05 (s, 1H), 6.58 (d, J = 0.6, 15.9 Hz, 1H); 13C NMR 
(75 MHz, CDCl3), δ 166.2, 145.7, 140.5, 134.5, 130.7, 129.1, 128.8, 128.4, 128.2, 127.4, 118.2, 
77.2.  
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/94% hexanes). 
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Benzhydryl 3-phenylpropiolate (2.32). White solid (0.55 g, 85%); mp = 98-100 °C; TLC Rf = 
0.54 (10% ethyl acetate/90% hexanes);  IR (KBr) 3030, 2210, 1959, 1692, 1490, 1445, 1301, 
1157, 863 cm-1; 1H NMR (300 MHz, CDCl3), δ 7.62-7.58 (m, 2H), 7.48-7.26 (m, 13H), 7.01 (s, 
1H); 13C NMR (75 MHz, CDCl3), δ 153.4, 139.5, 133.3, 130.9, 128.83, 128.80, 128.4, 127.5, 
119.8, 87.2, 80.9, 78.8. Anal. Calcd for C22H16O2: C, 84.59; H, 5.16. Found: C, 84.54; H, 5.34. 
 
Purified by method B using flash column chromatography (5% ethyl acetate/95% hexanes).  
Benzhydryl undec-10-ynoate (2.33). Colorless crystals (0.30 g, 79%); mp = 40-41 oC; TLC Rf 
= 0.46 (10% ethyl acetate/90% hexanes); IR (KBr) 3293, 2931, 2917, 2851, 1739 cm-1; 1H NMR 
(300 MHz CDCl3), δ 7.36-7.26 (m, 10H), 6.89 (s, 1H), 2.42 (t, J = 7.2 Hz, 2H), 2.17 (dt, J = 6.9, 
2.7 Hz, 2H), 1.95-1.93 (m, 2H), 1.68-1.63 (m, 1H), 1.53-1.46 (m, 2H), 1.38-1.29 (m, 8H); 13C 
NMR (75 MHz CDCl3), δ 172.9, 140.6, 128.7, 128.1, 127.3, 84.9, 76.8, 68.4, 34.8, 29.3, 29.2, 
29.1, 28.9, 28.7, 25.2, 18.6. Anal. Calcd for C24H28O2: C, 82.72; H, 8.10. Found: C, 82.40; H, 
7.81. 
 
Purified by method B using (5% ethyl acetate/95% hexanes). 
Benzhydryl pent-4-ynoate (2.34). Clear yellow oil (0.47 g, 88%); TLC Rf = 0.33 (5% ethyl 
acetate/95% hexanes); IR (thin film) 3294, 3088, 3064, 3032, 2924, 2120, 1739, 1247, 1160, 
978, 699 cm-1; 1H NMR (300 MHz, CDCl3), δ 7.37-7.26 (m, 10), 6.91 (s, 1H), 2.71-2.66 (m, 
2H), 2.58-2.51 (m, 2H), 1.96 (t, J = 2.4, 1H); 13C NMR (75 MHz, CDCl3), δ 170.7, 140.1, 128.6, 
128.0, 127.2, 82.5, 77.2, 69.4, 33.6, 14.4. Anal. Calcd for C18H16O2: C, 81.79; H, 6.10. Found: C, 
81.44; H, 6.33.  
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Purified by method A using flash column chromatography (1% triethylamine/10% ethyl 
acetate/89% hexanes). 
Benzhydryl benzoate (2.17). White solid (2.58 g, 99%); mp = 88-89 °C; TLC Rf = 0.42 (10% 
ethyl acetate/90% hexanes); IR (KBr) 3090, 3031, 2948, 1712, 1267, 1189 cm-1; 1H NMR (300 
MHz, CDCl3), δ 8.17-8.13 (m, 2H), 7.60-7.55 (m, 1H), 7.50-7.26 (m, 12H), 7.13 (s, 1H); 
13C 
NMR (75 MHz, CDCl3), δ 165.8, 140.5, 133.4, 130.4, 130.0, 128.8, 128.7, 128.2, 127.4, 77.7. 
Anal. Calcd for C20H16O2: C, 83.31; H, 5.59. Found: C, 83.37; H, 5.74.   
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/95% hexanes). 
Benzhydryl 2-bromobenzoate (2.35). Clear colorless oil (3.55 g, 97%); TLC Rf = 0.44 (10% 
ethyl acetate/90% hexanes); IR (thin film) 3087, 3063, 3031, 2939, 1728, 1236 cm-1; 1H NMR 
(300 MHz, CDCl3), δ 7.91-7.88 (m, 1H), 7.69-7.66 (m, 1H), 7.48-7.26 (m, 12H), 7.13 (s, 1H); 
13C NMR (75 MHz, CDCl3), δ 165.3, 140.1, 134.8, 133.0, 132.2, 131.8, 128.9, 128.3, 127.6, 
127.5, 122.2, 78.7. Anal. Calcd for C20H15BrO2: C, 65.41; H, 4.12. Found: C, 65.29; H, 4.24.   
 
Purified by method A using flash column chromatography (1% triethylamine/4% ethyl 
acetate/94% hexanes). 
Benzhydryl 2-methoxybenzoate (2.36). Clear colorless oil (0.23 g, 74%); TLC Rf = 0.21 (10% 
ethyl acetate/90% hexanes); IR (thin film) 3062, 3030, 2939, 2837, 2340, 2037, 1953, 1717, 
1601, 1293, 1128, 1079, 854, 617, 600 cm-1; 1H NMR (300 MHz, CDCl3), δ 7.94-7.91 (m, 1H), 
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7.52-7.44 (m, 4H), 7.37-7.25 (m, 7H), 7.10 (s, 1H), 7.02-6.97 (m, 2H), 3.92 (s, 3H); 13C NMR 
(75 MHz, CDCl3), δ 165.3, 159.8, 140.8, 134.0, 132.2, 128.7, 128.0, 127.4, 120.3, 120.0, 112.3, 
77.5, 56.1. Anal. Calcd for C21H18O3: C, 79.22; H, 5.70. Found: C, 78.93; H, 5.61.   
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/94% hexanes). 
Lit. ref. for characterization data: Muzart, J.; Pale, P.; Pete, J. P.; Riahi, A. Bull Chem. Soc. 
Fr. 1988 4, 731. 
Benzhydryl but-3-enoate (2.37). Clear colorless oil (0.35 g, 76%); TLC Rf = 0.44 (10% ethyl 
acetate/90% hexanes); IR (thin film) 3064, 3031, 2983, 2938, 1740, 1642, 1543, 1030 cm-1; 1H 
NMR (300 MHz, CDCl3) 7.35-7.26 (m, 10H), 6.90 (s, 1H), 6.02-5.90 (m, 1H), 5.15-5.22 (m, 
2H), 3.23-3.20 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 170.7, 140.5, 130.4, 128.9, 128.3, 127.4, 
119.1, 77.3, 39.6. 
 
Purified by method A using (1% triethylamine/ 5% ethyl acetate/94% hexanes). 
Benzhydryl 2-bromododecanoate (2.38). Clear colorless oil (0.40 g, 83%); TLC Rf = 0.78 
(10% ethyl acetate/90% hexanes); IR (thin film) 3064, 3032, 2924, 2854, 1741, 1495, 1454, 
1257, 1144, 1080, 600 cm-1; 1H NMR (300 MHZ CDCl3), δ 7.38-7.26 (m, 10H), 6.89 (s, 1H), 
4.31 (t, J = 7.5 Hz, 1H), 2.07-2.00 (m, 2H), 1.23 (br s, 16H), 0.88 (t, J = 6.3 Hz, 3H); 13C NMR 
(75 MHZ CDCl3), δ 169.0, 139.8, 139.7, 128.80, 128.79, 128.4, 127.4, 127.3, 78.5, 46.4, 35.2, 
32.2, 29.8, 29.7, 29.6, 29.1, 27.4, 23.0, 14.4. Anal. Calcd for C25H33O2Br: C, 67.41; H, 7.47. 
Found: C, 67.60; H, 7.66. 
63 
 
 
Purified by method C using (1% triethylamine/ 5% ethyl acetate/94% hexanes). 
Lit. ref. for characterization data: Murakami, M.; Hajima, M.; Takami, F.; Yoshioka, M. 
Heterocycles 1990, 31, 2055-2064. 
(2S,5R,6R)-benzhydryl 6-(2-phenoxyacetamido)-3,3-dimethyl-7–oxo-4-thia-1-aza-
bicyclo[3.2.0] heptane-2-carboxylate (2.39). White solid (0.19 g, 63%); [α]19 D = +123.3 (c = 
1.47, CHCl3); TLC Rf = 0.45 (15% ethyl acetate/85% toluene); IR (KBr) 3387, 3061, 3031, 
2970, 2930, 2867, 1787, 1744, 1692, 1598, 1519, 1494, 1205 cm-1; 1H NMR (300 MHz, CDCl3), 
δ 7.36-7.30 (m, 13H), 6.91-7.10 (m, 4H), 5.74 (dd, J = 4.2, 9.3 Hz, 1H), 5.61 (d, J = 4.2 Hz, 1H), 
4.56-4.55 (m, 3H), 1.58 (s, 3H), 1.27 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 173.2, 168.1, 166.9, 
157.1, 139.3, 139.2, 130.0, 128.9, 128.8, 128.7, 128.5, 127.8, 127.2, 122.6, 115.0, 78.7, 77.6, 
70.6, 68.2, 67.3, 65.2, 58.5, 32.5, 26.7. 
 
Purified by method A using (1% triethylamine/ 20% dichloromethane/79% hexanes). 
(S)-benzhydryl 2-(2-methoxynaphthalen-6-yl)propanoate ((+)-2.40). White solid (1.38 g, 
89%); mp = 132-134 °C; [α]20D = +55.7 (c = 1.10, CHCl3); TLC Rf = 0.42 (20% ethyl 
acetate/80% hexanes); IR (KBr) 3059, 3000, 2942, 2359, 1723, 1604, 1162, 705 cm-1; 1H NMR 
(300 MHz, CDCl3), δ 7.70-7.60 (m, 3H), 7.37 (dd, J = 1.8, 8.4 Hz, 1H), 7.29-7.04 (m, 12H), 6.84 
(s, 1H), 4.01-3.93 (m, 4H), 1.59 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3), δ 173.7, 157.8, 
140.4, 140.3, 135.7, 133.9, 129.5, 129.1, 128.7, 128.5, 128.1, 127.9, 127.4, 127.3 126.9, 126.7, 
126.3, 119.2, 105.8, 77.4, 55.5, 45.9, 18.6. Anal. Calcd for C27H24O3: C, 81.79; H, 6.10. Found: 
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C, 81.54; H, 6.11.  The enantiomeric ratio was determined by HPLC using a chiral column (OD-
H), n-hexane:i-PrOH = 99:1, 1 mL/min; tR = 11.4 min compared to a racemic sample which 
showed two peaks tR = 9.7 and 11.4 min. 
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/95% hexanes). 
tert-butyl (R)-1-((benzhydryloxy)carbonyl)ethylcarbamate (2.41). White solid (0.29 g, 76%); 
mp = 97-98 oC; [α]20D = +11.79 (c = 1.0, CHCl3); TLC Rf = 0.47 (10% ethyl acetate/90% 
hexanes); IR (KBr) 3364, 3063, 3003, 2979, 2935,1715, 1705, 1395, 1280 cm-1; 1H NMR (300 
MHz, CDCl3), δ 7.35-7.26 (m, 10H), 6.89 (s, 1H), 5.06 (br s, 1H) 4.48-4.43 (m, 1H), 1.43-1.40 
(m, 12H); 13C NMR (75 MHz, CDCl3), δ 172.6, 155.3, 140.0, 139.9, 128.8, 128.7, 128.3, 127.3, 
127.2, 80.0, 78.0, 49.6, 28.6, 18.7. Anal. Calcd for C21H25NO4: C, 70.96; H, 7.09. Found: C, 
71.26; H, 7.23. The enantiomeric ratio was determined by HPLC using a chiral column (OD-H), 
n-hexane:i-PrOH = 99:1, 1 mL/min; tR = 12.8 min compared to a racemic sample which showed 
two peaks tR = 12.6 and 14.4 min. 
 
Purified by method A using flash column chromatography (1% triethylamine/5% ethyl 
acetate/94% hexanes). 
Benzhydryl 2-acetoxybenzoate (2.42). White solid (0.30 g, 90%); mp = 103-105 °C; TLC Rf = 
0.26 (10% ethyl acetate/90% hexanes); IR (KBr) 3032, 2932, 1771, 1715, 1196 cm-1; 1H NMR 
(300 MHz, CDCl3), δ 8.12 (dd, J = 1.8, 7.8 Hz, 1H), 7.60-7.54 (m, 1H), 7.40-7.26 (m, 11H), 
7.12-7.09 (m, 2H),  2.05 (s, 3H); 13C NMR (75 MHz, CDCl3), δ 169.9, 163.8, 150.9, 140.0, 
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134.2, 132.2, 128.8, 128.3, 127.5, 126.3, 124.2, 123.7, 77.9, 20.9. Anal. Calcd for C22H18O4: C, 
76.29; H, 5.24.  Found: C, 76.22; H, 5.46.   
 
Purified by method A using flash column chromatography (1% triethylamine/30% ethyl 
acetate/69% hexanes). 
(±)-Diphenylmethyl-2-hydroxy-2-phenylacetate (2.43). White solid (0.58 g, 92%): mp = 113-
114 oC; TLC Rf = 0.65 (30% ethyl acetate/70% hexanes). IR (KBr) 3221, 2815, 2800, 1699, 
1240 cm-1;  1H NMR (300 MHz, CDCl3), δ 7.42-7.18 (m, 13H), 6.91-6.87 (m, 3H), 5.28 (d, J = 
5.4 Hz, 1H), 3.45 (d, J = 5.7 Hz, 1H); 13C NMR (75 MHz, CDCl3), δ 173.0, 139.5, 139.4, 138.3, 
128.9, 128.83, 128.79, 128.6, 128.5, 128.1, 127.6, 127.0, 126.5, 79.0, 73.3. Anal. Calcd for 
C21H18O3: C, 79.22; H, 5.70.  Found: C, 79.53; H, 5.40. 
 
Purified by method A using flash column chromatography (1% triethylamine/10% ethyl 
acetate/89% hexanes). 
(±)-Benzhydryl 3-hydroxy-3-phenylpropanoate (2.44). White solid (0.36 g, 79%); mp = 62-68 
oC; TLC Rf = 0.54 (40% ethyl acetate/60% hexanes); IR (KBr) 3430, 3085, 3058, 3028, 2927, 
1721, 1263, 1163  cm-1; 1H NMR (300 MHz, CDCl3), δ 7.38-7.26 (m, 15H), 6.92 (s, 1H), 5.17 
(dd, J = 4.2, 8.4 Hz, 1H), 3.12-3.08 (br s, 1H), 2.96-2.81 (m, 2H); 13C NMR (75 MHz, CDCl3), δ 
171.6, 142.8, 140.12, 140.06, 128.8, 128.33, 128.28, 128.1, 127.44, 127.35, 126.0, 77.7, 70.6, 
43.9. Anal. Calcd for C22H20O3: C, 79.50; H, 6.06. Found: C, 79.40; H, 5.88. 
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Purified by method B using flash column chromatography (10% acetone/90% hexanes). 
Benzhydryl picolinate (2.45). White solid (0.21 g, 71%); mp = 101-103 oC; TLC Rf = 0.23 
(20% acetone/80% hexanes); IR (KBr) 3052, 1744, 1130 cm-1; 1H NMR (300 MHz, CDCl3), δ 
8.80 (dq, J = 0.9, 4.8 Hz, 1H), 8.19 (dt, J = 1.1, 7.8 Hz, 1H), 7.85 (dt, J = 1.8, 7.8 Hz, 1H), 7.50-
7.44 (m, 5H), 7.39-7.27 (m, 6H), 7.22 (s, 1H); 13C NMR (75 MHz, CDCl3), δ 164.3, 150.3, 
148.3, 140.0, 137.1, 128.8, 128.2, 127.5, 127.1, 125.4, 78.2; Anal. Calcd for C19H15NO2: C, 
78.87; H, 5.23; N, 4.84. Found: C, 78.89; H, 5.36; N, 5.16. 
 
Purified by method B using silica gel chromatography (60% dichloromethane/40% hexanes). For 
preparation of the starting carboxylic acid see Plant, A.; Harder, A.; Mencke, N.; Bertram, H.-J. 
Pestic. Sci. 1996, 48, 351. 
Benzhydryl 3-(benzyloxy)thiophene-2-carboxylate (2.46). Light pink solid (0.26 g, 75%); mp 
= 91-95 °C; TLC Rf  = 0.29 (60% dichloromethane/40% hexanes); IR (KBr) 3065, 3033, 1710, 
1685, 1540, 1058 cm-1; 1H NMR (300 MHz, CDCl3), δ 7.50-7.22 (m, 16H), 7.01 (s, 1H), 6.87 (d, 
J = 5.4Hz, 1H), 5.24 (s, 2H); 13C NMR (75 MHz, CDCl3), δ 161.2, 161.1, 140.9, 136.5, 131.3, 
128.9, 128.7, 128.4, 128.0, 127.7, 127.3, 117.5, 111.0, 77.1, 73.7. Anal. Calcd for C25H20O3S: C, 
74.98; H, 5.03; Found: C, 74.76; H, 5.38. 
 
Diphenylmethyl trichloroacetimidate 2.20 (0.30 g, 0.913 mmol) was dissolved in 2 mL of 
toluene and heated to reflux.  After ~24 h the reaction was allowed to cool to room temperature 
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and preabsorbed on silica gel.  Purification by silica gel chromatography (5% ethyl acetate/95% 
hexanes) provided 138 mg (46% yield) of N-benzhydryl-trichloroacetamide 2.23 as an off-white 
solid. 
N-Benzhydryl-trichloroacetamide (2.23). mp = 121-123 °C; TLC Rf  = 0.65 (10% ethyl 
acetate/90% hexanes); 1H NMR (300 MHz, CDCl3) δ 7.11-7.32 (m, 11H), 6.09 (d, J = 7.8 Hz, 
1H); 13C NMR (75 MHz, CDCl3) δ 161.0, 139.9, 129.1, 128.3, 127.4, 92.8, 59.1; Anal Calcd for 
C15H12Cl3NO: C, 54.82; H, 3.68; N, 4.26; Found: C, 55.14; H, 3.73; N, 4.66. 
 
Lit. ref. for characterization data: Miller. K. J.; Abu-Omar. M. M; Eur. J. Org. Chem. 2003, 
1294-1299. 
To the diphenylmethyl imidate (0.30 g, 0.91 mmol) dissolved in 3.6 ml dichloromethane, 
camphor sulfonic acid (43 mg, 0.18 mmol) was added and the mixture was stirred at rt for 18 h. 
Silica gel was added to the mixture and concentrated; purification by silica gel chromatography 
(5% ethyl acetate/95% hexanes) provided 0.15 g (90%) of the ether as a white solid. 
Diphenylmethyl ether (2.24). White solid (0.15 g, 90%); mp = 107-108 °C; TLC Rf = 0.77 (5% 
ethyl acetate/95% hexanes); 1H NMR (300 MHz, CDCl3), δ 7.44-7.26 (m, 20H), 5.46 (s, 2H); 
13C NMR (75 MHz, CDCl3), δ 142.5, 128.7, 127.8, 127.6, 80.3. 
 
Racemization of (+)-2.40: 
Ester (+)-2.40 (0.47 g, 1.18 mmol) was dissolved in 5 mL tetrahydrofuran. DBU (0.21 mL, 1.42 
mmol) was added and the reaction mixture was heated to reflux. After ~18 h the reaction was 
allowed to cool to room temperature and the solvent was removed under reduced pressure. The 
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residue was dissolved in 10 mL ethyl acetate and washed with 1M HCl (2 x 20 mL) followed by 
20 mL brine. The organic layer was dried over magnesium sulfate and concentrated. Purification 
by silica gel column chromatography (10 % ethyl acetate/90% hexanes) gave 0.45 g (96%) of 
racemized ester (±)-2.40 as a white solid. The characterization data for this compound matched 
those reported for ester (+)-2.40 except the optical rotation was 0°. Analysis by chiral HPLC 
(OD-H column, n-hexane:i-PrOH = 99:1, 1 mL/min) showed two peaks of equal ratio, tR = 9.7 
and 11.4 min. 
 
Racemization of (+)-2.41: 
Ester (+)-2.41 (70 mg, 0.19 mmol) was dissolved in 1.5 mL toluene. DBU (30 mg, 0.19 mmol) 
was then added and the reaction mixture was heated to reflux. After ~18 h the reaction was 
allowed to cool to room temperature and the solvent was removed under reduced pressure. The 
residue was dissolved in 10 mL ethyl acetate and washed with 1M HCl (2 x 20 mL) followed by 
20 mL brine. The organic layer was dried over magnesium sulfate and concentrated to give crude 
product. Purification by column chromatography (10 % ethyl acetate/90% hexanes) gave 50 mg 
(72%) of racemized ester (±)-2.41 as a white solid. The characterization data for this compound 
matched those reported for ester (+)-2.41 except the optical rotation was 0°. Analysis by chiral 
HPLC (OD-H column, n-hexane:i-PrOH = 99:1, 1 mL/min) showed two peaks of equal ratio, tR 
= 12.6 and 14.4 min. 
 
Ester (+)-2.40 (0.52 mmol, 0.20 g) and 10% palladium on carbon (0.52 mmol, 55 mg) were 
placed in a flame-dried flask. The flask was evacuated and then filled with hydrogen gas using a 
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balloon. Anhydrous methanol (2.5 mL) was then added.  After 75 min the reaction mixture was 
vacuum filtered through a bed of Celite with methanol. The filtrate was concentrated and then 
purified by silica gel column chromatography (30% ethyl acetate/ 70 % hexanes) to give 0.10 g 
(83%) of the carboxylic acid 2.51 as a white solid.  
(S)-2-(2-methylnaphthalene-6-yl)propanoic acid (2.51). White solid (0.10 g, 83%); mp = 153-
155 °C; [α]20D = +56.9 (c = 1.0, CHCl3); TLC Rf = 0.11 (30% ethyl acetate/70% hexanes); 
1H 
NMR (300 MHz, CDCl3), δ 7.70 (dd, J = 2.4, 8.4 Hz, 3H), 7.41 (dd, J = 3.9, 8.7 Hz, 1H), 7.16-
7.10 (m, 2H), 3.91-3.85 (m, 4H), 1.60 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3), δ 181.3, 
157.9, 135.1, 134.0, 129.5, 129.1, 127.5, 126.40, 126.36, 119.3, 105.8, 55.5, 45.5, 18.3. The 
enantiomeric ratio was determined by HPLC using a chiral column (OD-H), n-hexane:i-PrOH = 
97:3, 1 mL/min; tR = 15.1 min compared to a racemic sample which showed two peaks tR = 12.9 
and 15.4 min. Racemic (±)-2.51 was prepared following the same procedure as (+)-2.51, only 
with racemic starting material prepared from the racemization of ester 2.40. 
 
Esterification of salicylic acid 2.47: 
Salicylic acid 2.47 (0.300 g, 2.17 mmol) and diphenylmethyl trichloroacetimidate 2.20 (0.93 g, 
2.83 mmol) were added to a flame dried round bottom flask. Anhydrous dichloromethane (8.7 
mL) was then added and the reaction stirred under argon for 18 h. Triethylamine (0.5 mL) was 
then added and the reaction mixture was preadsorbed on silica gel.  Purification by silica gel 
chromatography using a solvent gradient of 0%:5%:10%:20%:30%:50% ethyl acetate / hexanes 
70 
 
buffered with 1% triethylamine afforded 2.48 (0.510 g, 77%) as a colorless oil, 2.49 (0.150 g, 
15%) as a white sticky solid and 2.50 (0.020 g, 3%) as a white solid. 
Benzhydryl 2-hydoxybenzoate (2.48). Colorless oil (0.510 g, 77%); TLC Rf = 0.66 (20% ethyl 
acetate/80% hexanes); IR (thin film) 3189, 3090, 306, 3033, 1674, 1400, 1211, 1158 cm-1; 1H 
NMR (300 MHz, CDCl3), δ 10.67 (s, 1H), 8.07-8.03 (m, 1H), 7.51-7.29 (m, 11H), 7.13 (s, 1H), 
7.00-6.90 (m, 2H); 13C NMR (75 MHz, CDCl3), δ169.6, 162.3, 140.0, 136.3, 130.3, 129.0, 128.6, 
127.5, 119.6, 118.1, 112.8, 78.2. Anal. Calcd for C20H16O3: C, 78.93; H, 5.30. Found: C, 78.94; 
H, 5.20. 
Benzhydryl 2-(benzhydryloxy)benzoate (2.49). White sticky solid (0.15 g, 15%); TLC Rf = 
0.72 (50% ethyl acetate/50% hexanes); IR (KBr) 3064, 3031, 2929, 1724, 1600, 1247, 1164, 
1070 cm-1; 1H NMR (300 MHz, CDCl3), δ 7.90-7.87 (m, 1H), 7.45-7.21 (m, 21H), 7.15 (s, 1H), 
6.96-6.91 (m, 2H), 6.38 (s, 1H); 13C NMR (75 MHz, CDCl3), 166.1, 157.4, 141.0, 140.7, 133.6, 
132.4, 128.9, 128.7, 128.1, 128.0, 127.6, 127.3, 121.3, 120.6, 114.9, 82.0, 78.0. Anal. Calcd for 
C33H26O3: C, 84.23; H, 5.57. Found: C, 84.49; H, 5.66. 
2-(benzhydryloxy)benzoic acid (2.50). White solid (20 mg, 3%); TLC Rf = 0.57 (20% ethyl 
acetate/80% hexanes); IR (KBr) 3386, 1693, 1667, 1249 cm-1; 1H NMR (300 MHz, CDCl3), δ 
8.20 (dd, J = 1.5, 7.8 Hz, 1H), 7.44-7.32 (m, 12H), 7.12-7.07 (m, 1H), 6.99-6.96 (m, 1H), 6.47 
(s, 1H); 13C NMR (75 MHz, CDCl3), 165.6, 157.0, 139.0, 135.0, 134.0, 129.4, 129.0, 127.0, 
122.6, 118.5, 114.7, 84.8 . Anal. Calcd for C20H16O3: C, 78.93; H, 5.30. Found: C, 78.76; H, 
5.37. 
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Chapter 3 – Rearrangement of Benzylic Trichloroacetimidates to Trichloroacetamides: A 
Route to Functionalized Amines 
 
Abstract 
 The rearrangement of allylic trichloroacetimidates to allylic trichloroacetamides has been 
widely studied, as the method provides ready access to valuable allylic amines. In this chapter a 
related transformation is discussed: the rearrangement of benzylic trichloroacetimidates to 
benzylic trichloroacetamides. This transformation provides a pathway to access benzylic amines 
and their derivatives from readily available benzylic alcohols. Two different sets of conditions 
for the rearrangement have been established and the rearrangement of a number of different 
benzylic systems has been investigated. The trichloroacetamide products were shown to be 
useful precursors to related functional groups like ureas, carbamates and amines. A brief survey 
on the use of chiral catalysts to develop an asymmetric rearrangement of these benzylic systems 
was also carried out. 
 
 
 
 
 
 
 
 
 
 
 
78 
 
3.1 Introduction 
Benzylic amines form an important class of molecules that are widely distributed in 
alkaloids, agrochemicals, polymers and dyes.1-3 Due to the significance of these amines a variety 
of techniques have been developed for their synthesis from a number of different starting 
materials. Compounds with carbonyl groups and organic halides are often utilized as starting 
materials for the synthesis of amines in reductive amination and alkylation reactions, 
respectively. Reductive amination with ketones or aldehydes may lead to a mixture of primary, 
secondary and tertiary amines in some cases.4-10 The classical synthesis of amines from alkyl 
halides involves treatment with potassium phthalamide (the Gabriel synthesis), however 
significant waste is generated during deprotection of the phthalimide group.11-14 More recently 
transition metal catalyzed “borrowing hydrogen”︁ methodology has been developed as the most 
convenient alternative for synthesis of amines from readily available alcohols.2, 15-19  
Allylic amines are often prepared utilizing the unimolecular 3,3-sigmatropic 
rearrangements of allylic trichloroacetimidates to provide trichloroacetyl protected allylic 
amines.20-25 These trichloroacetyl groups can be removed to provide the free amines,22-23, 26-30 or 
transformed into ureas or carbamates. These protocols typically generate less waste than many 
other amine synthesis methods and may be performed under thermal conditions without an 
expensive transition metal catalyst. Adaptation of these conditions to the preparation of benzylic 
amines and related functionality was investigated, and the results are presented in this chapter. 
3.1.1 Rearrangement of Benzylic Trichloroacetimidates and Related Systems 
Application of trichloroacetimidate rearrangements to benzylic systems has received 
considerably less attention than allylic structures, but these transformations have the potential to 
provide an efficient route to protected benzylic amines. This rearrangement was first reported in 
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benzylic systems by Cramer and co-workers in the 1950s (Scheme 3.1).31-32 Cramer showed that 
the rearrangement of some benzylic trichloroacetimidates afforded the corresponding 
trichloroacetamides in low yields in the presence of BF3•OEt2. 
Scheme 3.1. Rearrangement of Benzylic Trichloroacetimidates 
 
Similar rearrangements have been observed in other systems that are precursors to highly 
stabilized cations. For example, propargylic imidates like 3.3 may act as alkylating agents under 
Lewis acid catalyzed conditions (Scheme 3.2).33 However when a secondary propargylic imidate 
like 3.5 was subjected to these conditions, the elimination product 3.6 and the rearranged product 
3.7 were isolated as the major products. In case of a secondary imidate that is both benzylic and 
propargylic like 3.8, the rearranged product 3.9 was isolated as the major product with an even 
higher yield (63%). 
Scheme 3.2. Rearrangement in Propargylic Trichloroacetimidates 
 
 These types of rearrangements have also been observed in several other nonallylic 
systems. For example, carbohydrate systems, doubly activated benzylic-allylic systems and 
diazo-substituted substrates (Scheme 3.3) all have been reported to undergo similar 
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rearrangements. A number of groups have shown that glycosyl imidates will rearrange to their 
corresponding acetamide, and these results have been reviewed.34-45 Motawia et al. developed 
conditions to promote this rearrangement by treating protected monosaccharides with TMSOTf. 
This provided the acetamide products in high yield, as shown for glycosyl trichloroacetimidate 
3.10 (Scheme 3.3, eq. 1).46 These rearrangements likely proceed through a cationic mechanism 
that is facilitated by the added stability of the oxygen stabilized cation formed at the anomeric 
position of the monosaccharide. Allylic trichloroacetimidates are mostly known for their 3,3-
sigmatropic rearrangements to provide allylic amines, however Rinaldi and co-workers 
demonstrated that the Baylis-Hillman adduct 3.12 rearranged in the presence of DABCO, 
undergoing a 1,3-type rearrangement to provide amides like 3.13 (Scheme 3.3, eq. 2).47-50 
Mechanistically this reaction was proposed to proceed via a tandem SN2’-SN2’ pathway. 
Nucleophilic attack of DABCO at the terminal alkene carbon results in elimination of the 
imidate, with the amide anion then adding back at the β-allylic position of unsaturated system 
providing the observed amide product 3.13 and regenerating the DABCO catalyst. This strategy 
was utilized by Jørgensen’s group to demonstrate asymmetric rearrangement in these systems 
using chiral form of DABCO 3.15 (Scheme 3.3, eq. 3).51 Alcohol substrates with a diazo 
substituent at the α position (like 3.17) also underwent rapid rearrangement when subjected to 
standard imidation reaction conditions.52-53 To date no conclusive evidence of the mechanism of 
rearrangement in these systems has been reported, but the reaction is proposed to proceed via a 
tight ion pair where the formation of the imidate is quickly followed by recombination with the 
trichloroacetamide. A radical pathway was ruled out by additional studies performed by Trost 
and co-workers.54  
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Scheme 3.3. Rearrangement in Specialized Systems 
 
Since compelling evidence for the rearrangement in benzylic trichloroacetimidates was 
found in activated systems in the literature, a study was initiated to develop optimal reaction 
conditions for simple benzylic systems and to determine the generality of these transformations. 
 
3.2 Results and Discussion 
3.2.1 Optimization of the Rearrangement 
 During our studies on the esterification of carboxylic acids using diphenylmethyl 
trichloroacetimidate (3.19), it was observed that improper storage of DPM imidate led to its 
partial rearrangement to the diphenylmethyl trichloroacetamide (3.20).55 Further investigation 
showed that upon heating imidate 3.19 to reflux in toluene, the amide 3.20 was obtained with a 
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promising 46% yield. These trichloroacetamide side products were also observed in other work 
from Chisholm lab that focused on displacement of imidates with other nucleophiles.56-59 
Scheme 3.4. Previous Observations 
 
Encouraged by these results we set out to develop a protocol that would facilitate such 
transformations with higher efficiency. Given that a general protocol was desired, imidate 3.19 
was not the ideal substrate for optimization since this imidate is a precursor to highly stable 
cation and if the reaction proceeds via an SN1 type-pathway rearrangement in this substrate will 
be favored. Also imidate 3.19 cannot undergo elimination that could be a competing reaction (as 
observed previously by Wang’s group with the propargylic imidates 3.5 and 3.8, Scheme 3.2). 
Therefore the secondary benzylic imidate 3.23 (phenethyl trichloroacetimidate) was chosen as a 
substrate for optimizing the reaction conditions since this imidate is the precursor to a less 
stabilized cation and can undergo elimination, as well as other competing reactions like 
hydrolysis and formation of the bis-ether (which is usually observed when the alcohol is formed 
and it reacts with the imidate). Initially the previously reported thermal conditions for allylic 
trichloroacetimidate were evaluated22-23 by refluxing imidate 3.23 in a non-polar solvent like m-
xylene. Under these conditions the starting material was consumed in 16 hours but no rearranged 
product was observed, instead this resulted in decomposition of the starting material (Table 3.1, 
entry 1). Polar solvents like t-amyl alcohol were also screened under thermal conditions, 
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however only starting material was recovered from this experiment (entry 2). More polar ethereal 
and nitrile containing solvents provided small amounts of the rearranged amide but mostly 
resulted in elimination of the imidate. Alternatively, nitromethane was shown to be an excellent 
solvent for these rearrangements (Table 3.1, entry 3 & 4). Nitromethane has been previously 
used for alkylation of aniline with tert-butyl imidate providing high yield of the alkylated 
product.60 This was attributed to improved stabilization of the tert-butyl cation in a polar solvent. 
Much to our satisfaction using nitromethane as the solvent provided the rearranged product with 
high yield (80%) (Table 3.1, entry 5). In order to reduce the reaction time some Brønsted and 
Lewis acids were screened as catalysts to accelerate the rearrangement. With Brønsted acids it 
was observed that stronger acids tended to provide more rapid reactions and higher yields. With 
less acidic catalysts like dibenzyl phosphate the reaction was incomplete even after 27 hours 
(Table 3.1, entry 6-8). Triflic acid provided the product 3.24 with the highest yield of 80% 
among all the other Brønsted acid catalysts but concern was expressed over the strong acidity of 
triflic acid, which might make these conditions less compatible with acid sensitive functional 
groups. Copper and zinc based Lewis acids provided the rearranged product with moderate to 
high yields but still required long reaction times as compared to triflic acid (Table 3.1, entry  9-
11).  
84 
 
Table 3.1. Optimization of the Reaction Conditions for the Rearrangement 
 
 aDetermined from 1H NMR using mesitylene as an internal standard. bStarting material decomposed. cStarting 
material was recovered unreacted. dStyrene was detected in the 1H NMR 
 
 Next Lewis acids were examined. When iron trichloride and BF3•OEt2 were evaluated, 
both provided the product 3.24 with very high yields in only 10 minutes (Table 3.1, entry 12 & 
13). Lowering the catalyst loading to 1 mol% clearly showed that BF3•OEt2 was a superior 
catalyst compared to FeCl3, providing 3.24 without any drop in yield or increase in reaction time 
(Table 3.1, entry 14 & 15). The screening of different conditions for optimal yield of 
rearrangement therefore provided us with two different set of conditions, 1) the optimized 
thermal conditions (Table 3.1, entry 5) and 2) the optimized Lewis acid catalyzed conditions 
(Table 3.1, entry 15). Different trichloroacetimidates tend to have different degrees of reactivity 
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and also some substrates may not be stable under one or the other conditions, hence having both 
these protocols can be advantageous. With the reaction screening complete for the 
rearrangement, the substrate scope of these rearrangements under both sets of conditions was 
investigated. 
3.2.2 Substrate Scope 
Subjecting simple electron rich secondary benzylic trichloroacetimidates to both 
optimized protocols provided the amide product with high yields (Table 3.2, entries 1-4). The 
addition of a deactivating halide substituent to the phenyl ring (as in 3.33) resulted in a slightly 
lower yield. Having a nitro group on the aromatic ring completely deadened the reactivity of the 
imidate 3.35. The rearranged product 3.36 was obtained in only a low yield under forcing 
conditions, involving 10 mol % of Lewis acid and refluxing the reaction mixture for 24 hours. 
Placing an ortho substituted aromatic ring in the system also moderately lowered the yield under 
both sets of the conditions, probably due to steric effects (entries 7-9). The hetero-aromatic 
indole imidate 3.43 (entry 10) was also subjected to both the conditions; however a high yield of 
product was only obtained under Lewis acid catalyzed conditions. Subjecting imidate 3.43 to the 
thermal rearrangement conditions resulted in rapid decomposition of the starting material within 
2 hours and no desired amide was observed in the crude 1H NMR spectra. This example further 
demonstrates the advantage of having two sets of conditions for these rearrangements. The 
reactivity of primary benzylic systems was also investigated (entries 11-13). Benzyl and 4-
methoxy benzyl imidates provided lower yields of the rearranged product under both sets of the 
conditions. The low yields were attributed to the decreased stability of the primary benzylic 
cation over the secondary benzylic cation and the higher reactivity of these systems towards 
Friedel-Crafts type reactions, which may lead to polymerization. Assuming the reaction proceeds 
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via a cationic intermediate where trichloroacetamide anion acts as a nucleophile, attempts to 
increase the yield by adding stoichiometric amount of trichloroacetamide were also pursued. No 
increase in yield was obtained for either of the imidate 3.45 or 3.47. The electron poor primary 
benzylic imidate 3.49 was found to be completely unreactive under both protocols; forcing 
conditions were not ventured for this substrate. During the course of this substrate scope it was 
also noticed that these rearrangements were quite sensitive to any moisture in solvent, which led 
to hydrolysis of the imidate group. Hence fresh anhydrous nitromethane (dried over 4 Å 
molecular sieves) had to be used for these reactions to obtain the reported yields. 
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Table 3.2. Rearrangement in Simple Benzylic Systems 
 
A = Thermal conditions (nitromethane, reflux, 24 h). B = Lewis acid catalyzed conditions (1 mol % BF3•OEt2, 
nitromethane, 0 °C, 10 min). cReaction stirred at rt for 1 h. d10 mol % BF3•OEt2, nitromethane, reflux, 24 h. 
eReaction stirred at rt for 72 h fReaction stirred at rt for 1 h. gStarting material decomposed. 
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In order to investigate the generality of this methodology some more complex 
trichloroacetimidate systems were evaluated (Table 3.3). Diphenylmethyl type systems like 
DPM-imidate (3.19) provided high yield of amide under both these conditions and showed a 
significant improvement in yield from previously obtained results in refluxing toluene. 
Diphenylmethyl imidate 3.51 with an ortho substituent again afforded a lower yield owing to 
steric effects. Diphenylmethyl system 3.53 with an electron withdrawing nitro group provided a 
high yield of product consistently under both the conditions. This result appears to indicate that 
the resonance stability provided by the phenyl rings outweigh the electronic effects of a nitro 
substituent. Secondary benzylic imidates with different aliphatic substituents at the benzylic 
position were also investigated (entries 4-7). Imidate 3.55 with a linear n-butyl chain at the 
benzylic position provided slightly lowered yields of the amide product under both conditions. 
The bulkier isopropyl group in 3.57 hindered the reactivity, providing a low yield of amide 3.58 
under thermal conditions. The Lewis acid catalyzed condition provided a higher yield of 41%. 
Imidates 3.59 and 3.61, which are highly prone to elimination, provided the amides with 
moderate yield under both the conditions. In all the three imidates 3.57, 3.59 and 3.61 
elimination was observed as the major side product accounting for the lower yields. Tertiary 
imidate 3.63 was also subjected to these conditions. The thermal conditions provided the amide 
3.64 with 53% yield, whereas under the Lewis acid catalyzed conditions the imidate decomposed 
rapidly. Next we also investigated heteroatomic substitution adjacent to the rearrangement 
carbon (entries 9 & 10). The phthalimide imidate 3.65 decomposed under the thermal conditions 
but provided a low yield of the amide under modified Lewis acid catalyzed condition. Glycosidic 
trichloroacetimidates have been previously shown to undergo these types of rearrangements,46 
hence we tested the glycosyl imidate 3.67. The imidate underwent rearrangement to provide 
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amide 3.68 with a slightly higher yield under Lewis acid catalyzed conditions. Under both 
conditions the starting material was exclusively the α stereoisomer, but the product was isolated 
as a nearly 1:1 mixture of both the anomers. Finally the aliphatic substrates, tert-butyl 
trichloroacetimidate (3.69) and ethyl trichloroacetimidate (3.71) were subjected to both the 
conditions (entries 11 & 12). Both substrates gave only trace amounts of the rearranged product, 
demonstrating the significance of a benzylic system. In case of the ethyl imidate the product 3.72 
a trace amount of product was detected in the crude 1H NMR (<5%), but it could not be isolated 
in pure form from the crude reaction mixture. 
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Table 3.3. Rearrangement in More Complex Systems 
 
A = Thermal Conditions (nitromethane, reflux, 24 h). B = Lewis acid catalyzed conditions (1 mol % BF3•OEt2, 
nitromethane, 0 °C, 10 min). c10 mol % BF3•OEt2, nitromethane, reflux  24 h. dIsolated as a 44:54 ( mixture of 
anomers eIsolated as a 58:42 ( mixture of anomers. f10 mol % BF3•OEt2, nitromethane, reflux, 48 h. gStarting 
material decomposed. 
 
91 
 
 In addition to the substrates discussed in tables 3.1 & 3.2, several additional substrates 
were also subjected to the above established conditions. The imidates 3.75 and 3.76 underwent 
rapid elimination and did not provide any rearranged product. The hetero-aromatic system 3.77 
was found to be completely unreactive under both the conditions whereas the furanyl imidate 
3.78 decomposed rapidly without providing any desired product. The complex pyrroloindoline 
imidate 3.79 mostly led to elimination under thermal conditions and provided complex mixtures 
in the presence of a Lewis acid catalyst. The cyclohexyl imidate 3.80 and the lactate 3.82 were 
also found to be unreactive under the standard sets of conditions. The tertiary propargyl imidate 
3.81 underwent elimination predominantly.  
Table 3.4. Failed Substrates 
 
3.2.3 Mechanistic Discussions and Attempted Asymmetric Rearrangement 
In order to gain some insight into the mechanistic pathway of the rearrangement some 
additional studies were conducted. The chiral imidate (S)-3.23 was subjected to both sets of 
optimized reaction conditions (Scheme 3.5). The products obtained from both the reactions were 
analyzed by chiral HPLC and it was found that the amide 3.24 was almost completely racemized 
in both cases.  
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Scheme 3.5. Rearrangement of Enantiopure Imidate 3.23 
 
The nearly complete racemization of the stereocenter, coupled with the favored reactivity 
in a polar solvent and the observed trends in the substrate scope were consistent with a cationic 
SN1 pathway (Figure 3.1). However an alternate, less likely, concerted bimolecular pathway 
involving the intermediate 3.23B may also be operative (Figure 3.1) in some cases. At this stage 
no conclusive proof was available to rule out a radical pathway, although the fact that the 
nitrophenyl imidate 3.35 was unreactive seemed to favor the cationic pathway over the radical 
pathway. 
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Figure 3.1. Proposed Mechanistic Pathways 
 
 Assuming this reaction was proceeding through an SN1 type pathway, we sought to 
influence the addition of the nucleophile by complexing the cation with a chiral counterion that 
could lead to the delivery of the nucleophile selectively from one face over the other to achieve 
enantioselectivity. The diphenylmethyl imidate 3.51 with the ortho substituted methoxy group 
was chosen as the reaction substrate for these experiments, in the hope that the steric bulk from 
the ortho methoxy group will enable easy differentiation between the two possible enantiotopic 
faces of the cation. Several thiourea61-63 and BINOL phosphoric acid catalysts64-66 which were 
closely related to the ones utilized to affect asymmetric transformations of trichloroacetimidates 
were evaluated. We attempted asymmetric rearrangement by subjecting the imidate 3.51 to 
Jacobsen’s conditions61 using the quinine based thiourea catalyst A and DCM as solvent (Table 
3.5, entry 1). The reaction provided very low yield of the product 3.52 but more importantly no 
enantio-enrichment was observed. Switching to the tert-leucine based thiourea catalysts B and C 
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provided a higher yield of the product but again no enantioselectivity was observed. Changing 
the solvent to nitromethane gave similar conversion and again, no enantioselectivity. The (R)-
TRIP catalyst (D) proved to be completely inactive under the reaction conditions. Given these 
initial results it is clear that significant development would be required in the future to engineer a 
catalyst that could control the enantioselectivity of these transformations. 
Table 3.5. Attempted Asymmetric Rearrangements 
 
entry  catalyst  conditions  yield er 
1 A 8% DNBSA, DCM, 4 Å mol. sieves rt, 24 h 21% 50:50 
2 B 8% DNBSA, DCM, 4 Å mol. sieves, rt, 1 h 37% 50:50 
3 C 8% DNBSA, DCM, 4 Å mol. sieves, rt, 2 h 40% 50:50 
4 B 8% DNBSA, MeNO2, 4 Å mol. sieves, rt, 1 h 40% 50:50 
5 D MeNO2, rt, 1 h N. R. -- 
 
3.2.4 Functionalization of Trichloroacetamide 
 The trichloroacetamide functionality has been transformed to various synthetically useful 
intermediates or targets like amines,46, 67-68 urea derivatives69-71 and carbamates.72-75 We also 
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explored the conversion of benzylic trichloroacetamide 3.28 into these intermediates (Scheme 
3.5). The amide 3.28 was efficiently converted into the urea 3.83 using cesium carbonate as a 
base and benzylamine. The trichloromethyl group was also displaced by methoxide ion to 
provide the methyl carbamate 3.84 with good yields. Finally the trichloroacetamide group was 
deprotected using sodium hydroxide to provide the free benzylic amine 3.85 in moderate yield. 
The carbamate 3.84 was also obtained as a minor side product in this reaction.  
Scheme 3.5. Derivatization of Trichloroacetamide Group 
 
 
3.3 Conclusions 
 A novel and efficient methodology for the synthesis of protected amine variants has been 
established utilizing the rearrangement of benzylic trichloroacetimidates. Two sets of reaction 
conditions were established, a neutral thermal protocol and a Lewis acid catalyzed protocol. A 
variety of secondary benzylic systems provided the trichloroacetamide product with high yields. 
Electron poor imidate systems and sterics seemed to play a role in limiting the yields of the 
product. Primary benzylic imidates also provided low yields of the product. The conversion of 
the trichloroacetamide into several different amine-based functional groups was also 
demonstrated. Results from these studies are most consistent with an SN1 type pathway that 
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proceeds through a cationic intermediate. Attempts to perform these reactions with a chiral 
catalyst to access enantioenriched product were also pursued, but these efforts did not result in a 
system which provided enantioselectivity.  
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3.4. Experimental 
The trichloroacetimidates 3.19,76 3.23,77 3.31,78 3.37,59 3.41,59 3.45,79 3.47,80 3.49,81-82 3.61,59 
3.63,83 3.67,84-85 and 3.6586 were synthesized as previously described (for characterization data 
see the listed references). tert-Butyl 2,2,2-trichloroacetimidate 3.69 and ethyl 2,2,2-
trichloroacetimidate 3.71 were purchased from commercial sources and used without further 
purification. The synthesis and analysis of the enantiopurity of the chiral trichloroacetimidate 
(S)-3.23 was performed as previously reported.78 
General procedure for synthesis of trichloroacetimidates. 
DBU (0.1 equiv.) was added to a solution of the alcohol (1.0 equiv.) in 4.0 mL anhydrous DCM 
under argon. The mixture was stirred at room temperature for 15 min and then cooled to 0 °C. 
Trichloroacetonitrile (1.2 equiv.) was then added, and the reaction mixture was allowed to warm 
to room temperature and stirred for 18 h. The reaction mixture was then concentrated and the 
residue purified by silica gel chromatography (using the listed solvent system) to give the 
trichloroacetimidate. 
General procedures for rearrangement of trichloroacetimidates to trichloroacetamides. 
Method A: Thermal conditions 
The imidate (1.0 equiv.) was dissolved in anhydrous nitromethane (1.0 mL) under an argon 
atmosphere. The resulting solution was heated to reflux for 24 h. The reaction mixture was then 
allowed to cool to room temperature and concentrated. The residue was purified by silica gel 
chromatography (using the listed solvent system) to provide the corresponding 
trichloroacetamide product. 
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Method B: Lewis acid catalyzed conditions 
The imidate (1.0 equiv.) was dissolved in anhydrous nitromethane (4.0 mL) under an argon 
atmosphere. The solution was cooled to 0 °C and BF3•OEt2 (0.01 equiv.) was added. The 
resulting solution was then stirred at 0 °C for the listed amount of time. The mixture was then 
quenched by the addition of a solution of sat. aq. sodium bicarbonate. The resulting suspension 
was then extracted with DCM (3 x 5 mL). The combined extracts were dried (Na2SO4), filtered 
and concentrated. The residue was purified by silica gel chromatography (using the listed solvent 
system) to provide the pure trichloroacetamide product. 
 
N-Benzhydryl-trichloroacetamide (3.20).55 Prepared using method A (0.16 g, 80%) and 
method B (0.25 g, 83%), purified using silica gel chromatography (5% ethyl acetate/94% 
hexanes/1% triethylamine). White solid; mp = 121-123 °C; TLC Rf = 0.65 (10% ethyl 
acetate/90% hexanes); 1H NMR (400 MHz, CDCl3) δ 7.40-7.31 (m, 6H), 7.26-7.25 (m, 4H), 7.16 
(d, J = 6.4 Hz, 1H), 6.18 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 160.9, 139.8, 129.0, 
128.2, 127.4, 92.7, 59.0. 
 
2,2,2-Trichloro-N-(1-phenylethyl)acetamide (3.24).77 Prepared using method A (0.12 g, 80%) 
and method B (0.24 g, 94%), purified using silica gel chromatography (10% ethyl acetate/89% 
hexanes/1% triethylamine). White solid; TLC Rf = 0.33 (10% ethyl acetate/90% hexanes); IR 
(thin film) 3310, 3064, 2991, 1681, 1519 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.39-7.28 (m, 5H), 
6.92 (br s, 1H), 5.07 (p, J = 7.2 Hz, 1H), 1.59 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
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161.0, 141.4, 129.0, 128.0, 126.1, 92.7, 51.1, 21.2. Chiral HPLC analysis: Chiralcel OJ 
(heptane/i-PrOH = 50/50, 0.5 mL/min, 254 nm, 25 °C): t1 = 11.1 min, t2 = 12.7 min. 
 
N-(1-(Benzo[d][1,3]dioxol-6-yl)ethyl)-2,2,2-trichloroacetimidate (3.27). Prepared using the  
general procedure for synthesis of trichloroacetimidates and purified using silica gel 
chromatography (10% ethyl acetate/89% hexanes/1% triethylamine). White solid  (3.10 g, 75%); 
mp = 39-42 °C; TLC Rf = 0.69 (10% ethyl acetate/90% hexanes); IR (thin film) 3338, 2982, 
2932, 2892, 1661 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.30 (br s, 1H), 6.93 (d, J = 1.2 Hz, 1H), 
6.88 (dd, J = 8.0, 1.6 Hz, 1H), 6.78 (d, J = 8.0 Hz, 1H), 5.95 (s, 2H), 5.90 (q, J = 6.4 Hz, 1H), 
1.61 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 161.5, 147.8, 147.3, 135.2, 119.6, 
108.2, 106.6, 101.1, 91.8, 77.0, 22.2. Anal. Calcd for C11H10Cl3NO3: C, 42.54; H, 3.25; N, 4.51; 
Found: C, 42.35; H, 3.17; N, 4.52. 
 
N-(1-(Benzo[d][1,3]dioxol-6-yl)ethyl)-2,2,2-trichloroacetamide (3.28). Prepared using method 
A (0.23 g, 75%) and method B (0.13 g, 87%), purified using silica gel chromatography (10% 
ethyl acetate/89% hexanes/1% triethylamine). White solid; mp = 112-115 °C; TLC Rf = 0.23 
(10% ethyl acetate/90% hexanes); IR (thin film) 3307, 2997, 2957, 2897, 1682 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.83-6.75 (m, 4H), 5.97 (s, 2H), 4.99 (p, J = 6.8 Hz, 1H), 1.57 (d, J = 6.8 
Hz, 3H) ; 13C NMR (100 MHz, CDCl3) δ 160.9, 148.1, 147.3, 135.2, 119.5, 108.5, 106.7, 101.3, 
92.7, 51.0, 21.2; Anal. Calcd for C11H10Cl3NO3: C, 42.54; H, 3.25; N, 4.51; Found: C, 42.54; H, 
3.25; N, 4.52. 
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2,2,2-Trichloro-N-(1-(4-methoxyphenyl)ethyl)acetimidate (3.29). Prepared using the general 
procedure for synthesis of trichloroacetimidates, purified using silica gel chromatography (10% 
ethyl acetate/89% hexanes/1% triethylamine). White solid (1.14 g, 53%); mp = 59-68 °C; TLC 
Rf = 0.66 (10% ethyl acetate/90% hexanes); IR (thin film) 3337, 3059, 2986, 2934, 1685, 1660, 
1513 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.28 (br s, 1H), 7.36 (dd, J = 6.4, 1.6 Hz, 2H), 6.90-
6.87 (m, 2H), 5.94 (q, J = 6.4 Hz, 1H), 3.80 (s, 3H), 1.63 (d, J = 6.4 Hz, 3H); 
13C NMR (100 
MHz, CDCl3) δ 161.6, 159.3, 133.3, 127.3, 113.8, 91.8, 76.9, 55.2, 22.0; Anal. Calcd for 
C10H9Cl4NO: C, 44.55; H, 4.08; N, 4.72; Found: C, 44.88; H, 4.13; N, 4.68. 
 
2,2,2-Trichloro-N-(1-(4-methoxyphenyl)ethyl)acetamide (3.30). Prepared using method A 
(0.25 g, 82%) and method B (0.12 g, 80%), purified using silica gel chromatography (5% ethyl 
acetate/94% hexanes/1% triethylamine). White solid; mp = 89-91 °C; TLC Rf = 0.25 (10% ethyl 
acetate/90% hexanes); IR (thin film) 3329, 2977, 2934, 2836, 1660, 1585, 1513 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.28-7.26 (m, 2H), 6.92-6.90 (m, 2H), 6.75 (br s, 1H), 5.04 (p, J = 7.2 Hz, 
1H), 3.81 (s, 3H), 1.59 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 160.9, 159.3, 133.4, 
127.4, 114.3, 92.8, 55.3, 50.6, 21.0; Anal. Calcd for C11H12Cl3NO2: C, 44.55; H, 4.08; N, 4.72; 
Found: C, 44.68; H, 4.24; N, 4.76. 
 
2,2,2-Trichloro-N-(1-p-tolylethyl)acetamide (3.32). Prepared using method A (0.24 g, 82%, 
purified using silica gel chromatography with 2% ethyl acetate/98% toluene) and method B 
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(0.084 g, 84%, purified using silica gel chromatography with 5% ethyl acetate/95% hexanes). 
Yellow solid; mp = 74-77 °C; TLC Rf = 0.44 (10% ethyl acetate/90% hexanes); IR (thin film) 
3322, 3026, 2980, 2927, 2873, 1697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.25-7.18 (m, 4H), 6.78 
(br s, 1H), 5.05 (p, J = 7.2 Hz, 1H), 2.35 (s, 3H), 1.58 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 160.9, 138.5, 138.4, 137.7, 129.6, 126.1, 92.8, 51.0, 21.1; Anal. Calcd for 
C11H12Cl3NO: C, 47.09; H, 4.31; N, 4.99; Found: C, 46.69; H, 4.38; N, 4.99. 
 
2,2,2-Trichloro-N-(1-(4-chlorophenyl)ethyl)acetimidate (3.33). Prepared using the  general 
procedure for synthesis of trichloroacetimidates and purified using silica gel chromatography 
(10% ethyl acetate/89% hexanes/1% triethylamine). White solid (2.40 g, 79%); mp = 39-41 °C; 
TLC Rf = 0.47 (10% ethyl acetate/90% hexanes); IR (thin film) 3341, 2983, 2933, 1663, 1375 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.32 (br s, 1H), 7.37-7.32 (m, 4H), 5.95 (q, J = 6.8 Hz, 1H), 
1.63 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 161.5, 139.9, 133.7, 128.7, 127.3, 91.6, 
76.4, 22.2; Anal. Calcd for C10H9Cl4NO: C, 39.90; H, 3.01; N, 4.65; Found: C, 39.66; H, 3.31; 
N, 4.55. 
 
2,2,2-Trichloro-N-(1-(4-chlorophenyl)ethyl)acetamide (3.34). Prepared using method A (0.22 
g, 72%) and using a modified method B where the reaction was allowed to proceed for 1 h (0.10 
g, 67%), purified using silica gel chromatography (10% ethyl acetate/89% hexanes/1% 
triethylamine). White solid; mp = 92-94 °C; TLC Rf = 0.33 (10% ethyl acetate/90% hexanes); IR 
(thin film) 3326, 3029, 2981, 2934, 1695, 1577 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.37-7.26 
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(m, 4H), 6.79 (br s, 1H), 5.05 (p, J = 6.8 Hz, 1H), 1.59 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 161.0, 140.0, 133.7, 129.1, 127.5, 92.6, 50.6, 21.2; Anal. Calcd for C10H9Cl4NO: C, 
39.90; H, 3.01; N, 4.65; Found: C, 39.48; H, 3.25; N, 4.45. 
 
2,2,2-Trichloro-N-(1-(4-nitrophenyl)ethyl)acetimidate (3.35). Prepared using the general 
procedure for synthesis of trichloroacetimidates and purified using silica gel chromatography 
(15% ethyl acetate/83% hexanes/2% triethylamine).White solid (1.80 g, 97%); mp = 56-59 °C; 
TLC Rf = 0.58 (30% ethyl acetate/70% hexanes); IR (thin film) 3340, 3083, 2987, 2936, 1666, 
1605 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.38 (br s, 1H), 8.24 (d, J = 8.8 Hz, 2H), 7.59 (d, J = 
8.8 Hz, 2H), 6.05 (q, J = 6.8 Hz, 1H), 1.68 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
161.3, 148.6, 147.5, 126.6, 123.9, 91.3, 75.9, 22.1; Anal. Calcd for C10H9Cl3N2O3: C, 38.55; H, 
2.91; N, 8.99; Found: C, 38.61; H, 2.92; N, 8.97. 
 
2,2,2-Trichloro-N-(1-(4-nitrophenyl)ethyl)acetamide (3.36). Prepared using a modified 
method B (0.065g, 32%) where 10 mol % BF3•OEt2 was used and the reaction was heated to 
reflux for 24 h. Purified using silica gel chromatography (5% ethyl acetate/94% hexanes/1% 
triethylamine). White solid; mp = 118-126 °C; TLC Rf = 0.35 (30% ethyl acetate/ 70% hexanes); 
IR (thin film) 3341, 2983, 2931, 1699, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.4 
Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 4.4 Hz, 1H), 5.14 (p, J = 6.8 Hz, 1H), 1.65 (d, J = 
7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 161.3, 148.8, 147.5, 126.9, 124.2, 92.3, 50.8, 21.5; 
Anal. Calcd for C10H9Cl3N2O3: C, 38.55; H, 2.91; N, 8.99; Found: C, 38.57; H, 2.85; N, 9.25. 
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2,2,2-Trichloro-N-(1-o-tolylethyl)acetamide (3.38). Prepared using method A (0.15 g, 56%) 
and method B (0.085 g, 85%), purified using silica gel chromatography (10% ethyl acetate/90% 
hexanes). White solid; mp = 116-120 °C; TLC Rf = 0.42 (10% ethyl acetate/90% hexanes); IR 
(thin film) 3335, 3053, 3025, 2979, 2933, 2873, 1695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.33-
7.19 (m, 4H), 6.79 (br s, 1H), 5.25 (p, J = 6.8 Hz, 1H), 2.39 (s, 3H), 1.58 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 160.8, 139.2, 136.1, 131.0, 128.0, 126.6, 124.6, 92.7, 47.9, 20.4, 
19.1. Anal. Calcd for C11H12Cl3NO: C, 47.09; H, 4.31; N, 4.99; Found: C, 46.96; H, 4.22; N, 
4.84. 
 
2,2,2-Trichloro-N-(1-(2-chlorophenyl)ethyl)acetimidate (3.39). Prepared using the  general 
procedure for synthesis of trichloroacetimidates and purified using silica gel chromatography 
(5% ethyl acetate/94% hexanes/1% triethylamine). Colorless oil (1.04 g, 86%); TLC Rf = 0.63 
(10% ethyl acetate/90% hexanes); 1H NMR (400 MHz, CDCl3) δ 8.35 (br s, 1H), 7.57 (dd, J = 
7.6, 1.6 Hz, 1H), 7.36 (dd, J = 7.6, 1.6 Hz, 1H), 7.31-7.21 (m, 2H), 6.31 (q, J = 6.4 Hz, 1H), 1.64 
(d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 161.2, 139.4, 131.7, 129.5, 128.9, 127.3, 
126.2, 91.6, 74.1, 20.9; Anal. Calcd for C10H9Cl4NO: C, 39.90; H, 3.01; N, 4.65; Found: C, 
39.70; H, 2.95; N, 4.51. 
 
2,2,2-Trichloro-N-(1-(2-chlorophenyl)ethyl)acetamide (3.40). Prepared using a modified 
method A where the reaction was refluxed for 72 h (0.11 g, 55%) and using a modified method B 
104 
 
where the reaction was allowed to proceed for 1 h (0.080 g, 59%), purified using silica gel 
chromatography (10% ethyl acetate/89% hexanes/1% triethylamine). White solid; mp = 127-128 
°C; TLC Rf = 0.32 (10% ethyl acetate/90% hexanes); IR (thin film) 3297, 3030, 2982, 2933, 
1691, 1520 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.24 (m, 4H), 7.10 (br s, 1H), 5.35 (p, J = 
6.8 Hz, 1H), 1.62 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 160.8, 138.6, 132.9, 130.4, 
129.1, 127.4, 127.2, 92.6, 49.6, 20.3; Anal. Calcd for C10H9Cl4NO: C, 39.90; H, 3.01; N, 4.65; 
Found: C, 40.04; H, 3.01; N, 4.97. 
 
N-(1-(5-Bromobenzo[d][1,3]dioxol-6-yl)ethyl)-2,2,2-trichloroacetamide (3.42). Prepared 
using method A (0.15 g, 73%) and method B (0.16 g, 62%), purified using silica gel 
chromatography (10% ethyl acetate/89% hexanes/1% triethylamine). White solid; mp = 139-141 
°C; TLC Rf = 0.62 (30% ethyl acetate/70% hexanes); IR (thin film) 3327, 2981, 2899, 1694 cm
-
1; 1H NMR (400 MHz, CDCl3) δ 7.03 (s, 1H), 6.92 (s, 1H), 6.82 (s, 1H), 5.99 (q, J = 1.2 Hz, 2H), 
5.23 (p, J = 7.2 Hz, 1H), 1.56 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 160.7, 148.0, 
147.9, 133.4, 113.6, 113.4, 106.8, 102.0, 92.5, 51.3, 20.4; Anal. Calcd for C11H9BrCl3NO3: C, 
33.92; H, 2.33; N, 3.60; Found: C, 33.67; H, 2.45; N, 3.83. 
 
Benzyl 3-(1-(2,2,2-trichloroacetimido)ethyl)-1H-indole-1-carboxylate (3.43). Prepared using 
the general procedure for synthesis of trichloroacetimidates and purified using silica gel 
chromatography (10% ethyl acetate/89% hexanes/1% triethylamine). White solid (1.47 g, 76%); 
mp = 78-85 °C; IR (thin film) 3338, 3089, 3034, 2982, 2936, 1740, 1662 cm-1; 1H NMR (400 
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MHz, CDCl3) δ 8.40 (s, 1H), 8.18 (d, J = 5.6 Hz, 1H), 7.68-7.67 (m, 2H), 7.50-7.22 (m, 7H), 
6.31 (q, J = 6.4 Hz, 1H), 5.44-5.37 (m, 2H), 1.77 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 161.8, 150.8, 135.9, 135.1, 128.9, 128.6, 128.4, 127.8, 125.1, 123.2, 123.0, 121.6, 
120.2, 115.5, 91.9, 71.2, 68.9, 19.8; Anal. Calcd for C20H17Cl3N2O3: C, 54.63; H, 3.90; N, 6.37; 
Found: C, 54.70; H, 3.92; N, 6.24. 
 
Benzyl 3-(1-(2,2,2-trichloroacetamido)ethyl)-1H-indole-1-carboxylate (3.44). Prepared using 
method B (0.072 g, 72%), purified using silica gel chromatography (10% ethyl acetate/90% 
hexanes). White solid; mp = 126-128 °C; TLC Rf = 0.53 (25% ethyl acetate/75% hexanes); IR 
(thin film) 3333, 3065, 3031, 2979, 2936, 1734, 1703, 1608 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.18 (d, J = 6.8 Hz, 1H), 7.62 (s, 1H), 7.58-7.55 (m, 1H), 7.50-7.47 (m, 2H), 7.45-7.34 (m, 4H), 
7.30-7.27 (m, 1H), 6.75 (d, J = 8.0 Hz, 1H), 5.50-5.34 (m, 3H), 1.71 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 161.1, 150.7, 135.9, 134.9, 128.90, 128.85, 128.61, 128.56, 125.4, 
123.5, 122.7, 121.9, 119.4, 115.5, 92.7, 69.0, 43.9, 19.4; Anal. Calcd for C20H17Cl3N2O3: C, 
54.63; H, 3.90; N, 6.37; Found: C, 54.67; H, 3.92; N, 6.50. 
 
N-Benzyl-2,2,2-trichloroacetamide (3.46).87 Prepared using method A (0.050 g, 25%) and 
method B (0.015 g, 15%), purified using silica gel chromatography (10% ethyl acetate/89% 
hexanes/1% triethylamine). White solid; mp = 87-92 °C; TLC Rf = 0.50 (20% ethyl acetate/ 80%  
hexanes); 1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 5H), 7.00 (br s, 1H), 4.55 (d, J = 5.6 Hz, 
2H); 13C NMR (100 MHz, CDCl3) δ 161.9, 136.3, 129.0, 128.2, 127.8, 92.6, 45.4. 
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N-(4-Methoxybenzyl)-2,2,2-trichloroacetamide (3.48). Prepared using method A (0.070 g, 
47%) and method B (0.013 g, 13%), purified using silica gel chromatography (10% ethyl 
acetate/89% hexanes/1% triethylamine). White solid; mp = 95-100 °C; TLC Rf = 0.18 (10% 
ethyl acetate/90% hexanes); IR (thin film) 3313, 3044, 3002, 2954, 1692, 1613 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.26-7.24 (m, 2H), 6.92-6.84 (m, 3H), 4.49 (d, J = 5.6 Hz, 2H), 3.81 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 161.8, 159.5, 129.3, 128.4, 114.4, 92.6, 55.3, 44.9; Anal. 
Calcd for C10H10Cl3NO2: C, 42.51; H, 3.57; N, 4.96; Found: C, 42.72; H, 3.77; N, 5.22. 
 
2,2,2-Trichloro-N-((2-methoxyphenyl)(phenyl)methyl)acetimidate (3.51). Prepared using the 
general procedure for synthesis of trichloroacetimidates and purified using silica gel 
chromatography (5% ethyl acetate/94% hexanes/1% triethylamine). White solid (2.76 g, 81%); 
mp = 93-96 °C; IR (thin film) 3337, 3064, 3032, 3005, 2960, 2938, 1665, 1601 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.36 (s, 1H), 7.50-7.46 (m, 3H), 7.35-7.25 (m, 5H), 6.97 (td, J = 7.6, 0.8 
Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 3.85 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 161.3, 156.4, 
139.7, 129.1, 128.5, 128.3, 127.8, 127.0, 126.8, 120.7, 110.7, 91.7, 76.2, 55.6; Anal. Calcd for 
C16H14Cl3NO2: C, 53.58; H, 3.93; N, 3.91; Found: C, 53.54; H, 3.82; N, 3.97. 
 
2,2,2-Trichloro-N-((2-methoxyphenyl)(phenyl)methyl)acetamide (3.52). Prepared using 
method A (0.072 g, 50%) and method B (0.100 g, 67%), purified using silica gel 
chromatography (5% ethyl acetate/95% hexanes). White solid; mp = 109-112 °C; TLC Rf = 0.34 
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(10% ethyl acetate/90% hexanes); IR (thin film) 3404, 3062, 3028, 2936, 2838, 1714, 1601 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.0 Hz, 1H), 7.37-7.20 (m, 7H), 7.01 (t, J = 7.6 Hz, 
1H), 6.96 (d, J = 8.0 Hz, 1H), 6.28 (d, J = 8.8 Hz, 1H), 3.80 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 161.0, 157.1, 140.1, 129.8, 129.6, 128.5, 127.4, 127.1, 126.4, 121.2, 111.7, 93.1, 56.8, 
55.6; Anal. Calcd for C16H14Cl3NO2: C, 53.58; H, 3.93; N, 3.91; Found: C, 53.86; H, 3.83; N, 
3.83. 
 
2,2,2-Trichloro-N-((4-nitrophenyl)(phenyl)methyl)acetimidate (3.53). Prepared using the  
general procedure for synthesis of trichloroacetimidates and purified using silica gel 
chromatography (10% hexanes/88% toluene/2% triethylamine). White solid (1.34 g, 86%); mp = 
89-93 °C; TLC Rf = 0.62 (30% ethyl acetate/ 70% hexanes); IR (thin film) 3339, 3039, 1667, 
1606, 1523 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.50 (br s, 1H), 8.21 (d, J = 8.8 Hz, 2H), 7.62 
(d, J = 8.8 Hz, 2H), 7.43-7.32 (m, 5H), 7.00 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 161.0, 
147.6, 146.9, 138.3, 128.9, 128.7, 127.6, 127.1, 123.9, 91.2, 80.3; Anal. Calcd for 
C15H11Cl3N2O3: C, 48.22; H, 2.97; N, 7.50; Found: C, 48.09; H, 2.97; N, 7.33. 
 
2,2,2-Trichloro-N-((4-nitrophenyl)(phenyl)methyl)acetamide (3.54). Prepared using method 
A (0.149 g, 74%) and method B (0.088 g, 88%), purified using silica gel chromatography (10% 
ethyl acetate/90% hexanes). White solid; mp = 145-148 °C; TLC Rf = 0.29 (20% ethyl acetate/ 
80% hexanes); IR (thin film) 3280, 3064, 1702, 1606 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.22 
(d, J = 8.8 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.43-7.36 (m, 3H), 7.26-7.22 (m, 3H), 6.22 (d, J = 
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7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 161.2, 147.6, 146.9, 138.4, 129.5, 129.0, 127.9, 
127.6, 124.2, 92.2, 58.7; Anal. Calcd for C15H11Cl3N2O3: C, 48.22; H, 2.97; N, 7.50; Found: C, 
48.23; H, 3.07; N, 7.49. 
 
2,2,2-Trichloro-N-(1-phenylpentyl)acetimidate (3.55). Prepared using the  general procedure 
for synthesis of trichloroacetimidates and purified using silica gel chromatography (8% ethyl 
acetate/90% hexanes/2% triethylamine). Yellow oil (1.69 g, 96%); TLC Rf = 0.71 (10% ethyl 
acetate/90% hexanes); IR (thin film) 3348, 3092, 3069, 3036, 2958, 2934, 2863, 1659 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.23 (br s, 1H), 7.41-7.27 (m, 5H), 5.81 (q, J = 5.6 Hz, 1H), 2.09-
2.00 (m, 1H), 1.89-1.80 (m, 1H), 1.50-1.41 (m, 1H), 1.38-1.30 (m, 3H), 0.89 (t, J = 6.8 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 161.7, 140.6, 128.4, 127.9, 126.2, 91.9, 81.0, 36.7, 27.7, 22.5, 
14.1; Anal. Calcd for C13H16Cl3NO: C, 50.59; H, 5.23; N, 4.54; Found: C, 50.32; H, 5.36; N, 
4.42. 
 
2,2,2-Trichloro-N-(1-phenylpentyl)acetamide (3.56). Prepared using method A (0.19 g, 63%) 
and method B (0.084 g, 56%), purified using silica gel chromatography (5% ethyl acetate/95% 
hexanes). White solid; mp = 57-61 °C; TLC Rf = 0.49 (10% ethyl acetate/90% hexanes); IR (thin 
film) 3431, 3067, 3033, 2957, 2931, 2861, 1698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.40-7.29 
(m, 5H), 6.81 (br s, 1H), 4.90 (q, J = 7.6 Hz, 1H), 1.94-1.87 (m, 2H), 1.39-1.24 (m, 4H), 0.89 (t, 
J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 161.1, 140.7, 128.9, 127.9, 126.5, 92.9, 55.8, 
35.6, 28.3, 22.4, 14.0; Anal. Calcd for C13H16Cl3NO: C, 50.59; H, 5.23; N, 4.54; Found: C, 
50.49; H, 5.18; N, 4.79. 
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2,2,2-Trichloro-N-(2-methyl-1-phenylpropyl)acetimidate (3.57). Prepared using the  general 
procedure for synthesis of trichloroacetimidates and purified using silica gel chromatography 
(5% ethyl acetate/93% hexanes/2% triethylamine). Colorless oil (3.01 g, 86%); TLC Rf = 0.63 
(10% ethyl acetate/ 90% hexanes); IR (thin film) 3339, 3088, 3062, 3032, 2979, 2961, 2925, 
2868, 1660 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.23 (br s, 1H), 7.41-7.28 (m, 5H), 5.57 (d, J = 
7.2 Hz, 1H), 2.29-2.17 (m, 1H), 1.10 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 161.7, 139.1, 128.2, 127.9, 126.9, 92.0, 85.8, 34.4, 19.0, 18.4; Anal. Calcd 
for C12H14Cl3NO: C, 48.92; H, 4.79; N, 4.75; Found: C, 48.72; H, 4.42; N, 4.64. 
 
2,2,2-Trichloro-N-(2-methyl-1-phenylpropyl)acetamide (3.58). Prepared using method A 
(0.049 g, 16%) and method B (0.062 g, 41%), purified using silica gel chromatography (1% ethyl 
acetate/99% toluene). White solid; mp = 78-82 °C; TLC Rf = 0.38 (10% ethyl acetate/ 90% 
hexanes); IR (thin film) 3338, 3066, 3033, 2963, 2934, 2873, 1693, 1515 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.38-7.34 (m, 2H), 7.31-7.24 (m, 3H), 6.96 (d, J = 6.8 Hz, 1H), 4.69 (t, J = 8.4 
Hz, 1H), 2.23-2.11 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 161.1, 139.7, 128.7, 127.8, 126.7, 93.0, 61.4, 33.6, 19.7, 18.5; Anal. Calcd for 
C12H14Cl3NO: C, 48.92; H, 4.79; N, 4.75; Found: C, 48.96; H, 4.86; N, 4.87. 
 
2,2,2-Trichloro-N-(2,3-dihydro-1H-inden-3-yl)acetimidate (3.59). Prepared using the  general 
procedure for synthesis of trichloroacetimidates and purified using silica gel chromatography 
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(10% ethyl acetate/89% hexanes/1% triethylamine). Clear colorless oil (0.73 g, 86%); TLC Rf = 
0.85 (10% ethyl acetate/90% hexanes); IR (thin film) 3340, 3028, 2943, 2852, 1660 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.39 (s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.34-7.22 (m, 3H), 6.35 (q, J = 
2.8 Hz, 1H), 3.19-3.11 (m, 1H), 2.96-2.89 (m, 1H), 2.67-2.58 (m, 1H), 2.27-2.19 (m, 1H); 13C 
NMR (100 MHz, CDCl3) δ 162.8, 144.5, 140.6, 129.2, 126.8, 125.7, 124.9, 91.9, 83.3, 32.0, 
30.2; Anal. Calcd for C11H10Cl3NO: C, 47.43; H, 3.62; N, 5.03; Found: C, 47.15; H, 3.95; N, 
5.27. 
 
2,2,2-Trichloro-N-(2,3-dihydro-1H-inden-3-yl)acetamide (3.60). Prepared using method A 
(0.072 g, 72%) and method B (0.074 g, 74%), purified using silica gel chromatography (5% ethyl 
acetate/94% hexanes/1% triethylamine). White solid; mp = 86-89 °C; TLC Rf = 0.51 (10% ethyl 
acetate/90% hexanes); IR (thin film) 3319, 3024, 2944, 2850, 1692, 1518 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.26-7.16 (m, 4H), 6.74 (s, 1H), 5.39 (q, J = 7.6 Hz, 1H), 3.02-2.95 (m, 1H), 
2.91-2.83 (m, 1H), 2.66-2.58 (m, 1H), 1.91-1.82 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 161.8, 
143.5, 141.5, 128.7, 127.2, 125.1, 124.0, 92.7, 56.8, 33.4, 30.3; Anal. Calcd for C11H10Cl3NO: C, 
47.43; H, 3.62; N, 5.03; Found: C, 47.09; H, 3.90; N, 4.95. 
 
2,2,2-Trichloro-N-(1,2,3,4-tetrahydronaphthalen-4-yl)acetamide (3.62). Prepared using 
method A (0.13 g, 60%) and method B (0.11 g, 70%), purified using silica gel chromatography 
(10% ethyl acetate/89% hexanes/1% triethylamine). White solid; mp = 129-130 °C; TLC Rf = 
0.33 (10% ethyl acetate/90% hexanes); IR (thin film) 3285, 3057, 2920, 2864, 1691, 1536 cm-1; 
111 
 
1H NMR (400 MHz, CDCl3) δ 7.28-7.14 (m, 4H), 6.80 (br s, 1H), 5.17-5.12 ( m, 1H), 2.90-2.76 
(m, 2H), 2.18-2.10 (m, 1H), 1.96-1.84 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 161.3, 137.7, 
134.9, 129.5, 128.5, 128.0, 126.7, 92.9, 49.9, 29.4, 29.1, 19.9; Anal. Calcd for C12H12Cl3NO: C, 
49.26; H, 4.13; N, 4.79; Found: C, 48.97; H, 4.13; N, 4.86. 
 
2,2,2-Trichloro-N-(1-methyl-2-oxo-3-phenylindolin-3-yl)acetamide (3.64). Prepared using 
method A (0.047 g, 47%), purified using silica gel chromatography (20% ethyl acetate/88% 
hexanes/2% triethylamine). White solid; mp = 197-205 °C; TLC Rf = 0.21 (20% ethyl 
acetate/80% hexanes); 1H NMR (400 MHz, CDCl3) δ 7.39-7.31 (m, 8H), 7.11 (td, J = 7.6, 0.8 
Hz, 1H), 6.87 (d, 7.6 Hz, 1H), 3.17 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.6, 160.5, 144.6, 
136.5, 130.2, 129.5, 129.3,  127.2, 126.7, 124.8, 123.2, 108.9, 91.8, 65.1, 27.0; Anal. Calcd for 
C17H13Cl3N2O2: C, 53.22; H, 3.42; N, 7.30; Found: C, 53.40; H, 3.43; N, 7.28. 
 
2,2,2-Trichloro-N-((1,3-dioxoisoindolin-2-yl)methyl)acetamide (3.66). Prepared using a 
modified method B (0.058 g, 29%) where the reaction was performed with 10 mol % BF3•OEt2 
at rt for 48 h, purified using silica gel chromatography (1% ethyl acetate/99% dichloromethane). 
White solid; mp = 218-223 °C; TLC Rf = 0.71 (2% ethyl acetate/ 98% dichloromethane); IR 
(thin film) 3317, 3123, 1709, 1514 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.93-7.89 (m, 2H), 7.80-
7.76 (m, 2H), 7.52 (br s, 1H), 5.31 (d, J = 6.4 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 167.1, 
161.6, 134.6, 131.7, 123.9, 92.0, 44.0; Anal. Calcd for C11H7Cl3N2O3: C, 41.09; H, 2.19; N, 8.71; 
Found: C, 41.04; H, 2.21; N, 8.74. 
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N-((2S,3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-((benzyloxy)methyl)-tetrahydro-2H-pyran-2-
yl)-2,2,2-trichloroacetamide (3.68a) and N-((2R,3R,4S,5R,6R)-3,4,5-Tris(benzyloxy)-6-
((benzyloxy)methyl)-tetrahydro-2H-pyran-2-yl)-2,2,2-trichloroacetamide (3.68b). 
Rearrangement of imidate 47 using method A provided 3.68a (0.040 g, 21%) and 3.68b (0.040g, 
21%) after purification with silica gel chromatography (10% ethyl acetate/90% hexanes). This 
rearrangement was also successful with method B, providing 3.68a (0.047 g, 47%) and 3.68b 
(0.020g, 20%) after purification with silica gel chromatography (10% ethyl acetate/90% 
hexanes). 
 
3.68a.85 Colorless oil (0.04 g, 21%); TLC Rf = 0.38 (20% ethyl acetate/80% hexanes); 
1H NMR 
(400 MHz, CDCl3) δ 7.33-7.24 (m, 19H), 7.15-7.12 (m, 2H), 5.60 (t, J = 5.6 Hz, 1H), 4.91 (d, J 
= 10.8 Hz, 1H), 4.79 (t, J = 11.2 Hz, 2H), 4.65-4.57 (m, 3H), 4.54-4.47 (m, 2H), 3.89-3.86 (m, 
1H), 3.80-3.76 (m, 2H), 3.69-3.64 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 162.2, 138.2, 137.9, 
137.8, 136.9, 128.7, 128.51, 128.50, 128.43, 128.39, 128.2, 128.1, 128.04, 127.98, 127.9, 127.8, 
92.4, 81.6, 77.0, 76.5, 75.5, 75.2, 73.6, 73.0, 71.9, 68.1. 
 
3.68b.85 White solid (0.04 g, 21%); mp = 121-126 °C; TLC Rf = 0.32 (20% ethyl acetate/80% 
hexanes); IR (thin film) 3325, 3064, 3031, 2924, 2858, 1706, 1520 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.37-7.25 (m, 18H), 7.14-7.12 (m, 2H), 6.98 (d, J = 8.8 Hz, 1H), 5.08 (t, J = 9.2 Hz, 
1H), 4.89 (s, 2H), 4.83-72 (m, 3H), 4.61 (d, J = 12.4 Hz, 1H), 4.51 (dd, J = 20.4, 10.8 Hz, 2H), 
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3.80-3.69 (m, 4H), 3.56-3.46 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 161.7, 138.2, 137.9, 137.6, 
137.4, 128.7, 128.52, 128.47, 128.46, 128.44, 128.2, 128.1, 127.90, 127.85, 92.2, 85.8, 81.0, 
79.8, 77.3, 76.9, 75.7, 75.0, 74.8, 73.6, 67.9; Anal. Calcd for C36H36Cl3NO6: C, 63.12; H, 5.30; 
N, 2.04; Found: C, 63.19; H, 5.37; N, 2.06. 
 
N-tert-Butyl-2,2,2-trichloroacetamide (3.70).88 Pink solid (0.012 g, 8%); TLC Rf = 0.40 (15% 
ethyl acetate/ 85% hexanes); 1H NMR (400 MHz, CDCl3) δ 6.48 (br s, 1H), 1.43 (s, 9H); 
13C 
NMR (100 MHz, CDCl3) δ 160.4, 93.3, 53.0, 28.1. 
 
1-(1-(Benzo[d][1,3]dioxol-6-yl)ethyl)-3-benzylurea (3.83). To a solution of 3.28 (50.0 g, 0.16 
mmol) in 0.6 mL DMF, Cs2CO3 (0.30 g, 0.96 mmol) and benzylamine (0.10 g, 0.96 mmol) were 
added and the resulting mixture was stirred at room temperature for 18 h. The mixture was then 
diluted with saturated sodium bicarbonate solution and dichloromethane (5 mL each). The 
organic layer was separated and the aqueous was extracted with dichloromethane (2 x 5 mL). 
The combined organic layers were dried over sodium sulfate and then filtered and concentrated 
to provide crude urea 3.83. The crude residue was then purified by silica gel chromatography 
(5% ethyl acetate/ 95% dichloromethane) to provide the pure urea 3.83 (0.079 g, 82%) as a white 
solid. 
mp = 143-147 °C; TLC Rf = 0.24 (40% ethyl acetate/60% toluene); IR (thin film) 3341, 3317, 
3031, 2969, 2872, 1618, 1572 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31-7.22 (m, 4H), 7.17 (d, J 
= 6.8 Hz, 2H), 6.78-6.74 (m, 3H), 5.93 (s, 2H), 4.68 (q, J = 6.8 Hz, 1H), 4.36-4.27 (m, 2H), 5.04-
3.96 (br s, 1H), 1.40 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 157.5, 148.1, 146.8, 
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138.9, 138.0, 128.6, 127.3, 119.0, 108.4, 106.4, 101.1, 77.2, 50.4, 44.5, 23.5; Anal. Calcd for 
C17H18N2O3: C, 68.44; H, 6.08; N, 9.39; Found: C, 68.21; H, 5.88; N, 9.42. 
 
Methyl 1-(benzo[d][1,3]dioxol-6-yl)ethylcarbamate (3.84). To a solution of 3.28 (0.050 g, 
0.16 mmol) in 0.5 mL methanol, sodium methoxide (0.086 g, 1.60 mmol) was added and the 
resulting mixture was stirred at reflux for 1 h. The mixture was then cooled to room temperature 
and was partitioned between dichloromethane and water (5 mL each). The organic layer was 
separated and the aqueous was extracted with dichloromethane (2 x 5 mL). The combined 
organic layers were dried over sodium sulfate and then filtered and concentrated to provide crude 
carbamate 3.84. The crude residue was then purified by silica gel chromatography (5% ethyl 
acetate/ 95% dichloromethane) to provide the pure carbamate 3.84 (0.025 g, 70%) as a colorless 
oil. TLC Rf = 0.23 (20% ethyl acetate/80% hexanes); IR (thin film) 3324, 2974, 2897, 1703, 
1504 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.79-6.74 (m, 3H), 5.94 (s, 2H), 4.91 (br s, 1H), 4.74 
(br s, 1H), 3.65 (s, 3H), 1.44 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 156.2, 147.8, 
146.7, 137.7, 119.1, 108.3, 106.6, 101.0, 52.1, 50.5, 22.5; Anal. Calcd for C11H13NO4: C, 59.19; 
H, 5.87; N, 6.27; Found: C, 59.10; H, 5.91; N, 6.35. 
 
1-(Benzo[d][1,3]dioxol-6-yl)ethanamine (3.85).89 To the solution of amide 3.28 (0.10 g, 0.32 
mmol) in 2.1 mL methanol, solution of sodium hydroxide (0.051 g in 0.5 mL water) was added 
and the reaction mixture was heated to reflux for 18 h. Then the mixture was cooled to room 
temperature and concentrated. The residue was partitioned between 10 mL water and 5 mL 
DCM. The organic layer was separated and the aqueous layer was extracted with DCM twice (2 
115 
 
x 5 mL). The combined organic layers were dried over sodium sulfate and then filtered and 
concentrated to provide crude amine 3.85. The crude residue was then purified by silica gel 
chromatography (1% triethylamine/ 2% methanol/ 97% dichloromethane) to provide the pure 
amine 3.85 (0.031 g, 58%). 1H NMR (400 MHz, CDCl3) δ 6.89 (d, J = 1.6 Hz, 1H), 6.82-6.74 
(m, 2H), 5.94 (s, 2H), 4.09 (q, J  = 6.8 Hz, 1H), 2.86 (br s, 2H), 1.39 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 147.8, 146.4, 141.1, 118.9, 108.1, 106.4, 100.9, 51.2, 25.3. 
Procedure for attempted asymmetric rearrangement of 3.51. 
To the imidate 3.51 (1.0 equiv.) dissolved in 4 mL of anhydrous DCM, the catalyst (0.1 equiv.) 
was added followed by the addition of dinitro benzene sulfonic acid (DNBSA) (0.08 equiv.). The 
reaction mixture was stirred at rt until completion by thin layer chromatography. After 
completion the mixture was diluted with DCM and the organic layer was washed with 10 mL of 
1M sodium hydroxide solution twice. The organic layer was then dried over sodium sulfate, 
filtered and concentrated to provide crude 3.52 that was then purified as reported before. 
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Chapter 4 – Trichloroacetimidates in the Synthesis of Pyrroloindolines 
 
Abstract 
 The pyrroloindoline unit forms the core structure of a large class of natural products 
possessing diverse biological activity. The C3a position of the pyrroloindoline is the most 
common point of diversity in these structures, and this position may be substituted with oxygen, 
nitrogen, sp3 or sp2 hybridized carbon atoms. Utilizing a trichloroacetimidate as a leaving group, 
a diversity-oriented approach to synthesize these structures has been developed. An efficient 
route to the desired C3a-trichloroacetimidate pyrroloindoline has been established and the 
reactivity of this intermediate was explored using a variety of nucleophiles. This 
trichloroacetimidate underwent facile displacement with a variety of nitrogen, oxygen, sulfur and 
carbon nucleophiles in the presence of a catalytic amount of a Lewis acid. The utility of this 
method has been demonstrated by accomplishing a formal synthesis of psychotriasine and the 
first total synthesis of arundinine. Currently this technology is being utilized in the synthesis of 
kapakahine C, a structurally related complex natural product. 
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4.1 Introduction 
4.1.1 Pyrroloindoline Containing Natural Products 
 The Hexahydropyrrolo[2,3-b]indole (HPI) unit (also known as a pyrroloindoline) is a 
common subunit in a large number of natural products.1-3 Alkaloids of this type have been 
isolated from both marine and terrestrial sources and exhibit a wide range of biological activity, 
but their low abundance has typically restricted further evaluation of their activities.4-7 Most 
pyrroloindoline natural products differ significantly in the substitution pattern at the C3a position 
which may be an aliphatic sp3 hybridized carbon (like in flustramine B (4.1)8 and neoxaline 
(4.2)9), an aromatic sp2 hybridized carbon (like in naseseazine A (4.3)10), a heteroaromatic 
substituent like the nitrogen of an indole or indoline (as in kapakahine C (4.4)11 and 
psychotriasine (4.5)12) or an oxygen atom (like in arundinine (4.6)13). These alkaloids have 
become popular targets for total synthesis due to their complex and intriguing architecture, low 
natural abundance and the promising bioactivity offered by these systems. The last few decades 
has seen development of several innovative strategies to provide these natural products in an 
expedited fashion. 
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Figure 4.1. Selected Pyrroloindoline Natural Products 
4.1.2 Known Strategies to Synthesize C3a Substituted Pyrroloindolines 
Several reported syntheses of pyrroloindoline natural products involve long linear 
sequences that are difficult to adapt to a diversity-oriented synthesis.14-16 Given the interest in 
these molecules, more rapid methods were developed to access HPI containing systems. These 
methods focus on single step alkylation-oxidative coupling cascade reactions (Scheme 4.1). For 
example, Baran and co-workers reported oxidative coupling of tryptamine derivative 4.7 with o-
iodoaniline in the presence of NIS as an oxidant to provide the C3a substituted aniline 4.9 in a 
single step (Scheme 4.1, eq. 1).17-18 Such intermediates were utilized to complete the synthesis of 
complex pyrroloindoline alkaloids like pyschotrimine, psychotetramine and kapakahines B and 
F. Reisman and co-workers demonstrated a copper catalyzed direct arylation of tryptamine 4.10 
using aryliodonium tetrafluoroborates like 4.11 to provide C3a-arylated pyrroloindolines like 
4.12 (Scheme 4.1, eq. 2).19 This strategy was restricted to aromatic electrophiles and mostly 
provided low yields of the cyclized product due to significant amounts of direct C-2 arylation of 
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the tryptamine, which was a competing reaction. Nucleophilic substitutions via sulfonium ion 
formation at the C3a position have also been evaluated to incorporate various anilines at the C3a 
position (Scheme 4.1, eq. 3).20-21  
Scheme 4.1. One Step Oxidative Coupling Reactions 
 
Given that these natural products often differ in the group at the C3a position, recent 
approaches have focused on utilizing a common hexahydropyrrolo[2,3-b]indole (HPI) subunit 
thereby facilitating the synthesis of diverse analogs. Danishefsky and co-workers first explored 
this type of route, employing the C3a-selenide 4.16 for accessing C3a-allylic compounds like 
4.18 (Scheme 4.2).22-27  
Scheme 4.2. Displacement of a C3a Selenide 
 
The use of a C3a pyrroloindoline bromide has become a popular choice for diversity-
oriented synthesis of these types of alkaloids. Some of the initial studies on using C3a-bromides 
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as leaving groups were reported by Rainier and co-workers (Scheme 4.3, eq. 1).15, 28-29 The C3a-
bromide 4.19 was synthesized from its tryptophan precursor using N-bromosuccinimide. This 
bromide was shown to undergo displacement with indole derivatives (like simple indole (4.20)) 
under basic conditions to provide the N-alkylated compounds like 4.21. However these reactions 
suffered from epimerization of the methyl ester to the thermodynamically favored endo isomer 
4.21, providing a mixture of diastereomers. The observed epimerization was rationalized to be 
arising from the formation of the cyclopropylazetoindoline intermediate 4.23, which resulted 
from the intramolecular displacement of the bromide by the enolate of the pendant ester. These 
reactions did not yield any alkylated product in the absence of the methyl ester substituent, 
stressing the need of the formation of the azetidine.15, 28-30 Nevertheless these studies 
demonstrated an excellent strategy to access pyrroloindolines derived from tryptophan. A 
number of other advances have been made in the displacement of C3a-bromides in systems 
without esters, including using ionic liquids31 or photoredox catalysis32 to incorporate various 
substituents at the C3a position.33 One of the most flexible examples was demonstrated by 
Movassaghi and co-workers wherein the bromide was displacement in the presence of silver salts 
(Scheme 4.3, eq. 2).7, 10, 34-37 The boron trifluoroborane nucleophile controls the regioselectivity 
in cases which involve alkylation of aromatic systems like 4.25. This methodology was utilized 
for the synthesis of natural products like naseseazine A (4.3). These conditions do not require the 
presence of a nearby methyl ester and have a broader substrate scope. The C3a-bromides have 
also undergone substitution under single electron transfer conditions.38-40 
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Scheme 4.3. Displacement of C3a-Bromides towards Synthesis of Natural Products 
 
Methods utilizing bromides provide a useful diversity oriented strategy for the synthesis 
of pyrroloindoline natural products, but they still depend on the use of stoichiometric amounts of 
expensive silver reagents and/or exhibit limited substrate scope. Hence an efficient alternative 
that employs milder conditions, generates fewer waste products and provides facile access to 
different functionalities at the C3a position is still desirable.  
4.1.3 C3a-Trichloroacetimidate Pyrroloindolines to Access HPI Systems 
Our recent success in the substitution of trichloroacetimidates with oxygen, sulfur and 
nitrogen nucleophiles (Scheme 4.4),41-45 led to the hypothesis that a C3a-trichloroacetimidate 
group could also be displaced with a similar variety of nucleophiles to provide a diversity 
oriented strategy for the synthesis of HPI containing systems.  
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Scheme 4.4. Recent Examples from Chisholm Group 
 
This hypothesis was further supported by a recent example from Sunazuka’s group. 
These researchers demonstrated that a C3a-hydroxyfuroindoline trichloroacetimidate could be 
displaced by prenyltin in the presence of a Lewis acid catalyst.46-47 This methodology was then 
utilized in the synthesis of neoxaline. A similar route in an HPI system (like 4.38) may provide 
rapid access to HPI systems under mild, Lewis-acid catalyzed conditions. 
Scheme 4.5. Sunazuka’s Approach and Proposed Diversity Oriented Strategy 
 
The first hurdle that had to be overcome was to establish a short and direct route for the 
synthesis of C3a-hydroxylated pyrroloindoline, the necessary precursor to the 
trichloroacetimidate 4.38. Fortunately due to the presence of several biologically active C3a-
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hydroxy pyrroloindoline natural products like protubonine A48, madindolines A49, chloptosin50 
and the okramines27, several procedures to install the hydroxyl group at the C3a position have 
been reported in literature.  
4.1.4 Reported Routes to Synthesize C3a-Hydroxypyrroloindolines 
One of the earliest examples for installing a C3a-hydroxyl group in an HPI system was 
reported by Danishefsky and co-workers.51-53 The tryptophan isomers 4.41 and 4.42 were 
converted into the C3a-hydroxyl diastereomers 4.40 and 4.43 using DMDO over several steps. 
The steric bulk of the protecting groups also played a significant role in accessing the 
diastereomers in high selectivity. Crich and co-workers also described a route to HPI 4.45 using 
H3PO4 under equilibrating conditions.
4, 39 Benzylic oxidation of 4.45 using ceric ammonium 
nitrate provided the C3a-hydroxylated compound 4.46 along with the nitrate ester 4.47. More 
recently Ley and co-workers reported a high yielding two-step sequence involving N-PSP (4.49) 
mediated selenocyclization to provide the selenide 4.50 followed by oxidative deselenation to 
afford the alcohol 4.51.26-27, 50 In addition several other methods have also been reported to 
synthesize C3a-hydroxy pyrroloindolines.48-49, 54-62 Perhaps the most rapid access to C3a-
hydroxylated HPI systems was reported by Takayama and co-workers. This one step oxidative 
cyclization of a protected tryptamine provided C3a-hydroxyl compound 4.53 in high yields using 
a mixture of m-CPBA and TFA.63 With a diversity oriented strategy in mind we incorporated 
Takayama’s approach to rapidly access the starting material necessary to explore the use of the 
trichloroacetimidate leaving group in HPI synthesis. 
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Scheme 4.6. Synthesis of C3a-Hydroxypyrroloindolines 
 
 
4.2 Results and Discussion 
4.2.1 Synthesis of the C3a-Trichloroacetimidate Pyrroloindoline Core 
Initially Ley’s two-step selenocyclization-oxidative deselenation method for the synthesis 
of the desired HPI C3a-alcohol was investigated (Scheme 4.7). The tryptamine amine was first 
converted into its methyl carbamate. The indole nitrogen was then protected with carboxybenzyl 
chloride (Cbz-Cl) to provide 4.55. The two different protecting groups provide an added 
advantage by enabling an easy means to differentiate between the two nitrogens in the desired 
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product. Indole 4.55 was then subjected to Ley’s conditions using N-(phenylseleno)phthalimide 
(N-PSP) that provided the selenide. This selenide was then used in an oxidative deselenation 
with excess of m-CPBA to provide the C3a-alcohol 4.56 in a 45% yield over the two steps. The 
alcohol 4.56 was then subjected to standard imidation conditions to provide the imidate 4.57 in 
good yields. Overall the sequence provided the imidate 4.57 in 5 steps and an overall yield of 
17%. 
Scheme 4.7. Synthesis of C3a-Trichloroacetimidate 4.57 using Ley’s Conditions 
 
In addition the N-PSP reagent itself also had to be synthesized from the rather expensive 
phenylselenyl chloride and potassium phthalimide adding another step to the sequence. 
Considering that we were not initially planning for enantioselective access to the imidate 4.57 
(which could be obtained from tryptophan using these conditions via decarboxylation after 
cyclization),4, 38 use of such specialized reagent seemed redundant and also rendered the 
synthesis of the imidate 4.57 long and laborious, which is not ideal for a diversity oriented 
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strategy. This drove our search for conditions that provide a more direct access to 4.56 without 
the use of any specialized reagents. Takayama’s one step oxidative cyclization using m-CPBA 
and TFA seemed to meet our requirements. However due to the lack of detailed procedure in the 
original report, the conditions to provide the alcohol 4.56 were optimized (Table 4.1). Upon 
subjecting the bis-protected tryptamine 4.55 to the oxidation conditions it was found that the 
oxindole product 4.60 was formed as the major product. The desired alcohol 4.56 was obtained 
with a best yield of only 30% after some optimization of these conditions. The low yield was 
attributed to the electron withdrawing carboxybenzyl (Cbz) group in 4.55, which favored 
opening of the epoxide to favor the C3 cation. 
Table 4.1. Initial Optimization of Oxidative Cyclization using Tryptamine 4.55 
 
NMR yields were obtained using mesitylene as a internal standard 
 
Alternatively when tryptamine 4.7 with the free indole nitrogen (Table 4.2) was subjected 
to these conditions a drastic change in the major reaction product was observed, providing the 
desired alcohol 4.61 as the major product and the corresponding oxindole as a minor side 
product. Optimization of these conditions eventually provided the alcohol 4.61 with a 
satisfactory yield of 59% (entry 6) using 2.0 equiv of m-CPBA and 8.0 equiv of TFA. 
Performing the reaction at room temperature and reducing the amount of TFA seemed to be 
detrimental. The use of N-Me tryptamine, which is similar to Takayama’s tryptamine (which was 
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reported to provide 92% yield of the C3a-alcohol), was forgone since the use of Cbz group 
provides more flexibility in terms of derivatization of the targets with the majority of 
pyrroloindoline compounds possessing a free indoline nitrogen atom. 
Table 4.2. Optimization of Oxidative Cyclization using Tryptamine 4.18 
 
All reactions were run at 0.25M concentration 
NMR yields were obtained using mesitylene as a internal standard 
 
With optimized conditions to obtain C3a-alcohol 4.61 established, the alcohol 4.61 was 
then Cbz protected to provide the alcohol 4.56. This alcohol was then converted into the C3a-
imidate 4.57 (Scheme 4.8). The modified sequence now provided the imidate 4.57 in only 4 steps 
with an overall yield of 32% without the need of any specialized reagent, a significant 
improvement from the previous conditions. 
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Scheme 4.8. Synthesis of C3a-Trichloroacetimidate Pyrroloindoline 4.57 
 
 
4.2.2 Optimization of the Displacement of C3a-Trichloroacetimidate Pyrroloindoline 
With the synthesis of the C3a-Trichloroacetimidate 4.57 established, the displacement of  
the imidate with a nucleophile was investigated (Table 4.3). 4-Bromophenol (4.62) was used as 
the nucleophile for the optimization since it could serve as a model to accomplish the synthesis 
of arundinine (4.6), and this molecule has an ethereal linkage at the C3a position. Utilizing 
Brønsted acid catalysts like CSA, the ether product 4.63 was obtained with a promising yield of 
63% although the reaction took 24 h to proceed to completion. In an attempt to shorten the 
reaction time, the reaction was heated to reflux and was found to be complete in 1 h with an 
improved yield. Using a stronger Brønsted acid like TfOH the reaction was complete in just 15 
min. However the strongly acidic nature of TfOH provided more side products as observed in the 
crude 1H NMR. Switching to Lewis acids like Cu(OTf)2 provided the product in 15 min and in 
good yields. BF3•OEt2 also provided the product in same amount of time with a slightly higher 
efficiency rendering BF3•OEt2 as the best catalyst (entry 5). Other solvents were also evaluated 
but they proved to be less effective and provided lower yields of the product. 
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Table 4.3. Optimization for the Displacement of C3a-Trichloroacetimidate 
 
4.2.3 Scope of Nucleophile for Substitutions with the C3a-Trichloroacetimidate 
Pyrroloindoline 
With the substitution conditions optimized, a variety of oxygen, sulfur and carbon based 
nucleophiles were evaluated with 4.57. Electron poor phenols were found to be excellent 
nucleophiles and provided the substituted products in high yield. Electron rich phenols (like 4.66 
and 4.67) provided a more moderate yield due to competing Friedel-Crafts alkylation reactions. 
Aliphatic alcohols participated well and provided the substituted products (4.68-4.71) in very 
high yields. Even sterically hindered alcohols performed well, as shown by the formation of 
ether 4.71 in high yields. Overall oxygen nucleophiles were found to be excellent reaction 
partners, providing good yields of the corresponding ether products. 
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Scheme 4.9. Addition of Oxygen Nucleophiles to Imidate 4.57 
 
a
Approximately 33% of Friedel-Crafts products was seen in the crude 1H NMR. 
Thiols were also evaluated as nucleophiles (Scheme 4.10). Both 1-phenyl-1H-tetrazole-5-
thiol and 2-mercaptobenzthiazole were found to provide the corresponding thioethers 4.72 and 
4.73 in high yields. Due to the wide distribution of aryl, allyl and prenyl groups at the C3a 
position in HPI natural products the reactivity of carbon nucleophiles towards substitution was 
also investigated (Scheme 4.10). Dimethoxy benzene provided the Friedel-Crafts alkylated 
product 4.74 in high yield. Allyl trimethylsilane was used as a source of carbon nucleophile that 
provided the allylated species 4.75 with high yields, but required more forcing conditions. 
Similarly prenyltributyltin was also used as a source of carbon nucleophile. Under forcing 
conditions the reverse prenylated product 4.76 was isolated in a moderate yield (48%). The lower 
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conversion observed from this reaction was attributed to sterics, arising from the formation of the 
new carbon-carbon bond between two all carbon quaternary centers. These two examples (4.75 
& 4.76) which provide allyl and reverse prenyl substituents at the C3a position demonstrate the 
ability of this method to provide access to substrates that are analogous to natural products like 
flustramine B (4.1), neoxaline (4.2) and several others. 
Scheme 4.10. Addition of Sulfur and Carbon Nucleophiles to Imidate 4.57 
 
a
Allyl tributyltin used as the nucleophile and reaction refluxed for 2 h; 
b
Prenyltributyltin used as 
nucleophile and reaction refluxed for 2 h. 
 
The use of anilines as nitrogen nucleophiles was also evaluated (Scheme 4.11). As 
observed with the phenols, electron poor systems provided the N-alkylated products (4.77-4.80) 
with very high yields. Electron rich anilines provided more moderate yields due to competing 
Friedel-Crafts alkylation side reactions (examples 4.81 & 4.82). Substrate 4.82 was also of 
interest since a very similar molecule was utilized to complete a synthesis of the natural product 
psychotriasine (4.5).18 Optimization of this system showed that an excess of the imidate 4.57 
gave better yields for the displacement, with eventually a 71% yield being achieved (using 
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imidate as limiting reagent 62% yield was obtained). More sterically hindered secondary anilines 
were also evaluated. N-Methylaniline provided the N-alkylated product 4.83 with a lower yield 
of 46%. In addition to N-alkylation, significant amounts of ortho and para substituted Friedel-
Crafts alkylation products were observed. 5-Bromoindoline also provided the N-alkyl product 
4.84 in moderate yield due to significant Friedel-Crafts alkylation at C-7. Blocking the C-7 
position with a bromide provided the product 4.85 with an improved yield (71%).  
Scheme 4.11. Addition of Nitrogen Nucleophiles to Imidate 4.57 
 
a
Reaction was performed at reflux for 30 min. 
b
Some apparent Friedel−Crafts products were observed in the crude 
1H NMR (~20% for 4.81, ~26% for 4.83, ~19% for 4.84). 
c
Excess imidate was used (1.3 equiv). 
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4.2.4 Formal Synthesis of (±)-Psychotriasine 
Psychotriasine was isolated from the leaves of psychotria calocarpa in 2010 by Hao and 
co-workers. Since its discovery several strategies to synthesize this molecule have been 
reported.18, 20-21, 64-65 The established imidate chemistry provides access to pyrroloindoline 4.82 
that is similar to Baran’s intermediate 4.9, which was utilized in the first synthesis of 
psychotriasine (4.5).18 This similarity led us to investigate a formal synthesis of the 
pyschotriasine using the substituted aniline 4.82. Subjecting aniline 4.82 to the reported Larock 
indole synthesis conditions18 using alkyne 4.86 provided the N-alkylated indole 4.87 in a 67% 
yield. Removal of the Cbz protected amine by hydrogenation then gave the penultimate 
pyschotriasine intermediate 4.88, intercepting Baran’s reported route to psychotriasine thereby 
completing a formal synthesis. To avoid this stepwise synthesis and access the coupled product 
4.87 more rapidly, the direct displacement of the imidate with the tryptamine carbamate 4.7 was 
also explored. The previous established conditions with BF3•OEt2 provided a complex mixture of 
products with this nucleophile, and the desired product could not be isolated. The enhanced 
nucleophilicity of the indole carbons coupled with the multiple alkylation sites on both carbon 
and nitrogen made selective N-alkylation challenging. After significant reoptimization, use of the 
weaker Lewis acid Cu(OTf)2 in mesitylene as a solvent resulted in the isolation of the N-
alkylated product with a yield of 25%. While low yielding this route does provide more rapid 
access to the key intermediate 4.87. 
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Scheme 4.12. Formal Synthesis of Psychotriasine 
 
4.2.5 First Total Synthesis of (±)-Arundinine 
In order to further demonstrate the utility of this new method to substituted 
pyrroloindoline systems, the chemistry was also applied in the synthesis of arundinine (4.6). 
Arundinine (4.6) was isolated by Abdullaev and co-workers in 1998 from the roots of the giant 
reed Arundo donax, which was harvested in Uzbekistan.13 Extracts from the roots of this plant 
have been used as a folk medicine with sudorific and diuretic properties. The structure of 
arundinine was established by X-ray diffraction. There has been no reported synthesis of this 
molecule to date. Synthesis of this molecule also provides an opportunity to evaluate the 
unknown biological activity of this molecule.  Retrosynthetically access to this molecule would 
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involve the etherification between the phenol of the serotonin analog 4.89 and the C3a position 
of the pyrroloindoline (Scheme 4.13). The phenol 4.89 was planned to be used as the 
nucleophile, with both tryptamine nitrogens protected as 2-nitrophenylsulfonamides. This 
protecting group was chosen due to the electron withdrawing nature of the nitrophenyl group that 
should deactivate the aromatic system towards Friedel-Crafts type reactions.  
Scheme 4.13. Retrosynthetic Analysis of Arundinine 
 
The synthesis of the phenol 4.89 involved protection of the serotonin 4.90 as the methyl 
carbamate (Scheme 4.14). The methyl carbamate was then reduced to a methyl group with 
LiAlH4 to provide 4.92. The intermediate 4.92 was then bis-nosylated to provide the protected 
serotonin 4.93. The methyl ether was then cleaved using boron tribromide to provide the 
deactivated phenolic nucleophile 4.89.  
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Scheme 4.14. Synthesis of the Phenolic Nucleophile 
 
The imidate 4.57 was treated with the phenol 4.89 under the established BF3•OEt2 
catalyzed conditions that provided the coupled product, but this provided only a low yield of 
17%. These conditions also resulted in the formation of a large number of side products that 
made isolation of the desired compound 4.94 difficult. Subjecting the imidate 4.57 and the 
phenol 4.89 to the milder Cu(OTf)2 catalyst afforded the etherified product with a more 
satisfactory 47% yield, considering the complexity of the nucleophile (Scheme 4.15). The nosyl 
groups were then removed under standard Fukuyama conditions66 followed by the reductive 
amination to provide the dimethylated product 4.95 in 75% yield over two steps. Synthesis of 
arundinine was completed by removal of the Cbz group with hydrogenation followed by 
reduction of the methyl carbamate. The characterization data of the synthetic material matched 
the data reported for the natural product. 
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Scheme 4.15. Synthesis of Arundinine 
 
 In the future the racemic arundinine will be resolved to provide both enantiomers of 
arundinine for biological testing. This will involve converting the racemic arundinine into the 
diastereomeric carbamates A and B using the enantiopure menthyl chloroformate (Scheme 4.16). 
The diastereomers will be then separated by column chromatography, and upon cleavage of the 
chiral carbamate will provide access to both enantiopure forms of arundinine. This enantiopure 
arundinine will be then evaluated for its biological activity. 
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Scheme 4.16. Enantiopure Arundinine Synthesis via Chiral Carbamate 
 
4.2.6 Advances towards the Synthesis of Kapakahine C 
The kapakahines are a family of cyclic peptides isolated from the marine sponge 
Cribrochalina olemda by Schueur and co-workers in the mid 1990’s.11, 67-68 Seven different 
members make up this family of natural products, with subtle differences in their core structure 
or peptide portion differentiating the members of the group (Figure 4.2). Several kapakahines 
showed moderate cytotoxicity against P388 murine leukemia cells, with IC50 values of ~5.0 
µg/mL. This activity coupled with their interesting architecture and low availability has 
prompted synthetic chemists to develop synthetic approaches to these molecules.  
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Figure 4.2. Kapakahine Natural Products 
Baran and co-workers have reported the synthesis of kapakahines B and F utilizing the 
oxidative coupling reactions (Scheme 4.1, eq. 1),18 whereas Rainier and co-workers have 
reported the synthesis of kapakahines E and F via displacement of C3a-bromides (Scheme 4.3, 
eq. 1).15 However no synthetic studies have been reported on kapakahines C and D, the most 
complex members of this family. Unlike the other members, kapakahine C consists of a 
polycyclic core with a pyrroloindoline unit fused through the nitrogen atom to a pyridinoindoline 
at the C3a position. Both these heterocyclic units are then further linked via a pentapeptide 
completing a 24 membered ring system. Preliminary examination of the biological activity of 
these molecules found kapakahine C to exhibit cytotoxic activity against P388 leukemia cells 
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with an IC50 value of 5.0 µg/mL. A study on the synthesis of kapakahine C using the newly 
established trichloroacetimidate chemistry was undertaken to access material for further 
biological evaluation and to test the limits of the new methodology. 
Retrosynthetically kapakahine C was broken into three fragments, the pyrroloindoline 
fragment A (4.100), the pyridinoindoline fragment B (4.101) and the pentapeptide fragment C 
(4.102) (Scheme 4.17). Fragment A could be synthesized using Takayama’s one step oxidative 
cyclization conditions from tryptophan. Alternatively Ley’s conditions using the N-PSP reagent 
are well established to provide the alcohol 4.100 with good yields and diastereoselectivity. 
Fragment B (4.101) was proposed to be synthesized by the oxidative cyclization of the dipeptide 
obtained from the coupling of tryptophan with tyrosine analogous to a procedure reported by 
Evano and co-workers for the synthesis of chaetominine.69 Critical to the synthesis of this 
fragment is the oxidative cyclization step to provide the C3a-hydroxyl group. The pentapeptide 
could be synthesized using Fmoc based solution phase peptide synthesis using the commercially 
available protected amino acids isoleucine, valine and proline.  
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Scheme 4.17. Retrosynthetic Analysis of Kapakahine C 
 
For the synthesis of the fragment A, the protected tryptophan 4.104 was subjected to the 
established m-CPBA/TFA mediated oxidative cyclization conditions to provide the alcohol 4.100 
(Scheme 4.18). These reaction conditions provided a inseparable mixture of the exo and endo 
isomer of 4.100 in a moderate yield of 25%. One current focus involves the optimization of this 
reaction to provide the exo isomer 4.100 as a single diastereomer with higher yield. Ley’s two 
step selenocyclization-oxidative deselenation that is well established to provide the desired exo 
isomer with good yield and selectivity could also be used to access this compound.  
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Scheme 4.18. Synthesis of Fragment A 
 
The first half of the synthesis of fragment B involved the synthesis of the dipeptide 4.109. 
Protected tyrosine (4.106) was obtained by simple protection of the carboxylic acid and amine 
functionality of tyrosine. The phenolic group was then benzyl protected using benzyl bromide to 
provide the benzyl ether 4.107. The coupling partner 4.108 was obtained by phthalimide 
protection of the tryptophan amine. The coupling of tyrosine 4.107 to the tryptophan 4.108 
proved to be challenging due to the ease of racemization of the highly enolizable stereocenter 
next to the phthalimide group in 4.108 that often resulted in the formation of both diastereomers. 
After significant optimization the dipeptide could be obtained with a good yield (65%).70 
Scheme 4.19. Synthesis of the Tyrosine-Tryptophan Dipeptide 4.10970 
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Focus was then shifted towards the synthesis of the more critical C3a-
hydroxypyridinoindoline using oxidative cyclization conditions. Application of the established 
m-CPBA/TFA mediated oxidative cyclization, which was applied for the cyclization of the 
tryptamine 4.7 (Scheme 4.8), resulted in complex mixtures and no product could be isolated. 
Next Danishefsky’s DMDO conditions51 and Deng's copper catalyzed radical cyclization 
conditions48 were investigated, but these conditions also led to complex mixtures and no desired 
product could be isolated. Epimerization of the enolizable stereocenter next to the phthalimide 
group may also be hampering the isolation of the desired product and resulting in complex 
mixtures. Next Evano’s conditions involving NCS and O2, which were used to provide an 
analogous intermediate in the synthesis of chaetominine, were applied to our dipeptide 4.109.69 
After significant optimization these conditions provided the desired C3a-alcohol 4.110 with 38% 
yield and the intermediate pyridoindole 4.111 with 27% yield. In addition to this the reaction 
also provided the diastereomer (S)-4.110 with a 24% yield. The intermediate 4.111 was 
converted into the C3a-alcohol product 4.110 with a 50% yield by simply bubbling oxygen 
through the solution of 4.111 in dichloromethane. 
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Scheme 4.20. Synthesis of C3a-hydroxypyridinoindoline70 
 
Current work in the lab is focused on scaling up the reaction to provide substantial 
quantity of the alcohol 4.110. Then the imine functionality in 4.110 will be converted to the C3a-
hydroxypyridinoindoline utilizing sodium cyanoborohydride as per the reported procedure by 
Evano.69 The alcohol will be then converted into the trichloroacetimidate 4.101 under standard 
imidation conditions thereby completing the synthesis of the fragment B. The fragments A and B 
will be then utilized to generate efficient conditions to provide the adduct 4.113. 
Scheme 4.21. Future Work towards Fragment B 
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 The synthesis of the pentapeptide was achieved using the standard Fmoc based solution 
phase peptide synthesis as per scheme 4.22. This work proceeded without incident and gave the 
peptide 4.119. 
Scheme 4.22. Synthesis of the Pentapeptide (Fragment C) 
 
After all the fragments have been synthesized, the primary approach would be to 
construct the C-N bond between fragments B and A respectively. The tertiary alcohol in 
fragment A may also be alkylated thus requiring it to be protected, and this will be addressed in 
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due course. After building the western side of the molecule the pentapeptide can then be coupled 
to the heterocyclic core using amide formation chemistry followed by deprotection to provide the 
target kapakahine C. 
Scheme 4.23. Planned Completion of Kapakahine C 
 
 
4.3 Conclusions and Future Work 
An effective strategy for the diversity oriented synthesis of HPI systems was established. 
This was based on the use of a C3a-trichloroacetimidate pyrroloindoline, which was readily 
synthesized from tryptamine. The trichloroacetimidate group was shown to undergo facile 
displacement with alcohols, thiols, carbon and aniline nucleophiles. This provided convenient 
access to differently substituted pyrroloindolines at the C3a position. The utility of this new 
method was demonstrated by completing a formal synthesis of psychotriasine and total synthesis 
of arundinine. Currently this method is being applied toward the synthesis of a complex 
heterocycle, kapakahine C. This strategy may be utilized for rapidly accessing a variety of 
differently substituted pyrroloindolines, thus demonstrating an excellent method for exploring 
the biological properties of these molecules. 
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4.4 Experimental 
 
 
cis-Methyl 1,2,3,3a,8,8a-hexahydro-3a-hydroxypyrrolo[2,3-b]indole-1-carboxylate (4.61).  
m-CPBA (0.16 g, 0.92 mmol) was dissolved in 7.6 mL of dichloromethane. Trifluoroacetic acid 
(0.42 g, 3.66 mmol) was added and the resulting mixture was stirred at rt for 1 h. The reaction 
was then cooled to -40 °C and tryptamine 4.7 (100 mg, 0.46 mmol) was added. After stirring at -
40 °C for 1 h the reaction was quenched by the addition of saturated aqueous sodium sulfite 
solution (10 mL), and then was allowed to warm to room temperature. The organic was 
separated and washed again with saturated aqueous sodium sulfite (10 mL). The organic layer 
was then washed with saturated aqueous sodium bicarbonate (2 x 10 mL). The resulting organic 
layer was dried over sodium sulfate, filtered and concentrated. Purification by silica gel 
chromatography (40% ethyl acetate/60% hexanes) provided alcohol 4.61 (60.0 mg, 59%) as a 
white solid.  
4.61. White solid (60.0 mg, 59%); TLC Rf = 0.26 (60% ethyl acetate/40% hexanes); IR (thin 
film) 3362, 3054, 3006, 2956, 2886, 1686, 1612 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.28-7.26 
(m, 1H), 7.16 (t, J = 7.6 Hz, 1H), 6.80 (q, J = 6.8 Hz, 1H), 6.60 (d, J = 8.0 Hz, 1H), 5.17-5.13 
(m, 1H), 3.74-3.66 (m, 4H), 3.15-3.06 (m, 2H), 2.46-2.33 (m, 2H); 13C NMR (100 MHz, CDCl3) 
δ 155.8, 155.0, 149.4, 149.2, 130.4, 130.3, 129.6, 123.73, 123.66, 119.7, 119.3, 110.3, 110.2, 
88.2, 87.1, 81.9, 81.3, 52.7, 52.5, 45.8, 45.5, 36.5, 36.2 (two sets of signals are observed due to 
the slow rotation of the carbamate, one aromatic resonance is not resolved); HRMS (ESI+) m/z 
calcd for C12H14N2O3 [M + Na
+] 257.0897, found 257.0897.  
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cis-8-Benzyl 1-methyl 3a-hydroxy-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indole-1,8-
dicarboxylate (4.56). Alcohol 4.61 (0.52 g, 2.22 mmol) was dissolved in 5.5 mL pyridine and 
the mixture was cooled to 0 °C. Carboxybenzyl chloride (1.90 g, 11.11 mmol) was added and the 
reaction mixture was allowed to warm to rt and stirred overnight. The reaction mixture was then 
diluted with dichloromethane (5 mL) and washed with 1M HCl (2 x 5 mL). The organic layer 
was then washed with saturated aqueous sodium bicarbonate (5 mL), dried over sodium sulfate, 
filtered and concentrated. The residue was purified by silica gel chromatography  (60% ethyl 
acetate/40% hexanes) to provide carbamate 4.56 (0.75 g, 92%) as a white foam. 
4.56. White foam (0.75 g, 92%), TLC Rf = 0.50 (60% ethyl acetate/40% hexanes); IR (thin film) 
3405, 3066, 3033, 2955, 2891, 2249, 1711, 1605 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J 
=  8.0 Hz, 1H), 7.46-7.31 (m, 7H), 7.13 (td, J = 7.6, 1.2 Hz, 1H), 6.08 (s, 1H), 5.32-5.24 (m, 2H), 
3.93-3.89 (m, 1H), 3.52 (br s, 3H), 2.94-2.86 (m, 1H), 2.39-2.35 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 155.3, 153.5, 142.4, 135.8, 132.3, 130.4, 128.5, 128.3, 128.2, 124.1, 123.6, 116.6, 86.3, 
81.8, 67.7, 52.5, 45.6, 37.4. Anal. calcd for C20H20N2O5: C, 65.21; H, 5.47; N, 7.60. Found: C, 
65.39; H, 5.54; N, 7.18. 
 
cis-8-Benzyl 1-methyl 3a-[(2,2,2-trichloroethanimidoyl)oxy]-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.57). Alcohol 4.56 (5.50 g, 14.98 mmol) was 
dissolved in 60 mL of anhydrous dichloromethane and DBU (2.73 g, 17.98 mmol) was added. 
The resulting mixture was stirred at rt for 15 min and then cooled to 0 °C. Trichloroacetonitrile 
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(9.28 g, 64.4 mmol) was added and the reaction mixture was allowed to warm to rt and stirred at 
rt for 18 h. The mixture was concentrated and the residue dissolved in a minimum amount of 
toluene. This solution applied to the top of a silica gel column and purified (2% 
triethylamine/15% ethyl acetate/83% hexanes) to provide the imidate 4.57 (5.80 g, 76%) as a 
white foam. 
4.57. White foam (5.80 g, 76%); TLC Rf = 0.56 (30% ethyl acetate/70% hexanes); IR (thin film) 
3335, 3033, 2954, 2892, 2250, 1710, 1672 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 
7.75 (d, J = 5.2 Hz, 1H), 7.43-7.29 (m, 7H), 7.09 (td, J = 7.6, 0.8 Hz, 1H), 6.67 (s, 1H), 5.34-
5.28 (m, 2H), 4.06-4.01 (m, 1H), 3.56 (br s, 3H), 2.88 (td, J = 5.6, 12.4 Hz, 1H), 2.64 (td, J = 
12.4, 8.0 Hz, 1H), 2.54 (dd, J = 12.0, 2.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 159.2, 155.1, 
153.7, 144.9, 136.2, 131.0, 128.5, 128.4, 128.2, 127.5, 123.9, 123.8, 116.6, 94.2, 91.1, 78.9, 67.7, 
52.7, 44.2, 38.1. Anal. calcd for C22H20Cl3N3O5: C, 51.53; H, 3.93; N, 8.19. Found: C, 51.31; H, 
3.92; N, 7.80. 
 
General procedures for displacement of trichloroacetimidate 9: 
Procedure A: Trichloroacetimidate 4.57 (1.0 mmol) was dissolved in 4 mL of anhydrous 1,2 – 
dichloroethane in a flame dried flask under argon. The nucleophile (1.2 mmol) was then added 
followed by BF3•OEt2 (0.1 mmol). The reaction was stirred at rt and monitored for completion 
by thin layer chromatography. After completion the reaction was quenched by the addition of 
1M NaOH (4 mL). The organic layer was separated and the aqueous layer was washed with 
dichloromethane (2 x 10 mL). The combined organic extracts were dried over sodium sulfate, 
filtered and concentrated. The residue was purified by silica gel chromatography (eluent given 
for each compound) to provide the observed product. 
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Procedure B: Trichloroacetimidate 4.57 (1.0 mmol) was dissolved in 4 mL of anhydrous 1,2 – 
dichloroethane in a flame dried flask under argon. The nucleophile (1.2 mmol) was then added 
followed by BF3•OEt2 (0.1 mmol) and the reaction was heated to reflux. The reaction was 
monitored for completion by thin layer chromatography. After completion the reaction was 
allowed to cool to rt and quenched with 1M NaOH (4 mL). The organic layer was separated and 
the aqueous layer was washed with dichloromethane (2 x 10 mL). The combined organic extracts 
were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel 
chromatography (eluent given for each compound) to provide the observed product. 
 
cis-8-Benzyl 1-methyl 3a-(4-bromophenoxy)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indole-
1,8-dicarboxylate (4.63). 
Synthesized from imidate 4.57 and 4-bromophenol following procedure A (5% ethyl acetate/ 
95% dichloromethane used as chromatography eluent). 
4.63. Clear sticky syrup (75.0 mg, 74%); TLC Rf = 0.53 (40% ethyl acetate/ 60% hexanes); IR 
(thin film) 3033, 2955, 2893, 1716, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.0 
Hz, 1H), 7.39-7.31 (m, 6H), 7.28-7.26 (m, 1H), 7.13-7.06 (m, 3H), 6.51-6.47 (m, 2H), 6.40 (s, 
1H), 5.22 (s, 2H), 4.00-3.95 (m, 1H), 3.53 (br s, 3H), 2.92 (td, J = 12.0, 5.6, 1H), 2.63 (td, J = 
12.0, 8.0 Hz, 1H), 2.48 (dd, J = 12.4, 5.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.0, 154.0, 
152.9, 143.6, 135.8, 132.2, 131.0, 128.6, 128.5, 128.3, 124.4, 124.1, 122.6, 116.8, 116.4, 93.4, 
78.5, 67.8, 52.6, 44.9, 38.0 (one resonance in the aromatic region was not resolved). HRMS 
(ESI+) m/z calcd for C26H23BrN2O5 [M + Na
+] 545.0683, found 545.0677. 
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cis-8-Benzyl 1-methyl 3a-(2,3,4,5,6-pentafluorophenoxy)-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.64). 
Synthesized from imidate 4.57 and pentafluorophenol following procedure A (5% ethyl acetate/ 
95% dichloromethane used as chromatography eluent). 
4.64. Clear viscous oil (0.10 g, 80%); TLC Rf = 0.51 (40% ethyl acetate/ 60% hexanes); IR (thin 
film) 3034, 2957, 2894, 1716, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.0 Hz, 
1H), 7.46-7.32 (m, 6H), 7.15 (d, J = 7.6 Hz, 1H), 7.01 (dt, J = 7.2, 0.8 Hz, 1H), 6.49 (s, 1H), 
5.36-5.29 (m, 2H), 3.98-3.93 (m, 1H), 3.54 (br s, 3H), 2.91(dt, J = 12.0, 5.6 Hz, 1H), 2.71 (dt, J 
= 12.0, 8.0 Hz, 1H), 2.58 (dd, J = 12.0, 5.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.0, 
153.1, 144.3-141.6 (m, 1C), 144.2, 139.8-136.1 (m, 2C), 135.9, 132.1, 132.1-129.1 (m, 1C) 
128.6, 128.3, 128.2, 125.8, 124.4, 123.8, 117.6, 96.6, 80.3, 68.0, 52.6, 45.9, 35.2; HRMS (ESI+) 
m/z calcd for C26H19F5N2O5 [M + Na
+] 557.1106, found 557.1097. 
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cis-8-Benzyl 1-methyl 3a-(2-chloro-4-fluorophenoxy)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.65). 
Synthesized from imidate 4.57 and 2-chloro-4-fluorophenol following procedure A (a gradient of 
5% ethyl acetate/ 95% dichloromethane to 20% ethyl acetate/80% dichloromethane used as 
chromatography eluent). 
4.65. Clear syrup (81.0 mg, 70%); TLC Rf = 0.51 (40% ethyl acetate/ 60% hexanes); IR (thin 
film) 3035, 2956, 2893, 1713, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 
1H), 7.42-7.29 (m, 7H), 7.07 (dt, J = 7.2, 0.4 Hz, 1H), 6.92 (dd, J = 8.0, 3.2 Hz, 1H), 6.53-6.48 
(m, 1H), 6.40-6.36 (m, 2H), 5.23 (s, 2H), 3.97-3.92 (m, 1H), 3.56 (br s, 3H), 2.93 (dt, J = 12.0, 
5.2 Hz, 1H), 2.72 (dt, J = 12.0, 8.0 Hz, 1H), 2.57 (dd, J = 12.0, 5.2 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ 158.4 (d, J = 245 Hz, 1C), 155.0, 153.0, 147.27, 147.24, 143.9, 135.9, 131.3, 
128.75 (d, J = 10 Hz, 1C), 128.6, 128.4, 128.3, 124.5, 124.1, 122.7 (d, J = 9 Hz, 1C) 117.3 (d, J 
= 25 Hz, 1C), 117.1, 114.1 (d, J = 22 Hz, 1C), 94.3, 78.9, 67.8, 52.6, 45.3, 36.5. HRMS (ESI+) 
m/z calcd for C26H22ClFN2O5 [M + Na
+] 519.1093. Found 519.1088. 
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cis-8-Benzyl 1-methyl 3a-(2-chloro-4-methoxyphenoxy)-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.66). 
Synthesized from imidate 4.57 and 2-chloro-4-methoxyphenol following procedure A (5% ethyl 
acetate/ 95% dichloromethane used as chromatography eluent). 
4.66. Clear sticky oil (73.0 mg, 61%); TLC Rf = 0.45 (40% ethyl acetate/60% hexanes); IR (thin 
film) 3068, 3013, 2956, 2894, 2838, 1713, 1603 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 
8.0 Hz, 1H), 7.42-7.31 (m, 7H), 7.09-7.05 (m, 1H), 6.76 (d, J = 2.8 Hz, 1H), 6.42-6.36 (m, 3H), 
5.18 (s, 2H), 3.95-3.90 (m, 1H), 3.64 (s, 3H), 3.53 (br s, 3H), 2.92 (td, J = 12.0, 5.6 Hz, 1H), 
2.70 (td, J = 12.4, 8.4 Hz, 1H), 2.55 (dd, J = 12.0, 5.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
156.2, 155.1, 153.1, 144.5, 143.9, 136.0, 131.1, 129.0, 128.64, 128.55, 128.22, 128.17, 124.5, 
124.0, 122.9, 117.1, 115.3, 112.9, 94.2, 79.0, 67.7, 55.6, 52.6, 45.4, 36.2. HRMS (ESI+) m/z 
calcd for C27H25ClN2O6 [M + Na
+] 531.1293, found 531.1288. 
 
cis-8-Benzyl 1-methyl 3a-(4-tert-butylphenoxy)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.67). 
Synthesized from imidate 4.57 and 4-tert-butylphenol following procedure A (20% ethyl acetate/ 
80% hexanes used as chromatography eluent). 
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4.67. White sticky solid (50.0 mg, 50%); TLC Rf =  (30% ethyl acetate/ 70% hexanes); IR (thin 
film) 3034, 2966, 2868, 1705 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.0 Hz, 1H), 7.41-
7.29 (m, 7H), 7.10-7.06 (m, 3H), 6.58-6.55 (m, 2H), 6.44 (s, 1H), 5.21 (s, 2H), 4.00-3.95 (m, 
1H), 3.49 (br s, 3H), 2.92 (dt, J = 12.0, 5.2 Hz, 1H), 2.64 (dt, J = 12.0, 8.0 Hz, 1H), 2.45 (dd, J = 
12.0, 5.2 Hz, 1H), 1.21 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 155.1, 153.0, 152.5, 146.2, 143.5, 
136.0, 130.7, 129.5, 128.6, 128.2, 126.0, 124.5, 124.0, 120.0, 116.6, 93.1, 78.4, 67.7, 52.5, 44.9, 
38.1, 34.2, 31.4 (one aromatic resonance was not resolved). HRMS (ESI+) m/z calcd for 
C30H32N2O5 [M + Na
+] 523.2203, found 523.2199. 
 
cis-8-Benzyl 1-methyl 3a-methoxy-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indole-1,8-
dicarboxylate (4.68).  
Synthesized from imidate 4.57 and methanol following procedure A (7.5% ethyl acetate/ 92.5% 
dichloromethane used as chromatography eluent). 
4.68. Clear oil (72.0 mg, 97%); TLC Rf = 0.39 (40% ethyl acetate/ 60% hexanes); IR (thin film) 
3066, 3033, 2953, 2892, 2828, 1713, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.0 
Hz, 1H), 7.45-7.30 (m, 7H), 7.13 (td, J = 7.6, 0.8 Hz, 1H), 6.23 (s, 1H), 5.33-5.26 (m, 2H), 3.95-
3.91 (m, 1H), 3.54 (br s, 3H), 3.05 (s, 3H), 2.93-2.85 (m, 1H), 2.36-2.29 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 155.2, 153.1, 143.7, 136.0, 130.6, 128.6, 128.33, 128.29, 128.27, 124.3, 124.0, 
116.5, 92.0, 78.1, 67.8, 52.9, 52.6, 45.3, 37.5. Anal. calcd for C21H22N2O5: C, 65.96; H, 5.80; N, 
7.33. Found: C, 65.93; H, 5.67; N, 7.01. 
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8-Benzyl 1-methyl 3a-(prop-2-en-1-yloxy)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indole-1,8-
dicarboxylate (4.69). 
Synthesized from imidate 4.57 and methanol following procedure A (20% ethyl acetate/ 80% 
hexanes used as chromatography eluent). 
4.69. Clear oil (72.0 mg, 91%); TLC Rf = 0.55 (40% ethyl acetate/ 60% hexanes); IR (thin film) 
3068, 3033, 2982, 2954, 2890, 1714, 1604 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.0 
Hz, 1H), 7.45-7.31 (m, 7H), 7.13 (td, J = 7.2, 0.8 Hz, 1H), 6.24 (br s, 1H), 5.84-5.74 (m, 1H), 
5.34-5.26 (m, 2H), 5.14 (dq, J = 17.2, 1.6 Hz, 1H), 5.07 (dq, J = 10.0, 1.2 Hz, 1H), 3.96-3.91 (m, 
1H), 3.70-3.54 (m, 5H), 2.87 (td, J = 11.6, 6.4 Hz, 1H), 2.42-2.30 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 155.2, 153.1, 143.7, 136.0, 134.1, 130.7, 128.7, 128.6, 128.4, 128.3, 124.3, 124.0, 
117.1, 116.5, 91.6, 78.5, 67.7, 66.5, 52.6, 45.1, 37.9. Anal. calcd for C23H24N2O5: C, 67.63; H, 
5.93; N, 6.86. Found: C, 67.70; H, 5.76; N, 6.93. 
 
cis-8-Benzyl 1-methyl 3a-[(2-nitrophenyl)methoxy]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.70). 
Synthesized from imidate 4.57 and 2-nitrobenzyl alcohol following procedure A (25% ethyl 
acetate/ 75% hexanes used as chromatography eluent). 
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4.70. Clear oil (86.0 mg, 88%); TLC Rf = 0.43 (40% ethyl acetate/ 60% hexanes); IR (thin film) 
3034, 2954, 2891, 1710, 1605 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.99 (dd, J = 8.0, 1.2 Hz, 
1H), 7.81 (d, J = 8.4 Hz, 1H), 7.64-7.62 (m, 1H), 7.57 (td, J = 7.2, 1.2 Hz, 1H), 7.46-7.30 (m, 
8H), 7.13 (td, J = 7.2, 0.8 Hz, 1H), 6.31 (s, 1H), 5.35-5.28 (m, 2H), 4.68-4.67 (d, J  = 13.6 Hz, 
1H), 4.56 (d, J = 13.6 Hz, 1H), 3.97-3.94 (m, 1H), 3.53 (br s, 3H), 2.93 (td, J = 11.6, 8.8 Hz, 
1H), 2.48-2.41 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 155.2, 153.1, 147.3, 143.6, 136.0, 133.8, 
133.5, 131.0, 129.1, 128.6, 128.4, 128.2, 128.1, 124.6, 124.3, 124.1, 116.9, 91.8, 78.6, 67.9, 64.1, 
52.6, 45.3, 37.0 (one aromatic resonance was not resolved). Anal. calcd for C27H25N3O7: C, 
64.41; H, 5.00; N, 8.35. Found: C, 64.17; H, 4.91; N, 8.75. 
 
cis-8-Benzyl 1-methyl 3a-[(2-methylbut-3-yn-2-yl)oxy]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.71). 
Synthesized from imidate 4.57 and 2-methyl-3-butyn-2-ol following procedure A (5% ethyl 
acetate/ 95% dichloromethane used as chromatography eluent). 
4.71. White solid (75.0 mg, 89%); mp = 124-125 °C; TLC Rf = 0.69 (40% ethyl acetate/ 60% 
hexanes); IR (thin film) 3224, 3062, 3036, 3011, 2974, 2899, 2862, 2099, 1713, 1697, 1600 cm-
1; 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 6.8 Hz, 2H), 7.40-7.29 (m, 
5H), 7.07 (td, J = 7.2, 0.8 Hz, 1H), 6.66 (s, 1H), 5.34-5.23 (m, 2H), 3.96-3.91 (m, 1H), 3.55 (br s, 
3H), 2.76 (td, J = 12.4, 5.2 Hz, 1H), 2.47 (td, J = 12.0, 8.0 Hz, 1H), 2.29 (dd, J = 12.0, 5.2 Hz, 
1H), 2.10 (s, 1H), 1.45 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.3, 153.3, 143.6, 
136.3, 130.9, 130.3, 128.5, 128.4, 128.2, 125.3, 123.2, 116.2, 91.4, 85.4, 79.3, 74.6, 69.9, 67.4, 
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52.5, 44.2, 40.8, 32.6, 31.9. Anal. calcd for C25H26N2O5: C, 69.11; H, 6.03; N, 6.45. Found: C, 
69.01; H, 6.19; N, 6.20. 
 
cis-8-Benzyl 1-methyl 3a-[(1-phenyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]-1H,2H,3H,3aH,8H, 
8aH-pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.72). 
Synthesized from imidate 4.57 and 1-phenyl-1H-tetrazole-5-thiol following procedure A (50% 
ethyl acetate/ 50% hexanes used as chromatography eluent). 
4.72. Light yellow solid (80.0 mg, 78%); TLC Rf = 0.14 (40% ethyl acetate/ 60% hexanes); IR 
(thin film) 3065, 3031, 2952, 2889, 1708, 1598 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.73 (br s, 
1H), 7.53-7.49 (m, 3H), 7.44-7.22 (m, 9H), 7.03 (td, J = 7.2, 0.8 Hz, 1H), 6.77 (s, 1H), 5.35-5.28 
(m, 2H), 4.03 (br s, 1H), 3.56 (br s, 3H), 3.02-2.96 (m, 2H), 2.52-2.50 (m, 1H); 13C NMR (100 
MHz, CDCl3) δ 155.1, 153.3, 150.9, 142.8, 135.9, 133.2, 130.8, 130.4, 129.8, 129.2, 128.6, 
128.29, 128.26, 124.3, 124.2, 123.6, 117.1, 81.3, 67.9, 63.9, 52.7, 45.4, 36.5. Anal. calcd for 
C27H24N6O4S: C, 61.35; H, 4.58; N, 15.9. Found: C, 61.66; H, 4.63; N, 15.86. 
 
cis-8-Benzyl 1-methyl 3a-(1,3-benzothiazol-2-ylsulfanyl)-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.73). 
Synthesized from imidate 4.57 and 2-mercaptobenzothiazole following procedure A (5% ethyl 
acetate/ 95% dichloromethane used as chromatography eluent). 
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4.73. White solid (90.0 mg, 90%); mp = 153-156 °C; TLC Rf = 0.52 (40% ethyl acetate/ 60% 
hexanes); IR (thin film) 3064, 3031, 2990, 2952, 1704 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.78-
7.69 (m, 3H), 7.40-7.25 (m, 9H), 7.07 (td, J = 7.6, 0.8 Hz, 1H), 6.86 (s, 1H), 5.25 (s, 2H), 4.07-
4.02 (m, 1H), 3.47 (br s, 3H), 2.98 (td, J = 12.0, 5.2 Hz, 1H), 2.73 (td, J = 12.0, 7.6 Hz, 1H), 2.46 
(dd, J = 12.4, 5.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 161.3, 155.2, 153.4, 153.2, 143.2, 
136.0, 135.7, 130.2, 130.1, 128.5, 128.2, 128.1, 126.2, 125.0, 124.1, 123.8, 122.5, 120.9, 116.5, 
82.1, 67.6, 64.3, 52.6, 45.1, 37.8. Anal. calcd for C27H23N3O4S2: C, 62.65; H, 4.48; N, 8.12. 
Found: C, 62.47; H, 4.50; N, 7.87. 
 
cis-8-Benzyl 1-methyl 3a-(2,5-dimethoxyphenyl)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b] 
indole-1,8-dicarboxylate (4.74). 
Synthesized from imidate 4.57 and 2,4-dimethoxybenzene following procedure A (15% ethyl 
acetate/ 85% hexanes used as chromatography eluent). 
4.74. White solid (75.0 mg, 79%); mp = 116-120 °C; TLC Rf = 0.23 (30% ethyl acetate/ 70% 
hexanes); IR (thin film) 3003, 2953, 1702, 1653 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.75 (br s, 
1H), 7.42-7.30 (m, 5H), 7.26-7.22 (m, 1H), 7.14 (d, J = 6.8 Hz, 1H), 7.05 (t, J = 7.6 Hz, 1H), 
6.78-6.72 (m, 3H), 6.59 (br s, 1H), 5.32-5.23 (m, 2H), 4.05 (br s, 1H), 3.69 (s, 3H), 3.56 (br s, 
6H), 2.92 (td, J = 12.0, 4.8 Hz, 1H), 2.71 (td, J = 11.6, 7.2 Hz, 1H), 2.26 (dd, J = 11.6, 4.8 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 155.4, 153.5, 153.3, 151.7, 142.6, 136.4, 133.8, 131.5, 
128.52, 128.48, 128.2, 128.1, 124.8, 123.5, 116.2, 115.4, 112.2, 111.9, 81.6, 67.4, 59.4, 55.70, 
55.66, 52.4, 45.7, 37.5. Anal. Calcd for C28H28N2O6: C, 68.84; H, 5.78; N, 5.73. Found: C, 68.96; 
H, 5.74; N, 5.67. 
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cis-8-Benzyl 1-methyl 3a-(prop-2-en-1-yl)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indole-1,8-
dicarboxylate (4.75). 
Synthesized from imidate 4.57 and allyl tri-n-butyltin following procedure B (15% ethyl acetate/ 
85% hexanes used as chromatography eluent and then repurified using 1% ethyl acetate/ 99% 
dichloromethane). 
4.75. Clear oil (95.0 mg, 62%); TLC Rf = 0.34 (30% ethyl acetate/ 70% hexanes); IR (thin film) 
3077, 2907, 1716, 1602  cm-1; 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 7.2 Hz, 1H), 7.44-7.32 
(m, 5H), 7.25-7.21 (m, 1H), 7.14 (dd, J = 7.2, 0.8 Hz, 1H), 7.06 (td, J = 7.6, 1.2 Hz, 1H), 6.04 (br 
s, 1H), 5.59-5.49 (m, 1H), 5.29 (dd, J = 27.6, 12.4 Hz, 2H), 5.03 (dd, J = 17.2, 1.6 Hz, 1H), 4.97 
(dd, J = 10.0, 0.4 Hz, 1H), 3.83-3.78 (m, 1H), 3.55 (br s, 3H), 2.92 (td, J = 12.0, 5.6 Hz, 1H), 
2.53-2.48 (m, 1H), 2.41 (dd, J = 13.6, 8.0 Hz, 1H), 2.12 (dd, J = 12.4, 5.6 Hz, 1H), 2.02 (td, J = 
12.0, 8.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.1, 153.4, 142.3, 136.3, 134.5, 132.8, 
128.52, 128.49, 128.2, 128.1, 123.8, 122.9, 119.1, 116.6, 80.1, 67.5, 56.6, 52.4, 45.8, 42.5, 35.8. 
HRMS (ESI+) m/z calcd for C23H24N2O4 [M + Na
+] 415.1628. Found 415.1626. 
 
cis-8-benzyl 1-methyl 3a-(2-methylbut-3-en-2-yl)-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.76). 
Synthesized from imidate 4.57 and tri-n-butyl(3-methyl-2-butenyl)tin following procedure B 
(5% ethyl acetate/ 95% toluene used as chromatography eluent). 
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4.76. Clear oil (40.0 mg, 48%); TLC Rf = 0.45 (10% ethyl acetate/ 90% toluene); IR (thin film) 
2956, 2883, 1709, 1655, 1601 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.65 (br s, 1H), 7.44-7.26 (m, 
5H), 7.23-7.18 (m, 2H), 7.04 (td, J = 7.2, 0.8 Hz, 1H), 6.15 (br s, 1H), 5.83 (dd, J = 17.2, 10.8 
Hz, 1H), 5.30 (q, J = 12.8 Hz, 2H), 5.03-4.96 (m, 2H), 3.79-3.75 (m, 1H), 3.55 (br s, 3H), 2.84-
2.77 (m, 1H), 2.20 (td, J = 12.0, 8.0 Hz, 1H), 1.98 (dd, J = 12.0, 5.6 Hz, 1H), 1.04 (s, 3H), 0.92 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 155.0, 153.2, 143.6, 142.9, 136.4, 133.2, 128.6, 128.5, 
128.2, 128.1, 124.7, 123.3, 116.9, 114.2, 78.5, 67.5, 63.1, 52.4, 46.0, 40.6, 31.9, 23.2, 22.3. Anal. 
calcd for C25H28N2O4: C, 71.41; H, 6.71; N, 6.66. Found: C, 71.72; H, 6.82; N, 6.66. 
 
cis-8-Benzyl 1-methyl 3a-[(2,5-dichlorophenyl)amino]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.77). 
Synthesized from imidate 4.57 and 2,5-dichloroaniline following procedure A (15% ethyl 
acetate/ 85% hexanes used as chromatography eluent). 
4.77. White foam (80.0 mg, 80%); TLC Rf = 0.31 (30% ethyl acetate/ 70% hexanes); IR (thin 
film) 3415, 3033, 2980, 2872, 1709, 1590 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.4 
Hz, 1H), 7.41-7.26 (m, 7H), 7.16-7.09 (m, 2H), 6.62 (dd, J = 8.4, 2.4 Hz, 1H), 6.42 (s, 1H), 6.14 
(d, J = 2.4 Hz, 1H), 5.33-5.25 (m, 2H), 4.80 (s, 1H), 4.13-4.09 (m , 1H), 3.51 (br s, 3H), 2.97 (td, 
J = 12.0, 5.6 Hz, 1H), 2.50 (td, J = 12.0, 8.0 Hz, 1H), 2.30 (dd, J = 12.0, 5.2 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 155.0, 153.1, 142.6, 141.5, 135.9, 133.4, 130.7, 130.5, 130.1, 128.6, 
128.34, 128.28, 124.4, 123.3, 118.6, 115.9, 113.4, 78.4, 71.9, 67.8, 52.8, 44.3, 40.1 (one 
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aromatic resonance was not resolved). Anal. calcd for C26H23Cl2N3O4: C, 60.95; H, 4.52; N, 
8.20. Found: C, 60.79; H, 4.48; N, 8.36. 
 
cis-8-Benzyl 1-methyl 3a-{[3,5-bis(trifluoromethyl)phenyl]amino}-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.78). 
Synthesized from imidate4.57 and 3,5-bis(trifluoromethyl)aniline following procedure A (20% 
ethyl acetate/ 80% hexanes used as chromatography eluent). 
4.78. White foam (95.0 mg, 84 %); TLC Rf = 0.27 (30% ethyl acetate/ 70% hexanes); IR (thin 
film) 3458,  2362, 1686, 1622 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.0 Hz, 1H), 
7.38-7.24 (m, 6H), 7.16 (s, 1H), 7.09 (td, J = 7.2, 0.8 Hz, 1H), 6.71 (s, 2H), 6.41 (s, 1H), 5.30-
5.23 (m, 2H), 4.72 (s, 1H), 4.13-4.08 (m, 1H), 3.49 (br s, 3H), 2.96 (td, J = 12.0, 5.6 Hz, 1H), 
2.40 (td, J = 12.0, 7.6 Hz, 2H), 2.32 (dd, J = 12.0, 5.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
155.0, 153.0, 145.6, 142.8, 135.7, 132.5 (q, J = 32.0 Hz, 1C), 130.6, 130.0, 128.6, 128.4, 124.4, 
123.4, 123.2 (q, J = 271 Hz, 1C), 115.9, 113.8 (q, J = 3 Hz, 1C), 111.7 (hep, J = 4.0 Hz, 1C), 
78.5, 72.0, 67.9, 52.8, 44.2, 40.6 (one aromatic resonance was not resolved). Anal. calcd for 
C28H23F6N3O4: C, 58.03; H, 4.00; N, 7.25. Found: C, 58.04; H, 4.10; N, 7.27. 
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cis-8-Benzyl 1-methyl 3a-[(2-nitrophenyl)amino]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.79). 
Synthesized from imidate 4.57 and 2-nitroaniline following procedure A (20% ethyl acetate/ 
80% hexanes used as chromatography eluent). 
4.79. Yellow foam (80.0 mg, 84%); TLC Rf = 0.44 (40% ethyl acetate/ 60% hexanes); IR (thin 
film) 3362, 3064, 3031, 2952, 2890, 1686, 1614 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 
1H), 8.17 (dd, J = 8.8, 1.6 Hz, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.40-7.32 (m, 6H), 7.25-7.23 (m, 
1H), 7.16-7.12 (m, 1H), 7.08 (td, J = 7.2, 0.8 Hz, 1H), 6.69-6.65 (m, 1H), 6.50 (br s, 1H), 6.19 
(dd, J = 8.4, 0.8 Hz, 1H), 5.34-5.25 (m, 2H), 4.14 (br s, 1H), 3.50 (br s, 3H), 3.00 (td, J = 11.6, 
6.0 Hz, 1H), 2.52-2.40 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 154.9, 153.1, 142.7, 142.4, 
136.1, 135.8, 133.6, 130.33, 130.25, 128.6, 128.5, 128.4, 127.2, 124.4, 123.4, 116.9, 115.6, 
114.9, 78.8, 71.5, 67.8, 52.8, 43.9, 42.9. Anal. calcd for C26H24N4O6: C, 63.93; H, 4.95; N, 11.47. 
Found: C, 63.95; H, 4.96; N, 11.11. 
 
cis-8-Benzyl 1-methyl 3a-[(2-chloro-4-methylphenyl)amino]-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.80). 
Synthesized from imidate 4.57 and 2-chloro-4-methylaniline following procedure B (15% ethyl 
acetate/ 85% hexanes used as chromatography eluent). 
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4.80. Clear oil (83.0 mg, 87%); TLC Rf = 0.53 (40% ethyl acetate/ 60% hexanes); IR (thin film) 
3418, 3034, 2954, 2892, 1710, 1613 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.0 Hz, 
1H), 7.39-7.25 (m, 7H), 7.09-7.05 (m, 2H), 6.66 (dd, J = 8.4, 1.2 Hz, 1H), 6.39 (br s, 1H), 6.03 
(d, J = 8.4 Hz, 1H), 5.35-5.22 (m, 2H), 4.61 (s, 1H), 4.06 (br s, 1H), 3.46 (br s, 3H), 2.97 (td, J = 
12.0, 6.0 Hz, 1H), 2.42 (td, J = 12.0, 8.0 Hz, 1H), 2.31 (dd, J = 12.0, 5.2 Hz, 1H), 2.15 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 155.1, 153.2, 142.6, 138.4, 136.0, 131.4, 130.0, 129.9, 128.8, 
128.5, 128.3, 128.23, 128.22, 124.2, 123.4, 120.8, 115.8, 114.0, 78.7, 72.2, 67.6, 52.6, 44.1, 41.0, 
20.1. Anal. calcd for C27H26ClN3O4: C, 65.92; H, 5.33; N, 8.54. Found: C, 65.91; H, 5.26; N, 
8.52. 
 
cis-8-Benzyl 1-methyl 3a-{[4-(methylsulfanyl)phenyl]amino}-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.81). 
Synthesized from imidate 4.57 and 4-(methylthio)aniline following procedure B (15% ethyl 
acetate/ 85% hexanes used as chromatography eluent and repurified using 10% ethyl acetate/ 
90% DCM). 
4.81. White foam (40.0 mg, 44%); TLC Rf = 0.2 (40% ethyl acetate/60% hexanes); IR (thin film) 
3385, 3032, 2953, 2899, 1703 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.0 Hz, 1H), 
7.37-7.29 (m, 7H), 7.08 (td, J = 7.2, 0.8 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 6.41-6.33 (m, 3H), 
5.23 (s, 2H), 3.96 (m, 1H), 3.68-3.47 (m, 7H), 2.94 (td, J = 11.6, 6.0 Hz, 1H), 2.42-2.28 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 155.2, 154.0, 153.3, 142.7, 138.0, 136.0, 132.3, 129.9, 128.6, 
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128.24, 128.20, 124.1, 123.6, 119.1, 116.3, 114.7, 78.4, 73.1, 67.6, 55.51, 52.53, 44.5, 39.3. 
Anal. calcd for C27H27N3O5: C, 66.24; H, 5.56; N, 8.58. Found: C, 66.12; H, 5.56; N, 8.66. 
 
cis-8-Benzyl 1-methyl 3a-[(2-iodophenyl)amino]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.82). 
Synthesized from imidate 4.57 and 2-iodoaniline following procedure B (1% ethyl acetate/ 85% 
DCM used as chromatography eluent).  
4.82. White amorphous solid (65.0 mg, 71%); TLC Rf = 0.73 (5% ethyl acetate/ 95% 
dichloromethane); IR (thin film) 3388, 3017, 2954, 2892, 1710, 1586 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.86 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.0, 1.6 Hz, 1H), 7.39-7.24 (m, 7H), 7.07 (td, J = 
7.6, 0.8 Hz, 1H), 6.95-6.91 (m, 1H), 6.45-6.41 (m, 2H), 6.06 (dd, J = 8.0, 1.2 Hz, 1H), 5.30-5.22 
(m, 2H), 4.64 (s, 1H), 4.08 (br s, 1H), 3.46 (br s, 3H), 2.97 (td, J = 12.0, 5.6 Hz, 1H), 2.45 (td, J 
= 12.0, 8.0 Hz, 1H), 2.32 (dd, J = 12.0, 5.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.1, 
153.2, 144.2, 142.6, 139.4, 135.9, 131.1, 130.0, 129.3, 128.6, 128.33, 128.25, 124.2, 123.4, 
120.3, 115.7, 113.1, 88.0, 78.6, 72.5, 67.7, 52.6, 44.1, 41.2. Anal. calcd for C26H24IN3O4: C, 
54.84; H, 4.25; N, 7.38. Found: C, 54.50; H, 4.63; N, 7.22. 
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cis-8-Benzyl 1-methyl 3a-[methyl(phenyl)amino]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-
b]indole-1,8-dicarboxylate (4.83). 
Synthesized from imidate 4.57 and N-methylaniline following procedure B (a gradient of 15% 
ethyl acetate/ 85% hexanes to 25% ethyl acetate/ 75% hexanes used as chromatography eluent). 
4.83. White solid (0.12 g, 46%); TLC Rf = 0.37 (10% ethyl acetate/ 90% dichloromethane); IR 
(thin film) 3065, 3017, 2955, 2889, 2802, 1713, 1597 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 
(br s, 1H), 7.42-7.28 (m, 6H), 7.20-7.04 (m, 5H), 6.92 (d, J = 7.6 Hz, 2H), 6.28 (br s, 1H), 5.17 
(br s, 2H), 3.76 (br s, 1H), 3.50 (br s, 3H), 2.85 (td, J = 11.6, 5.2 Hz, 1H), 2.63 (s, 3H), 2.45 (td, 
J = 12.0, 8.0 Hz, 1H), 2.21 (dd, J = 11.6, 4.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.0, 
152.8, 149.2, 143.2, 136.1, 130.6, 129.7, 128.5, 128.2, 127.0, 125.5, 124.3, 123.6, 117.2, 78.4, 
67.5, 53.4, 52.4, 45.7, 38.8, 35.5 (two aromatic resonances were not resolved). Anal. Calcd for 
C27H27N3O4: C, 70.88; H, 5.95; N, 9.18. Found: C, 70.97; H, 5.69; N, 8.98. 
 
cis-8-Benzyl 1-methyl 3a-(5-bromo-2,3-dihydro-1H-indol-1-yl)-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.84). 
Synthesized from imidate 4.57 and 5-bromoindoline following procedure B (7% ethyl 
acetate/93% hexanes used as chromatography eluent). 
4.84. White solid (40.0 mg, 50%); TLC Rf = 0.23 (20% ethyl acetate/80% hexanes); IR (thin 
film) 3067, 3034, 2955, 2894, 2852, 1711, 1598 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 
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8.0 Hz, 1H), 7.38-7.28 (m, 7H), 7.12 (s, 1H), 7.05 (dt, J = 7.6, 0.8 Hz, 1H), 6.98 (dd, J = 8.4, 2.0 
Hz, 1H), 6.41 (s, 1H), 6.17 (d, J = 8.4 Hz, 1H), 5.28 (s, 2H), 4.03 (br s, 1H), 3.51-3.37 (m, 4H), 
3.19 (q, J = 9.2 Hz, 1H), 2.95 (td, J = 5.2, 11.6 Hz, 1H), 2.83-2.72 (m, 3H), 2.41 (dd, J = 12.0, 
5.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.0, 153.1, 148.4, 142.8, 136.0, 134.2, 130.4, 
130.1, 129.8, 128.6, 128.3, 127.9, 124.4, 124.1, 116.4, 110.9, 110.8, 78.4, 75.1, 67.8, 52.7, 51.4, 
45.3, 36.5, 29.7, 27.9. Anal. calcd for C28H26BrN3O4: C, 61.32; H, 4.78; N, 7.66. Found: C, 
61.40; H, 4.89; N, 7.47. 
 
cis-8-Benzyl 1-methyl 3a-(5,7-dibromo-2,3-dihydro-1H-indol-1-yl)-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.85). 
Synthesized from imidate 4.57 and 5,7-dibromoindoline following procedure A (using 15% ethyl 
acetate/ 85% hexanes as chromatography eluent and repurified using a gradient of 1% ethyl 
acetate/ 99% dichloromethane to 5% ethyl acetate/ 95% DCM). 
4.85. White foam (80.0 mg, 71 %); TLC Rf = 0.39 (30% ethyl acetate/ 70% hexanes); IR (thin 
film) 3066, 3031, 2952, 2887, 1710 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 6.0 Hz, 
1H), 7.50-7.31 (m, 7H), 7.19 (d, J = 0.8 Hz, 1H), 7.03 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 7.2 Hz, 
1H), 6.32 (s, 1H), 5.39-5.26 (m, 2H), 3.80 (br s, 1H), 3.52 (br s, 3H), 3.24-3.12 (m, 2H), 2.90 (td, 
J = 11.6, 7.6 Hz, 1H), 2.76-2.65 (m, 2H), 2.36 (dd, J = 11.6, 11.6 Hz, 1H), 2.18-2.11 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ 154.9, 153.1, 148.1, 143.7, 142.7, 136.0, 134.2, 131.5, 130.2, 
128.6, 128.3, 128.2, 127.0, 124.3, 124.0, 117.4, 117.0, 114.7, 79.6, 79.2, 67.8, 52.5, 52.3, 45.8, 
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36.3, 30.8. Anal. calcd for C28H25Br2N3O4: C, 53.61; H, 4.02; N, 6.70. Found: C, 53.66; H, 4.12; 
N, 6.69. 
 
cis-8-Benzyl 1-methyl 3a-(3-{2-[(methoxycarbonyl)amino]ethyl}-1H-indol-1-yl)-1H,2H,3H, 
3aH,8H,8aH-pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.87). 
Indole 4.7 (40.0 mg, 0.18 mmol), imidate 4.57 (80.0 mg, 0.15 mmol) and 0.11 g of 4 Å 
molecular sieves were suspended in 0.60 mL of 1,2-dichloroethane. Then Cu(OTf)2 (16.0 mg, 
0.044 mmol) was added to the reaction and the resulting suspension was stirred at rt for 18 h. 
The reaction mixture was then filtered and washed with 1M NaOH (5 mL). The organic layer 
was separated and the aqueous layer was extracted with DCM (2 x 10 mL). The combined 
organic layers were dried over sodium sulfate, filtered and concentrated. The residue was 
purified using silica gel chromatography (5% ethyl acetate/ 95% dichloromethane) to provide 
21.0 mg (25%) of indole 4.87.  
4.87. White foam (21.0 mg, 25%); TLC Rf = 0.22 (50% ethyl acetate/50% hexanes); IR (thin 
film) 3358, 3013, 2954, 1716, 1603, 1525 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 8.4 
Hz, 1H), 7.58 (d, J = 5.6 Hz, 1H), 7.41-7.24 (m, 7H), 7.14-7.04 (m, 4H), 6.90 (s, 1H), 6.77 (s, 
1H), 5.30-5.23 (m, 2H), 4.72 (br s, 1H), 4.22-4.19 (m, 1H), 3.66 (s, 3H), 3.47-3.42 (m, 5H), 3.17 
(td, J = 12.0, 7.6 Hz, 1H), 3.05 (td, J = 11.2, 4.4 Hz, 1H), 2.88 (t, J = 6.8 Hz, 2H), 2.54 (dd, J = 
11.6, 4.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 157.0, 155.0, 153.0, 142.6, 135.8, 135.3, 
130.8, 129.9, 129.5, 128.6, 128.3, 128.2, 124.6, 124.3, 124.0, 122.4, 119.9, 119.5, 116.7, 112.4, 
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111.3, 79.9, 74.4, 67.8, 52.7, 52.0, 45.3, 41.3, 37.2, 25.7. Anal. calcd for C32H32N4O6: C, 67.59; 
H, 5.67; N, 9.85; Found: C, 67.71; H, 5.81; N, 9.62. 
 
cis-Methyl 3a-(3-{2-[(methoxycarbonyl)amino]ethyl}-1H-indol-1-yl)-1H,2H,3H,3aH,8H, 
8aH-pyrrolo[2,3-b]indole-1-carboxylate (4.88). 
Benzyl carbamate 4.87 (0.17 g. 0.30 mmol) and 10% palladium on carbon (3.20 mg, 0.03 mmol) 
were suspended in 1.5 mL of methanol. The flask was then evacuated and filled with hydrogen 
gas from a balloon. After 1 h the mixture was filtered through a bed of Celite and the Celite bed 
was washed with methanol. The filtrate was concentrated and then purified with silica gel 
chromatography using 5% ethyl acetate/ 95% dichloromethane to provide 0.12 g (92%) of 
indoline 4.88. This compound has been previously prepared (see Newhouse, T.; Lewis, C. A.; 
Eastman, K. J.; Baran, P. S. J. Am. Chem. Soc., 2010, 132, 7119-7137). 
4.88. Clear oil (0.12 g, 92%); 1H NMR (400 MHz, CDCl3) δ 7.59-7.56 (m, 1H), 7.38-7.32 (m, 
1H), 7.22-7.07 (m, 4H), 6.96 (d, J = 8.8 Hz, 1H), 6.83-6.79 (m, 1H), 6.71 (d, J = 8.4 Hz, 1H), 
5.94 (s, 0.5H), 5.87 (s, 0.5H), 5.36 (br s, 0.5H), 4.96 (br s, 0.5H), 4.86 (br s, 1H), 4.06-3.98 (m, 
0.4H), 3.95-3.87 (m, 0.6H), 3.74 (d, J = 11.2 Hz, 3H), 3.63 (s, 3H), 3.43-3.42 (m, 2H), 3.33-3.21 
(m, 2H), 2.86 (br s, 2H), 2.67-2.57 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 157.1, 155.5, 154.7, 
149.4, 149.1, 135.3, 130.7, 129.8, 126.8, 124.8, 124.2, 124.1, 122.0, 119.7, 119.6, 119.4, 119.3, 
112.1, 112.0, 111.8, 110.5, 110.3, 79.5, 79.0, 75.8, 74.6, 52.9, 52.6, 52.0, 45.6, 45.4, 41.4, 35.8, 
35.7, 25.8. 
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Methyl N-[2-(6-methoxy-1H-indol-3-yl)ethyl]carbamate (4.91). 
5-Methoxytryptamine hydrochloride (2.0 g, 8.80 mmol) was dissolved in 22 mL anhydrous 
DCM under argon. Triethylamine (2.25 mL, 17.6 mmol) was added to the above solution and the 
resulting mixture was cooled to 0 °C. Methyl chloroformate (1.36 mL, 17.6 mmol) was then 
slowly added. After 3 h the reaction was quenched with 1M HCl (20 mL) and the organic layer 
was separated. The organic layer was washed with saturated aq. NaHCO3 (20 mL) and brine (20 
mL), dried over sodium sulfate, filtered and concentrated. The residue was purified via silica gel 
chromatography (50% ethyl acetate/ 50% hexanes) to provide methyl carbamate 4.91 (1.90 g, 
87%). 
4.91. Brown solid (1.90 g, 87%); TLC Rf = 0.56 (60% ethyl acetate/40% hexanes); IR (thin film) 
3405, 3342, 3113, 2993, 2943, 2832, 1703, 1623 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.14 (br s, 
1H), 7.25-7.22 (m, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.97 (s, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 
4.82 (br s, 1H), 3.85 (s, 3H), 3.66 (s, 3H), 3.50 (q, J = 6.4 Hz, 2H), 2.92 (t, J = 6.8 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 157.5, 153.9, 131.8, 127.8, 123.2, 112.3, 112.2, 100.6, 56.0, 52.1, 
41.5, 25.8 (one resonance was not resolved). Anal. calcd for C13H16N2O3: C, 62.89; H, 6.50; N, 
11.28. Found: C, 62.97; H, 6.51; N, 10.99. 
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[2-(6-Methoxy-1H-indol-3-yl)ethyl](methyl)amine (4.92). 
Carbamate 4.91 (1.50 g, 6.05 mmol) was dissolved in 12 mL anhydrous THF under argon. The 
mixture was cooled to 0 °C and LiAlH4 (0.69 g, 18.14 mmol) was added to it in small portions. 
After the addition was complete the reaction mixture was warmed to room temperature and then 
heated to reflux for 1 h. The reaction was cooled to 0 °C and diluted with ethyl acetate (12 mL). 
Water (5 mL) was added very slowly followed by the slow addition of 1M NaOH (10 mL). The 
salts were filtered and the organic layer was separated and washed with brine (10 mL). The 
organic layer was dried over sodium sulfate, filtered and concentrated. Purification of the residue 
via silica gel chromatography (10% methanol/ 2% triethylamine/ 88% DCM) provided amine 
4.92 (0.93 g, 76%). 
4.92. Brown solid (0.93 g, 76 %); TLC Rf = 0.66 (70% ethyl acetate/30% hexanes); IR (thin 
film) 3409, 3307, 3041, 2936, 2903, 1624, 1583 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.00 (br s, 
1H), 7.25 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.86 (dd, J = 
8.8, 2.4 Hz, 1H), 3.86 (s, 3H), 2.97-2.89 (m, 4H), 2.45 (s, 3H), 1.31 (br s, 1H); 13C NMR (100 
MHz, CDCl3) δ 153.9, 131.7, 127.7, 123.0, 113.6, 112.1, 111.9, 100.8, 56.0, 52.1, 36.3, 25.7. 
Anal. calcd for C12H16N2O: C, 70.56; H, 7.90; N, 13.71. Found: C, 70.80; H, 7.71; N, 13.69. 
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N-(2-{6-Methoxy-1-[(2-nitrobenzene)sulfonyl]-1H-indol-3-yl}ethyl)-N-methyl-2-
nitrobenzene-1-sulfonamide (4.93). 
To the amine 4.92 (2.97 g, 11.98 mmol) in 80 mL anhydrous DCM, tetrabutylammonium 
bromide (3.09 g, 9.58 mmol) and sodium hydroxide (2.87 g, 71.85 mmol) were added and the 
resulting mixture was stirred at rt for 20 min. 2-Nitrobenzenesulfonyl chloride (7.96 g, 35.9 
mmol) was added to the above solution and the resulting mixture was stirred at rt overnight. 
Water (50 mL) was then added and the organic layer was separated. The aqueous layer was then 
extracted with DCM (3 x 30 mL). The combined organic layers were dried over sodium sulfate, 
filtered and concentrated. Purification of the residue via silica gel chromatography (a gradient 
from 30% to 80% ethyl acetate/hexanes) to provide pure bisnosylate 4.93 (4.10 g, 60%). 
4.93. Tan colored solid (4.10 g, 60%); TLC Rf = 0.40 (60% ethyl acetate/40% hexanes); IR (thin 
film) 3097, 3023, 2938, 2836, 1611, 1543 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.89-7.87 (m, 
1H), 7.70-7.58 (m, 8H), 7.38 (s, 1H), 7.05 (d, J = 2.0 Hz, 1H), 6.92 (dd, J = 8.8, 2.0 Hz, 1H), 
3.86 (s, 3H), 3.58 (t, J = 7.2 Hz, 2H), 3.04-2.98 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 157.0, 
148.1, 147.7, 134.7, 133.6, 132.7, 132.2, 131.9, 131.6, 131.5, 130.5, 129.5, 129.4, 125.1, 124.8, 
124.2, 118.9, 114.5, 114.3, 102.1, 55.8, 49.6, 34.8, 24.2. Anal. calcd for C24H22N4O9S2: C, 50.17; 
H, 3.86; N, 9.75. Found: C, 50.22; H, 4.02; N, 9.82. 
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N-(2-{6-Hydroxy-1-[(2-nitrobenzene)sulfonyl]-1H-indol-3-yl}ethyl)-N-methyl-2-
nitrobenzene-1-sulfonamide (4.89). 
Methyl ether 4.93 (0.50 g, 0.87 mmol) was dissolved in 9 mL of anhydrous DCM and cooled to -
25 °C. Boron tribromide (1.09 g, 4.34 mmol) was then added slowly. The resulting mixture was 
kept between -15 to -25 °C for 90 min after which water (10 mL) and saturated aq. NaHCO3 (10 
mL) were added slowly. The organic layer was separated and the aqueous layer was washed with 
DCM (3 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and 
concentrated. Purification of the residue via silica gel chromatography (a gradient of 45 to 50% 
ethyl acetate/ hexanes) provided 0.27 g (56%) of phenol 4.89. 
4.89. Tan colored foam (0.27 g, 56%); TLC Rf = 0.16 (60% ethyl acetate/40% hexanes); IR (thin 
film) 3483, 3099, 3025, 2930, 2360, 2341, 1592, 1543 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.72 
(d, J = 2.0 Hz, 1H), 7.59-7.38 (m, 8H), 7.38 (s, 1H), 6.99 (d, J = 2.4 Hz, 1H), 6.85 (dd, J = 8.8, 
2.4 Hz, 1H), 4.90 (br s, 1H), 3.55 (t, J = 7.2 Hz, 2H), 3.00-2.97 (m, 5H); 13C NMR (100 MHz, 
CDCl3) δ 152.9, 148.0, 147.7, 134.7, 133.7, 132.7, 132.1, 131.81, 131.75, 131.68, 130.4, 129.6, 
129.4, 125.4, 124.8, 124.2, 118.6, 114.6, 114.2, 104.9, 49.7, 34.8, 24.0. Anal. calcd for 
C23H20N4O9S2: C, 49.28; H, 3.60; N, 10.00. Found: C, 49.44; H, 3.41; N, 9.60. 
184 
 
 
cis-8-Benzyl 1-methyl 3a-[(3-{2-[N-methyl(2-nitrobenzene)sulfonamido]ethyl}-1-[(2-
nitrobenzene)sulfonyl]-1H-indol-6-yl)oxy]-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indole-1,8-
dicarboxylate (4.94). 
Phenol 4.89 (0.2 g, 0.36 mmol), imidate 4.57 (0.23 g, 0.45 mmol) and 0.40 g of 4 Å mol. sieves 
were suspended in 7 mL of 1,2-dichloroethane. Cu(OTf)2 (39.0 mg, 0.11 mmol) was added and 
the resulting mixture was stirred at rt for 18 h. The reaction mixture was then filtered and washed 
with 1M NaOH (5 mL). The organic layer was separated and the aqueous layer was washed with 
DCM (2 x 10 mL). The combined organic layers were dried over sodium sulfate, filtered and 
concentrated. The residue was purified by silica gel chromatography (5% ethyl acetate/ 95% 
hexanes) to provide 0.15 g (47%) of ether 4.94.  
4.94. Brown amorphous solid (0.15 g, 47%); TLC Rf = 0.56 (15% ethyl acetate/85% 
dichloromethane); IR (thin film) 3096, 3023, 2956, 2927, 1711, 1604, 1544 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.79 (d, J = 0.8 Hz, 1H), 7.77-7.49 (m, 9H), 7.35-7.28 (m, 8H), 7.07 (td, J = 7.6, 
0.8 Hz, 1H), 6.72-6.69 (m, 2H), 6.45 (s, 1H), 5.12-5.06 (m, 2H), 4.00-3.95 (m, 1H), 3.53 (br s, 
3H), 3.43-3.31 (m, 2H), 2.87 (td, J = 12.0, 5.2 Hz, 1H), 2.87 (s, 3H), 2.79-2.65 (m, 3H), 2.54 
(dd, J = 12.0, 5.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 155.1, 153.0, 151.6, 148.0, 147.7, 
143.7, 135.8, 134.7, 133.5, 132.8, 132.4, 131.8, 131.5, 131.4, 131.0, 130.9, 130.5, 129.4, 129.0, 
128.6, 128.3, 128.1, 125.6, 124.8, 124.7, 124.2, 124.1, 119.5, 118.5, 116.8, 114.2, 111.1, 93.5, 
78.7, 67.7, 52.6, 49.3, 45.2, 37.3, 34.6, 23.5. Anal. calcd for C43H38N6O13S2: C, 56.70; H, 4.20; 
N, 9.23. Found: C, 56.65; H, 4.26; N, 8.87. 
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cis-8-Benzyl 1-methyl 3a-({3-[2-(methylamino)ethyl]-1H-indol-6-yl}oxy)-1H,2H,3H,3aH,8H, 
8aH -pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.94a). 
Thiophenol (0.63 g, 5.71 mmol) was dissolved in 20 mL acetonitrile and the solution was cooled 
to 0°C. Potassium hydroxide (0.5 mL, 11M aq., 5.5 mmol) was added and the mixture was then 
stirred at 0 °C for 10 min and then warmed to rt. Ether 4.94 (1.30 g, 1.43 mmol) dissolved in 28 
mL acetonitrile was added and the resulting mixture was warmed to 50 °C for 4 h. Then mixture 
was then cooled to rt, diluted with water (20 mL) and extracted with DCM (3 x 20 mL). The 
combined organic layers were dried over sodium sulfate, filtered and concentrated to give crude 
indole 4.94a. Purification by silica gel chromatography (2% methanol/ 2% triethylamine/ 96% 
DCM) gave indole 4.94a contaminated with some triethylammonium salts. The compound was 
dissolved in DCM (10 mL) and washed with 1M NaOH (5 mL). The organic layer was separated 
and the aqueous layer was washed with DCM (2 x 10 mL). The combined organic layers were 
dried over sodium sulfate, filtered and concentrated to provide 0.70 g (91%) of pure indole 
4.94a. 
4.94a. White solid (0.70 g, 91%); TLC Rf = 0.36 (2% triethylamine/ 15% methanol/ 83% 
dichloromethane); IR (thin film) 3361, 3032, 2952, 2892, 2850, 1713, 1605 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.80 (s, 1H), 7.66 (d, J = 6.8 Hz, 1H), 7.37-7.26 (m, 8H), 7.08 (td, J = 7.6, 0.8 
Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 2.0 Hz, 1H), 6.85 (d, J  = 2.4 Hz, 1H), 6.63 (dd, J 
= 8.8, 2.4 Hz, 1H), 6.48 (s, 1H), 5.09-5.06 (m, 2H), 3.97-3.92 (m, 1H), 3.51 (br s, 3H), 2.94 (td, J 
= 12.0, 5.2 Hz, 1H), 2.76-2.66 (m, 5H), 2.52 (dd, J = 12.0, 5.2 Hz, 1H), 2.39 (s, 3H); 13C NMR 
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(100 MHz, CDCl3) δ 155.2, 153.1, 147.8, 143.8, 136.0, 133.4, 130.6, 129.9, 128.5, 128.1, 128.0, 
127.5, 124.8, 123.8, 123.2, 117.2, 117.0, 113.7, 111.4, 111.2, 93.4, 78.7, 67.6, 52.5, 51.7, 45.4, 
36.7, 36.3, 25.5. Anal. calcd for C31H32N4O5: C, 68.87; H, 5.97; N, 10.36. Found: C, 69.06; H, 
5.78; N, 10.35. 
 
cis-8-Benzyl 1-methyl 3a-({3-[2-(dimethylamino)ethyl]-1H-indol-6-yl}oxy)-1H,2H,3H,3aH, 
8H,8aH-pyrrolo[2,3-b]indole-1,8-dicarboxylate (4.95). 
A solution of 37% formaldehyde (51.0 mg, 1.70 mmol) in 1.7 mL methanol was added to a 
solution of compound 4.94a (0.46 g, 0.85 mmol), sodium cyanoborohydride (64.0 mg, 1.02 
mmol) and glacial acetic acid (0.26 g, 4.26 mmol) in 14 mL methanol. The reaction mixture was 
stirred at rt for 1 h. The reaction mixture was then concentrated and the residue was dissolved in 
dichloromethane (20 mL) and washed with 1M NaOH (20 mL). The organic layer was separated 
and the aqueous layer was washed with DCM (2 x 10 mL). The combined organic layers were 
dried over sodium sulfate, filtered and concentrated. The residue was then purified via silica gel 
chromatography (1% ammonium hydroxide/ 1% methanol/ 98% DCM) to give 0.39 g (83%) of 
tryptamine 4.95. 
4.95. White foam (0.39 g, 83%); TLC Rf = 0.42 (1% triethylamine/ 10% methanol/ 89% 
dichloromethane); IR (thin film) 2950, 2859, 2821, 2778, 1716, 1604 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.07-7.98 (br s, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.35-7.28 (m, 7H), 7.09 (td, J = 7.6, 0.8 
Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 6.93 (s, 1H), 6.81 (d, J = 2.0 Hz, 1H), 6.62 (dd, J  = 8.4, 1.6 
Hz, 1H), 6.60 (br s, 1H), 5.09-5.03 (m, 2H), 3.96-3.92 (m, 1H), 3.50 (br s, 3H), 2.95 (td, J = 
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12.0, 5.2 Hz, 1H), 2.75-2.65 (m, 3H), 2.54-2.45 (m, 3H), 2.31 (s, 6H); 13C NMR (100 MHz, 
CDCl3) δ 155.2, 153.1, 147.8, 143.8, 136.0, 133.4, 130.6, 130.1, 128.5, 128.1, 128.0, 127.4, 
124.8, 123.9, 123.1, 117.10, 117.06, 113.5, 111.5, 111.1, 93.4, 78.7, 67.5, 59.8, 52.5, 45.4, 45.2, 
36.7, 23.3. Anal. calcd for C32H34N4O5: C, 69.30; H, 6.18; N, 10.10. Found: C, 69.14; H, 6.05; N, 
10.24. 
 
cis-Methyl 3a-({3-[2-(dimethylamino)ethyl]-1H-indol-6-yl}oxy)-1H,2H,3H,3aH,8H,8aH-
pyrrolo[2,3-b]indole-1-carboxylate (4.95a). 
Benzyl carbamate 4.95 (0.33 g. 0.60 mmol) and 10% palladium on carbon (20 mg, 0.19 mmol) 
were suspended in 3 mL of methanol. The flask was evacuated and filled with hydrogen gas 
from a balloon. After 7 h the reaction mixture was filtered through a bed of Celite using 
methanol. The filtrate was concentrated and the residue was purified via silica gel 
chromatography (1% ammonium hydroxide/ 4% methanol/ 95% dichloromethane) to give 0.25 g 
(99%) of pure indoline 4.95a. 
4.95a. White foam (0.25 g, 99%); TLC Rf = 0.56 (1% triethylamine/ 10% methanol/ 89% 
dichloromethane); IR (thin film) 3349, 3084, 3010, 2951, 2860, 2823, 2780, 1696, 1612 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.14-7.06 (m, 2H), 6.92 (s, 
2H), 6.77-6.70 (m, 2H), 6.58-6.56 (m, 1H), 5.68 (d, J = 0.8 Hz, 0.55H), 5.61 (d, J = 1.2 Hz, 
0.45H), 5.05 (s, 0.6H), 4.74 (s, 0.4H), 3.91-3.85 (m, 0.5H), 3.79-3.71 (m, 3.5H), 3.24-3.12 (m, 
1H), 2.84-2.75 (m, 3H), 2.54-2.47 (m, 3H), 2.31 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 155.8, 
155.1, 150.5, 150.2, 148.4, 148.3, 133.2, 133.1, 130.5, 127.5, 127.1, 127.0, 125.0, 122.8, 122.7, 
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119.2, 119.0, 117.2, 117.1, 113.9, 111.3, 111.2, 111.0, 110.6, 110.2, 110.0, 95.8, 94.7, 78.3, 77.8, 
60.1, 52.7, 52.5, 45.5, 45.4, 45.2, 37.21, 37.15, 23.6 (multiple signals are observed for many 
resonances due to restricted rotation around the methyl carbamate); Anal. calcd for C24H28N4O3: 
C, 68.55; H, 6.71; N, 13.32. Found: C, 68.33; H, 6.60; N, 13.20. 
 
Arundinine (4.6). 
The carbamate 4.95a (85 mg, 0.20 mmol) was azeotropically dried by removing benzene three 
times via a rotovap, and then dissolved in 20 mL of anhydrous toluene. Red-Al (0.34 mL, 1.01 
mmol) was added to the above solution slowly at rt and the mixture was stirred at rt for 1h before 
being heated to 50 °C for 30 min. After cooling the mixture to rt the reaction was quenched with 
10 mL of Rochelle’s salt. The biphasic mixture was concentrated on the rotovap and the resulting 
residue was partitioned using 10 mL each of water and DCM. The organic layer was separated 
and the aqueous layer was washed twice with 10 mL of DCM. The combined organic layers 
were dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel 
chromatography (1% ammonium hydroxide/ 1.5% methanol/ 97.5% DCM) to provide 65 mg 
(86%) of pure arundinine (4.6). Data matched those reported in the literature (see Zhalolov, I.; 
Khuzhaev, V. U.; Tashkhodzhaev, B.; Levkovich, M. G.; Aripova, S. F.; Abdullaev, N. D. 
Chem. Nat. Compd. 1998, 34, 706). 
Arundinine (4.6). White solid (65 mg, 86%); TLC Rf = 0.31 (1% triethylamine/ 10% methanol/ 
89% dichloromethane); IR (thin film) 3396, 3137, 3079, 3036, 2947, 2919, 2867, 2826, 1606, 
1470 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.95 (br s, 1H), 7.31-7.29 (m, 1H), 7.11 (td, J = 7.6, 
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1.2 Hz, 1H), 7.07 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 2.0 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 6.77 (td, 
J = 7.6, 0.8 Hz, 1H), 6.69 (dd, J = 8.8, 2.4 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 4.92 (d, J = 3.6 Hz, 
1H), 4.17 (d, J = 3.2 Hz, 1H), 2.91-2.87 (m, 1H), 2.80-2.66 (m, 4H), 2.47-2.43 (m, 5H), 2.35-
2.28 (m, 7H); 13C NMR (100 MHz, CDCl3) δ 151.0, 149.6, 132.4, 130.5, 129.7, 127.6, 124.9, 
122.2, 119.3, 116.8, 114.3, 111.2, 110.4, 109.2, 96.8, 84.6, 60.1, 51.9, 45.4, 40.9, 37.5, 23.6. 
HRMS (ESI+) m/z calcd for C23H28N4O [M + Na
+] 377.2336. Found 377.2333. 
 
(4.100-exo and 4.100-endo) Please see synthesis of compound 4.61 for procedure. 
Lime green foam (0.295 g, 25%); TLC Rf = 0.52 (60% ethyl acetate/40% hexanes); 
1H NMR 
(400 MHz, CDCl3) endo δ 7.97 (d, J = 8.0 Hz, 1H), 7.75-7.66 (m, 1H), 7.36-7.31 (m, 8H), 6.26-
6.22 (m, 1H), 5.39-5.11 (m, 2H ), 4.96 (t, J = 7.6 Hz, 1H), 4.48 (br s, 1H), 3.54 (s, 3H), 3.11-2.99 
(m, 1H), 2.80-2.75 (m, 1H); 1H NMR (400 MHz, CDCl3) exo δ 8.15 (d, J = 8.0 Hz, 1H), 7.75-
7.66 (m, 1H), 7.36-7.31 (m, 8H), 6.26-6.22 (m, 1H), 5.39-5.11 (m, 2H ), 4.81 (dd, J = 9.6, 1.2 
Hz, 1H), 4.22 (br s, 1H), 3.75 (s, 3H), 3.11-2.99 (m, 1H), 2.80-2.75 (m, 1H); 13C NMR (100 
MHz, CDCl3) exo/endo mixture δ 173.4, 173.1, 172.3, 170.5, 160.9, 160.4, 151.2, 151.1, 143.4, 
142.8, 136.3, 136.0, 134.8, 134.7, 128.8, 128.63, 128.58, 128.57, 128.5, 128.4, 128.2, 128.0, 
127.94, 127.90, 106.3, 106.2, 79.7, 79.0, 68.8, 68.7, 56.5, 56.4, 53.1, 52.5, 40.3, 39.6; Anal. 
calcd for C20H20N2O5: C, 65.21; H, 5.47; N, 7.60. Found: C, 65.09; H, 5.69; N, 7.94. 
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Prepared using Fmoc based solution phase peptide synthesis. 
4.11. White foam (0.3 g); TLC Rf = 0.52 (100% ethyl acetate); 
1H NMR (400 MHz, CDCl3) δ 
7.76-7.74 (m, 2H), 7.61-7.49 (m, 3H), 7.40-7.26 (m, 13H), 6.91 (s, 1H), 4.74-4.18 (m, 8H), 3.85-
3.51 (m, 4H), 2.20-1.74 (m, 12H), 1.26-0.52 (m, 24H); 13C NMR (100 MHz, CDCl3) δ171.7, 
171.6, 171.5, 171.4, 171.1, 156.5, 143.92, 143.87, 141.3, 139.8, 139.6, 128.5, 128.1, 127.9, 
127.7, 127.6, 127.1, 126.9, 125.3, 125.2, 119.9, 77.8, 67.1, 59.9, 59.7, 56.7, 55.7, 47.9, 47.8, 
47.2, 38.2, 38.0, 31.7, 28.4, 27.9, 25.2, 25.1, 24.6, 24.4, 19.3, 18.0, 15.4, 15.3, 11.6, 11.1. 
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Chapter 5 – Tandem C3-Alkylation Dearomatization of 2,3-Disubsitituted Indoles Using 
Trichloroacetimidates 
 
Abstract 
 Trichloroacetimidates have been utilized for the selective C3-alkylation of 2,3-
disubstituted indoles to provide dearomatized indolenine motifs. These substructures are 
prevalent in many complex alkaloids. The most effective conditions for these transformations 
utilize a catalytic amount of a Lewis acid to activate the imidate alkylating agent. The scope of 
these alkylation reactions in terms of the indole substituent and the imidate coupling partner has 
also been investigated. In order to demonstrate the utility of this new technology, this method has 
been applied to a synthesis of the core structure of the communesin natural products. The new 
Lewis acid catalyzed protocol provides an excellent alternative to the existing transition metal 
catalyzed or base promoted approaches to complex indolenines. 
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5.1 Introduction 
5.1.1 Natural Products with a Dearomatized Indole Scaffold 
 Indole and indoline based structures are widely distributed in natural products and 
pharmaceutical agents, possessing a wide array of biological activity.1-4 The significance of these 
compounds has led to a plethora of techniques that have been developed to selectively 
functionalize indoles at the N1, C2 or C3 position.5-7 Of these possible alkylation products, 
selective alkylation of C3-substituted indoles to provide the quaternary dearomatized 3,3’-
disubstituted indolenine is of particular interest. These indolenine products form the core 
structure of a number of indole alkaloids such as strictamine (5.1)8-11, cathafoline (5.2),12 
aspidophylline A (5.3),10, 13-14 koumine (5.4),15-18 tubifoline (5.5),19 and communesin B (5.6)20-26 
(Figure 5.1). Indolenines therefore may serve as building blocks for the synthesis of this complex 
set of molecules and their derivatives.27-40 
 
Figure 5.1. Indolenine Based Natural Products 
5.1.2 Base Promoted Dearomatized C3-Alkylation of 2,3-Disubstituted Indoles 
C3-Alkylation of 2,3-disubstituted indoles under standard conditions requires the use of a 
strong base and an alkyl halide.41-44 Typically these reactions also provide poor yields of the 
desired product. For example, Nakazaki reported C-3-alkylation of 2,3-dimethylindole (5.7) 
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using alkyl halides as the electrophile and sodium amide as a base which provided the indolenine 
products in low yield (Scheme 5.1, eq. 1).41 As an alternative Grignard reagents have also been 
utilized as a base for similar C3-alkylations (Scheme 5.1, eq. 2).44 These reactions are proposed 
to proceed via the formation of indolyl magnesium salt, which then favors C-alkylation due to 
the polarized nature of the C2-C3 alkene. Recently Hashim and co-workers demonstrated the 
accessibility of such indolenine products using alkyl and benzyl bromides under base and 
triethylboron promoted conditions (Scheme 5.1, eq. 3).45 Reportedly the formation of the N-B 
bond leads to a more electron rich aromatic ring and the tight association of boron with indole 
nitrogen prevents not only the formation of N-alkyl product but also the C2-alkylation (where 
C2-position is unsubstituted). 
Scheme 5.1. Base Promoted Selective C3-Alkylation of Indoles 
 
5.1.3 Palladium Catalyzed Reactions for Formation of Indolenine 
A) Utilizing -allyl Complexes Formed from Alcohols and Carbonates 
A number of groups have reported selective C3-allylation of unsubstituted indoles in the 
presence of transition metal catalysts.15, 17, 46-54 The first example of a palladium catalyzed 
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regioselective alkylation of C3-substituted indoles was reported by Tamaru’s group. This 
transformation involved the use of allylic alcohols as electrophiles in the presence of a boron 
complex, like triethylborane (Scheme 5.2, eq. 1).55 Encouraged by these findings Trost 
demonstrated an enantioselective C3-allylation of C3-substituted indoles under similar 
conditions using the ligand 5.17 to provide the product 5.18 with good enantioselectivity 
(Scheme 5.2, eq. 2).56 Even though these allylation reports provided the indolenines from C3-
substituted indoles efficiently, the direct allylation of sterically encumbered 2,3-disubstituted 
indole still posed a challenge.57 In related work, Rawal and co-workers demonstrated a palladium 
catalyzed decarboxylative C3-allylation and alkylation of 2,3-disubstituted indoles to provide 
indolenines (Scheme 5.2, eq. 3). Some of these examples utilize allylic or benzylic carbamates 
(5.20)58-59 as the coupling partners with indoles, while alternatively unimolecular 
decarboxylative alkylation using N-alloc and N-Cbz indoles (5.22) have also been 
demonstrated.60  
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Scheme 5.2. Palladium Catalyzed C3-Allylation of C3-Monosubstituted Indoles 
 
B) Via C-H Activation 
Other reported approaches to 3,3'-disubstituted indolenines involve C-H activation 
chemistry. For example, a palladium catalyzed electrophilic alkylation has been reported using 
methyl alkynes to provide the cinnamyl substituted indolenine 5.26 (Scheme 5.3, eq. 1).61 
Palladium catalyzed alkylation of indoles via C-H activation of alkenes has also been reported 
(Scheme 5.3, eq. 2).62 These strategies provide an excellent alternative to palladium catalyzed 
alkylation using carbamates, although the reaction conditions do tend to be more stringent and 
requires higher temperatures. 
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Scheme 5.3. Pd Catalyzed C3-Allylation Via C-H Activation 
 
5.1.4 Other Methods for Formation of 3,3'-Indolenines 
Bandini and co-workers have employed electron rich allenamides like 5.27 as 
electrophiles in the C3-allylation of 2,3-disubstituted indoles (Scheme 5.4). The early reports of 
this work involve the use of a gold catalyst and silver trifluoroacetic acid salts (Scheme 5.4, eq. 
1).63-64 Using AgTFA in a counterion metathesis formed the more reactive gold trifluoroacetate 
salt, which then facilitated the complete conversion of the starting material and provided a high 
regioselectivity for C3-allylation over N-allylation. This methodology also proved effective in a 
gold-free setting where the BINOL Brønsted acid catalyst 5.30 was utilized to provide the 
indolenine product 5.31 with high enantioselectivity (Scheme 5.4, eq. 2).65 Various indoles were 
found to be reactive under these conditions but the scope of the allene was limited to electron 
rich allenamides. 
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Scheme 5.4. Gold and Phosphoric Acid Catalyzed Reactions with Allenamides 
 
5.1.5 Trichloroacetimidates as Electrophiles in the C3-Alkylation of Indoles 
 Trichloroacetimidates are also excellent alkylating agents when activated by a catalytic 
amount of a Lewis acid, and could provide an exceptional strategy for the synthesis of these 
indolenines under mild conditions without the use of heavy metals. Trichloroacetimidates have 
already been utilized for selective alkylation of unsubstituted indoles,66-69 however there have 
been no reports on the use of trichloroacetimidates for the synthesis of indolenine substrates. Our 
recent findings on the use of trichloroacetimidates for a number of alkylation reactions70-76 
encouraged us to investigate the reactivity of electron rich aromatic systems like indoles to 
provide indolenine structures. Based on the reactivity of imidates, various alkyl, allyl and benzyl 
groups could be substituted at the C3 position of the 2,3-disubstituted indoles in the presence of 
mild Brønsted or Lewis acid catalysts (Scheme 5.5). These reactions would proceed through the 
activated imidate 5.32A, which could be then displaced directly (SN2) or via the formation of the 
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cation 5.32B (SN1) that could undergo nucleophilic attack by the indole leading to the formation 
of the product 5.33. 
Scheme 5.5. Proposed Formation of Indolenines Using Trichloroacetimidates 
 
 
5.2 Results and Discussion 
5.2.1 Optimization of Reaction Conditions 
 Based on our hypothesis the reaction of allyl trichloroacetimidate (5.34) with 2,3-
dimethylindole (5.7) was investigated to determine conditions for the efficient synthesis of these 
indolenine substrates. A variety of catalysts were evaluated, with TMSOTf emerging as the most 
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effective catalyst (Table 5.1, entry 11, 79% yield). These reactions were found to be favored in 
nonpolar halogenated solvents, and required just 3 h to proceed to completion. Lowering the 
catalyst loading to 10 mol % resulted in incomplete consumption of the starting material. 
Table 5.1. Optimization of Reaction Conditions 
 
Entry Conditions Conversiona Yieldb 
1 20 mol % PPTS, DCE, rt, 21 h 5c - 
2 20 mol % CSA, DCE, rt, 21 h 10c - 
3 20 mol % TfOH, DCE, rt, 21 h - 50 
4 20 mol % Cu(OTf)2, DCE, rt, 21 h - 14 
5 20 mol % ZnBr2, DCE, rt, 21 h 28
c - 
6 20 mol % BF3•OEt2, DCE, rt, 21 h - 5 
7 20 mol % TMSOTf, DCE, rt, 21 h - 70 
8 20 mol % TMSOTf, DCM, rt, 21 h - 69 
9 20 mol % TMSOTf, PhCF3, rt, 21 h - 9 
10 20 mol % TMSOTf, THF, rt, 21 h - 21 
11 20 mol % TMSOTf, DCE, rt, 3 h - 79 
12 20 mol % TMSOTf, DCE, rt, 1 h 76c - 
aConversion (%) was determined by the ratio of starting material to product in the crude 1H NMR. bIsolated yield 
(%). cSome starting material still remained. 
5.2.2 Substrate Scope 
With the optimized conditions in hand, the reactivity of different trichloroacetimidates 
towards the C3-alkylation of 2,3-disubstituted indoles was evaluated (Table 5.2). The propargyl 
imidate (5.36) proved to be less reactive and provided the indolenine product 5.37 with 67% 
yield under more forcing conditions (reflux), with a second aliquot of TMSOTf being necessary 
to drive the reaction to completion. Benzylic trichloroacetimidates with electron withdrawing 
groups (entries 3-6) provided the product with significantly higher yields as compared to those 
with electron donating groups (entries 8 & 9). The electron rich imidates were found to provide 
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more side products that formed from alkylating the 5 and 7 position of the indole ring. Benzylic 
imidates with ortho substitution provided the indolenine products with a decreased yield owing 
to steric reasons (entry 10 & 11). Addition of another phenyl ring at the benzylic position like the 
imidate 5.56 provided the product with a high yield (entry 12). 
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Table 5.2. Alkylation of 2,3-Dimethylindole with Trichloroacetimidates 
 
aReaction was heated to reflux for 24 h, then another 20 mol % of TMSOTf was added and the reaction was refluxed 
for another 24 h prior to workup. bReaction was stirred at rt for 48 h. cReaction was heated to reflux for 24 h. 
dReaction was stirred at rt for 18 h. eReaction was heated to reflux for 6 h. 
 Next the role of sterics and electronics on the indole nucleophile was explored (Table 
5.3). Incorporation of a chloride substituent at the 5 position of the indole (5.58) reduced the 
reactivity of the indole and the reaction needed to be heated to reflux to provide 60% yield of the 
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product (entry 1). Deactivated indole 5.60 with bromide substituents at the 5 and 7 position also 
decelerated the reaction but provided a higher yield of the product, which was rationalized to be 
due to the fewer available sites on the indole ring for competing Friedel-Crafts type reactions. 
The effect of increasing the steric bulk at the 2 and 3 positions of the indole was also evaluated 
by using the carbocyclic rings tethered between the 2 and 3 positions (entry 3 & 4). The six 
membered tether 5.62 provided the product with good yields however the larger eight membered 
tether 5.64 gave a significantly lower yield and the reaction needed to be heated to proceed to 
completion. The protected γ-carboline indole 5.66 also successfully provided the indolenine 
product although in moderate yield (entry 5). The phthalimide protected tryptamine 5.68 
participated in the alkylation reaction, and the product was isolated with a satisfactory yield of 
52% (entry 6). Substituting the methyl group at 2-position of indole with a phenyl group did 
provide the desired product 5.71, albeit in a lower yield than the corresponding methyl 
compound. 
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Table 5.3. Alkylation of Different 2,3-Substituted Indole with Allyl Trichloroacetimidates 
 
aReaction was heated to reflux for 3 h. bReaction was heated to reflux for 2 h. cReaction was heated to reflux for 8 h. 
dReaction was heated to reflux for 18 h. 
 In order to demonstrate the utility of this methodology it was applied towards the 
synthesis of the communesin core structure 5.73 (Scheme 5.6). Subjecting indole 5.7 and the 
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benzylic imidate 5.72 (synthesized over 2 steps from 2-aminobenzyl alcohol) to the reaction 
conditions provided the imine 5.73. The expected tetracyclic core 5.74 was not obtained in one 
step, wherein the pendant acetamide group would undergo an intramolecular cyclization into the 
imine functionality. After further optimization this methodology may be utilized for the synthesis 
of the core structure of similar complex natural products or to obtain their analogs. 
Scheme 5.6. Synthesis of Communesin Core Ring System 
 
 
5.3 Conclusions and Future Work 
 In conclusion we have reported the use of trichloroacetimidates for selective C3-
alkylation of 2,3-disubstituted indoles under Lewis acid catalyzed conditions. A number of 
benzylic, allylic and propargylic substituted indolenine motifs could be obtained using this 
method. This protocol is also being applied towards the synthesis of communesin core to 
demonstrate its utility. This methodology provides an excellent alternative to the currently 
existing metal catalyzed conditions. In the future chiral catalysts will be explored to access 
enantioenriched indolenine motifs. 
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5.4 Experimental 
The trichloroacetimidates 5.34,77 5.36,78 5.40,79 5.44,80 5.5480 and 5.5681 were synthesized as 
previously described (for characterization data see the listed references). Imidates 5.46 and 5.50 
were obtained from commercially available sources. 
General procedure for synthesis of trichloroacetimidates. 
DBU (0.1 equiv.) was added to a solution of the alcohol (1.0 equiv.) in 4.0 mL anhydrous DCM 
under argon. The mixture was stirred at room temperature for 15 min and then cooled to 0 °C. 
Trichloroacetonitrile (1.2 equiv.) was then added, and the reaction mixture was allowed to warm 
to room temperature and stirred for 18 h. The reaction mixture was then concentrated and the 
residue purified by silica gel chromatography (using the listed solvent system) to give the 
trichloroacetimidate. 
 
Purified by silica gel chromatography using 2% triethylamine/10% ethyl acetate/90% hexanes. 
4-Nitrobenzyl 2,2,2-trichloroethanimidoate (5.38). Tan solid (5.61 g, 96%); mp = 81-83 °C; 
TLC Rf = 0.63 (30% ethyl acetate/70% hexanes); IR (neat) 3318, 3110, 2944, 2845, 1665 cm
-1; 
1H NMR (400 MHz, CDCl3)  8.49 (br s, 1H), 8.26 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H), 
5.45 (s, 2H); 13C NMR (100 MHz, CDCl3)  162.1, 147.8, 142.8, 127.9, 123.8, 90.94, 69.1; 
Anal. calcd for C9H7Cl3N2O3: C, 36.33; H, 2.37; N, 9.42. Found: C, 36.07; H,2.48; N, 9.67. 
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Purified by silica gel chromatography using 5% triethylamine/5% ethyl acetate/10% hexanes. 
4-(Trifluoromethyl)benzyl 2,2,2-trichloroethanimidoate (5.42). Clear oil (3.05 g, 98%); TLC 
Rf = 0.33 (10% ethyl acetate/90% hexanes); IR (neat) 3346, 2951, 2888, 1671, 1622 cm
-1; 1H 
NMR (400 MHz, CDCl3)  8.45 (br s, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 8.0 Hz, 2H), 
5.40 (s, 2H); 13C NMR (100 MHz, CDCl3)  162.3, 139.6, 130.4 (q, J = 32.0 Hz), 127.7, 125.5 
(q, J = 3.0 Hz), 124.1 (q, J = 271.0 Hz), 91.2, 69.6; Anal. calcd for C10H7Cl3F3NO: C, 37.47; H, 
2.20; N, 4.37. Found: C, 37.49; H, 2.24; N, 4.41. 
 
Purified by silica gel chromatography using 5% triethylamine/5% ethyl acetate/10% hexanes. 
4-Methylbenzyl 2,2,2-trichloroethanimidoate (5.48). White solid (3.57 g, 95%); mp = 51-54 
°C; TLC Rf = 0.50 (10% ethyl acetate/90% hexanes); IR (neat) 3322, 2945, 1670, 1514 cm
-1; 1H 
NMR (400 MHz, CDCl3)  8.36 (br s, 1H), 7.32 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 7.6 Hz, 2H), 
5.30 (s, 2H), 2.36 (s, 3H); 13C NMR (100 MHz, CDCl3)  162.6, 138.2, 132.5, 129.2, 128.0, 
91.5, 70.8, 21.3; Anal. calcd for C10H10Cl3NO: C, 45.06; H, 3.78; N, 5.26. Found: C, 44.93; H, 
3.77; N, 5.43. 
 
Purified by silica gel chromatography using 2% triethylamine/10% ethyl acetate/88% hexanes. 
2-Nitrobenzyl 2,2,2-trichloroethanimidoate (5.52). Clear oil (3.50 g, 90%); TLC Rf = 0.31 
(10% ethyl acetate/90% hexanes); IR (neat) 3339, 3085, 2958, 2860, 1668, 1526 cm-1; 1H NMR 
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(400 MHz, CDCl3)  8.50 (br s, 1H), 8.14 (dd, J = 8.0, 0.8 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 
7.72-7.68 (m, 1H), 7.54-7.50 (m, 1H), 5.76 (s, 2H); 13C NMR (100 MHz, CDCl3)  161.9, 147.3, 
133.9, 131.9, 128.8, 128.5, 125.0, 91.0, 67.4; Anal. calcd for C9H7Cl3N2O3: C, 36.33; H, 2.37; N, 
9.42. Found: C, 36.42; H, 2.38; N, 9.35. 
 
Purified by silica gel chromatography using 2% triethylamine/98% ethyl acetate. 
2-(Acetylamino)benzyl 2,2,2-trichloroethanimidoate (5.72). White Solid (1.19 g, 99%); mp = 
96 °C – charred; TLC Rf = 0.41 (100% ethyl acetate); IR (neat) 3334, 3270, 3062, 3037, 1665, 
1590, 1529 cm-1; 1H NMR (400 MHz, CDCl3)  9.31 (br s, 1H), 8.40 (br s, 1H), 7.93 (d, J = 8.4 
Hz, 1H), 7.45-7.38 (m, 2H), 7.17 (t, J = 7.2 Hz, 1H), 5.35 (s, 2H), 2.21 (s, 3H); 13C NMR (100 
MHz, CDCl3)  168.6, 163.3, 137.1, 131.7, 130.2, 125.3, 124.9, 124.2, 91.1, 68.4, 24.3; Anal. 
calcd for C11H11Cl3N2O2: C, 42.68; H, 3.58; N, 9.05. Found: C, 42.68; H, 3.60; N, 8.95. 
 
General procedure for C3-alkylation of 2,3-disubstituted indoles. 
In a flame dried flask the imidate (1.0 equiv.) was dissolved in anhydrous 1,2-dichloroethane 
(0.15 M) followed by the addition of the indole (1.5 equiv.). To this solution freshly distilled 
TMSOTf (0.2 equiv.) was added and the resulting mixture was stirred at rt for 3 h. The reaction 
mixture was quenched with 10 mL 1M NaOH. The organic layer was separated and the aqueous 
layer was washed with DCM (2 x 5 mL). The combined organic layers were dried over sodium 
sulfate and then filtered and concentrated to provide the crude mixture. The crude mixture was 
then purified by silica gel chromatography using the solvent systems listed for each compound. 
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Purified by silica gel chromatography using 20% ethyl acetate/80% hexanes. 
Lit. ref. for characterization data: Chen, J.; Cook, M. J. Org. Lett. 2013, 15, 1088-1091. 
2,3-Dimethyl-3-(prop-2-en-1-yl)-3H-indole (5.35). Yellow oil (82.0 mg, 79%); TLC Rf = 0.11 
(10% ethyl acetate/90% hexanes); IR (neat) 3079, 3009, 2966, 2827, 2869, 1579 cm-1; 1H NMR 
(400 MHz, CDCl3)  7.52 (d, J = 8.0 Hz, 1H), 7.33-7.21 (m, 2H), 7.19 (td, J = 7.2, 0.8 Hz, 1H), 
5.21-5.11 (m, 1H), 4.98-4.85 (m, 2H), 2.66-2.60 (m, 1H), 2.42 (dd, J = 14.0, 8.0 Hz, 1H), 2.26 
(s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3)  186.6, 154.2, 143.4, 132.5, 127.7, 125.0, 
121.8, 119.8, 118.0, 57.5, 41.2, 21.8, 15.9. 
 
Prepared using modified general conditions: Reaction was heated to reflux for 24 h, then another 
20 mol % of TMSOTf was added and the reaction was refluxed for another 24 h prior to workup. 
Purified by silica gel chromatography using 30% ethyl acetate/70% hexanes. 
2,3-Dimethyl-3-(prop-2-yn-1-yl)-3H-indole (5.37). Brown oil (0.25 g, 67%); TLC Rf = 0.32 
(40% ethyl acetate/60% hexanes); IR (neat) 3291, 3048, 2966, 2869, 2118, 1728, 1580 cm-1; 1H 
NMR (400 MHz, CDCl3)  7.54 (d, J = 7.6 Hz, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.33 (dt, J = 7.6, 
1.2 Hz, 1H), 7.21 (t, J = 7.2 Hz, 1H), 2.60 (dd, J = 16.8, 2.8 Hz, 1H), 2.43 (dd, J = 16.8, 3.2 Hz, 
1H), 2.32 (s, 3H), 1.97 (t, J = 2.8 Hz, 1H), 1.40 (s, 3H); 13C NMR (100 MHz, CDCl3)  185.4, 
154.1, 143.0, 128.2, 125.2, 121.9, 120.0, 79.3, 70.9, 55.6, 26.5, 20.7, 16.0; Anal. calcd for 
C13H13N: C, 85.21; H, 7.15; N, 7.64. Found: C, 85.19; H, 7.15; N, 7.48. 
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Prepared using modified general conditions: Reaction was stirred at rt for 48 h. 
Purified by silica gel chromatography using 25% ethyl acetate/75% hexanes. 
2,3-Dimethyl-3-(4-nitrobenzyl)-3H-indole (5.39). Yellow oil (0.26 g, 92%); TLC Rf = 0.13 
(40% ethyl acetate/60% hexanes); IR (neat) 2964, 2928, 2855, 1604, 1578 cm-1; 1H NMR (400 
MHz, CDCl3)  7.94-7.91 (m, 2H), 7.40 (d, J = 7.6 Hz, 1H), 7.29 (td, J = 7.2, 1.2 Hz, 1H), 7.20 
(td, J = 7.2, 1.2 Hz, 1H), 7.14 (d, J = 9.2 Hz, 1H), 6.90-6.87 (m, 2H), 3.28 (d, J = 13.6 Hz, 1H), 
3.03 (d, J = 13.6 Hz, 1H), 2.37 (s, 3H), 1.44 (s, 3H); 13C NMR (100 MHz, CDCl3)  185.0, 
154.2, 146.8, 143.8, 142.1, 129.9, 128.3, 125.1, 123.0, 122.2, 120.2, 58.4, 42.6, 22.1, 16.2; Anal. 
calcd for C17H16N2O2: C, 72.84; H, 5.75; N, 9.99. Found: C, 73.01; H, 5.82; N, 9.75. 
 
Prepared using modified general conditions: Reaction was heated to reflux for 24 h. 
Purified by silica gel chromatography using 50% ethyl acetate/50% hexanes. 
4-[(2,3-Dimethyl-3H-indol-3-yl)methyl]benzonitrile (5.41). Purple oil (0.20 g, 71%); TLC Rf = 
0.13 (40% ethyl acetate/60% hexanes); IR (neat) 3050, 2965, 2929, 2869, 2227, 1607, 1577 cm-
1; 1H NMR (400 MHz, CDCl3)  7.41 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.31-7.26 (m, 
1H), 7.19 (t, J = 7.2 Hz, 1H), 7.12-7.10 (m, 1H), 6.84 (d, J = 8.4 Hz, 2H), 3.23 (d, J = 13.6 Hz, 
1H), 2.97 (d, J = 13.6 Hz, 1H), 2.36 (s, 3H), 1.42 (s, 3H); 13C NMR (100 MHz, CDCl3)  185.2, 
219 
 
154.1, 142.1, 141.6, 131.6, 129.9, 128.2, 125.1, 122.2, 120.2, 118.7, 110.7, 58.4, 42.9, 22.1, 
16.2; Anal. calcd for C18H16N2: C, 83.04; H, 6.19; N, 10.76. Found: C, 83.37; H, 6.05; N, 10.83. 
 
Prepared using modified general conditions: Reaction was stirred at rt for 18 h. 
Purified by silica gel chromatography using 15% ethyl acetate/85% hexanes. 
2,3-Dimethyl-3-[4-(trifluoromethyl)benzyl]-3H-indole (5.43). Pink oil (0.20 g, 69%); TLC Rf 
= 0.31 (40% ethyl acetate/60% hexanes); IR (neat) 2966, 2929, 2871, 1617, 1578 cm-1;  1H NMR 
(400 MHz, CDCl3)  7.43 (d, J = 7.6 Hz, 1H), 7.35-7.27 (m, 3H), 7.19 (t, J = 7.6 Hz, 1H), 7.10-
7.09 (m, 1H), 6.87 (d, J = 8.0 Hz, 2H), 3.24 (d, J = 13.6 Hz, 1H), 2.94 (d, J = 13.6 Hz, 1H), 2.36 
(s, 3H), 1.41 (s, 3H); 13C NMR (100 MHz, CDCl3)  185.5, 154.3, 142.5, 140.3, 129.5, 128.9 (q, 
J = 32.0 Hz), 128.0, 124.9, 124.1 (q, J = 270.0 Hz), 124.7 (q, J = 4.0 Hz), 122.4, 120.1, 58.3, 
42.5, 22.0, 16.2; Anal. calcd for C18H16F3N: C, 71.28; H, 5.32; N, 4.62. Found: C, 71.50; H, 
5.24; N, 4.75. 
 
Prepared using modified general conditions: Reaction was stirred at rt for 18 h. 
Purified by silica gel chromatography using 17% ethyl acetate/83% hexanes. 
Lit. ref. for characterization data: Lin, A.; Yang, J.; Hashim, M. Org. Lett. 2013, 15, 1950-
1953. 
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 3-(4-Chlorobenzyl)-2,3-dimethyl-3H-indole (5.45). Yellow oil (0.16 g, 58%); TLC Rf = 0.58 
(40% ethyl acetate/60% hexanes); IR (neat): 3047, 3028, 2917, 2868, 1578 cm-1; 1H NMR (400 
MHz, CDCl3)  7.42 (d, J = 7.6 Hz, 1H), 7.30-7.25 (m, 1H), 7.16 (td, J = 7.2, 0.8 Hz, 1H), 7.08-
7.03 (m, 3H), 6.69 (d, J = 8.8 Hz, 2H), 3.14 (d, J = 13.6 Hz, 1H), 2.84 (d, J = 13.6 Hz, 1H), 2.33 
(s, 3H), 1.38 (s, 3H); 13C NMR (100 MHz, CDCl3)  185.8, 154.3, 142.7, 134.6, 132.6, 130.6, 
127.94, 127.92, 124.8, 122.5, 120.0, 58.4, 42.2, 21.9, 16.3. 
 
Prepared using modified general conditions: Reaction was stirred at rt for 48 h. 
Purified by silica gel chromatography using 25% ethyl acetate/75% hexanes. 
Lit. ref. for characterization data: Zhu, Y.; Rawal, V. H. J. Am. Chem. Soc. 2012, 134, 111-
114. 
3-Benzyl-2,3-dimethyl-3H-indole (5.47). Pink oil (0.07 g, 50%); TLC Rf = 0.37 (40% ethyl 
acetate/60% hexanes); 1H NMR (400 MHz, CDCl3)  7.42 (d, J = 7.6 Hz, 1H), 7.29-7.25 (m, 
1H), 7.17-7.04 (m, 5H), 6.80 (d, J = 9.2 Hz ,2H), 3.17 (d, J = 13.6 Hz, 1H), 2.85 (d, J = 13.2 Hz, 
1H), 2.35 (s, 3H), 1.39 (s, 3H); 13C NMR (100 MHz, CDCl3)  186.3, 154.4, 143.1, 136.2, 129.5, 
127.8, 127.7, 126.7, 124.7, 122.7, 119.9, 58.5, 42.8, 22.0, 16.3. 
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Purified by silica gel chromatography using 20% ethyl acetate/80% hexanes. 
Lit. ref. for characterization data: Lin, A.; Yang, J.; Hashim, M. Org. Lett. 2013, 15, 1950-
1953. 
2,3-Dimethyl-3-(4-methylbenzyl)-3H-indole (5.49). Orange oil (0.13 g, 47%); TLC Rf = 0.31 
(40% ethyl acetate/60% hexanes); IR (neat) 3023, 2963, 2923, 1578 cm-1; 1H NMR (400 MHz, 
CDCl3)  7.42 (d, J = 7.6 Hz, 1H), 7.28-7.24 (m, 1H), 7.15 (dt, J = 7.6, 1.2 Hz, 1H), 7.06 (d, J = 
8.0 Hz, 1H), 6.90 (d, J = 8.0 Hz, 2H), 6.68 (d, J = 8.0 Hz, 2H), 3.13 (d, J = 13.6 Hz, 1H), 2.80 (d, 
J = 13.2 Hz, 1H), 2.32 (s, 3H), 2.23 (s, 3H), 1.36 (s, 3H); 13C NMR (100 MHz, CDCl3)  186.5, 
154.3, 143.2, 136.2, 133.1, 129.3, 128.5, 127.7, 124.6, 122.7, 119.8, 58.5, 42.4, 21.9, 21.0, 16.3. 
 
Purified by silica gel chromatography using 5% ethyl acetate/95% dichloromethane. 
3-(4-Methoxybenzyl)-2-methyl-3-(prop-2-en-1-yl)-3H-indole (5.51). Pink oil (88.0 mg, 55%); 
TLC Rf = 0.22 (5% ethyl acetate/95% dichloromethane); IR (neat) 3062, 2959, 2925, 2836, 
1611, 1579 cm-1; 1H NMR (400 MHz, CDCl3)  7.42 (d, J =7.6 Hz, 1H), 7.28-7.24 (m, 1H), 7.14 
(td, J = 7.2, 0.8 Hz, 1H), 7.05 (d, J = 7.2 Hz, 1H), 6.72-6.62 (m, 4H), 3.71 (s, 3H), 3.11 (d, J = 
13.6 Hz, 1H), 2.78 (d, J = 13.6 Hz, 1H), 2.32 (s, 3H), 1.36 (s, 3H); 13C NMR (100 MHz, CDCl3) 
 186.4, 158.3, 154.4, 143.2, 130.4, 128.3, 127.7, 124.6, 122.6, 119.8, 113.2, 58.6, 55.1, 42.0, 
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21.8, 16.3; Anal. calcd for C18H19NO: C, 81.47; H, 7.22; N, 5.28. Found: C, 81.27; H, 7.00; N, 
4.93. 
 
Purified by silica gel chromatography using 30% ethyl acetate/60% hexanes. 
2-Methyl-3-(2-nitrobenzyl)-3-(prop-2-en-1-yl)-3H-indole (5.53). Brown oil (0.10 g, 43%); 
TLC Rf = 0.15 (40% ethyl acetate/60% hexanes); IR (neat) 3146, 3067, 2964, 2928, 2868, 1608, 
1577 cm-1;  1H NMR (400 MHz, CDCl3)  7.70 (dd, J = 7.6, 1.2 Hz, 1H), 7.41 (d, J = 7.6 Hz, 
1H), 7.32-7.23 (m, 3H), 7.11-7.08 (m, 1H), 6.92 (d, J = 7.2 Hz, 1H), 6.81 (dd, J = 7.6, 1.2 Hz, 
1H), 3.85 (d, J = 14.0 Hz, 1H), 3.18 (d, J = 14.0 Hz, 1H), 2.35 (s, 3H), 1.34 (s, 3H); 13C NMR 
(100 MHz, CDCl3)  185.7, 154.1, 150.0, 142.1, 132.1, 131.9, 131.1, 128.0, 127.8, 125.2, 124.6, 
122.3, 120.0, 58.4, 37.0, 22.0, 16.0; Anal. calcd for C17H16N2O2: C, 72.84; H, 5.75; N, 9.99. 
Found: C, 72.91; H, 5.52; N, 9.80. 
 
Prepared using modified general conditions: Reaction was heated to reflux for 6 h. 
Purified by silica gel chromatography using 5% ethyl acetate/95% dichloromethane. 
3-(2-Chlorobenzyl)-2-methyl-3-(prop-2-en-1-yl)-3H-indole (5.55). Pink oil (0.12 g, 52%); 
TLC Rf = 0.4 (40% ethyl acetate/60% hexanes); IR (neat) 3060, 3022, 2963, 2925, 2866, 1576 
cm-1;  1H NMR (400 MHz, CDCl3)  7.48 (d, J = 7.6 Hz, 1H), 7.29-7.25 (m, 2H), 7.12-7.05 (m, 
2H), 7.00-6.97 (m, 2H), 6.71 (dd, J = 7.6, 1.6 Hz, 1H), 3.36 (d, J = 14.4 Hz, 1H), 3.01 (d, J = 
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14.0 Hz, 1H), 2.35 (s, 3H), 1.39 (s, 3H); 13C NMR (100 MHz, CDCl3)  186.5, 154.1, 143.0, 
134.6, 134.4, 130.8, 129.5, 128.1, 127.8, 126.3, 124.8, 122.7, 119.9, 58.1, 38.0, 22.2, 16.2; Anal. 
calcd for C17H16ClN: C, 75.69; H, 5.98; N, 5.19. Found: C, 75.50; H, 5.67; N, 5.24. 
 
Purified by silica gel chromatography using 17% ethyl acetate/83% hexanes. 
3-(Diphenylmethyl)-2-methyl-3-(prop-2-en-1-yl)-3H-indole (5.57). Orange oil (0.20 g, 71%); 
TLC Rf = 0.34 (40% ethyl acetate/60% hexanes); IR (neat) 3062, 3027, 2964, 2928, 2868, 1578 
cm-1; 1H NMR (400 MHz, CDCl3)  7.58 (d, J = 8.0 Hz, 1H), 7.40-7.24 (m, 6H), 7.12-7.03 (m, 
4H), 6.65 (d, J = 9.6 Hz, 2H), 6.59 (d, J = 7.2 Hz, 1H), 4.39 (s, 1H), 2.16 (s, 3H), 1.37 (s, 3H); 
13C NMR (100 MHz, CDCl3)  186.9, 155.0, 142.0, 140.3, 139.2, 130.7, 128.5, 128.1, 127.9, 
127.8, 127.10, 127.05, 124.7, 124.5, 120.3, 60.5, 57.0, 24.8, 16.4; Anal. calcd for C23H21N: C, 
88.71; H, 6.80; N, 4.50. Found: C, 88.68; H, 6.64; N, 4.62. 
 
Prepared using modified general procedure: Reaction was heated to reflux for 3 h. 
Purified by silica gel chromatography using 30% ethyl acetate/70% hexanes. 
5-Chloro-2,3-dimethyl-3-(prop-2-en-1-yl)-3H-indole (5.59). Pink oil (72.0 mg, 60%); TLC Rf 
= 0.43 (40% ethyl acetate/60% hexanes); IR (neat) 3079, 2967, 2927, 1640, 1578 cm-1;  1H NMR 
(400 MHz, CDCl3)  7.44 (d, J = 8.4 Hz, 1H), 7.28 (dd, J = 8.0, 2.0 Hz, 1H), 7.24 (d, J = 1.6 Hz, 
1H), 5.21-5.11 (m, 1H), 4.99-4.89 (m, 2H), 2.61 (dd, J = 14.0, 6.4 Hz, 1H), 2.42 (dd, J = 14.0, 
8.0 Hz, 1H), 2.27 (s, 3H), 1.31 (s, 3H); 13C NMR (100 MHz, CDCl3)  187.3, 152.4, 145.2, 
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131.9, 131.0, 128.0, 122.4, 120.6, 118.6, 58.0, 41.1, 21.7, 15.9; Anal. calcd for C13H14ClN: C, 
71.07; H, 6.42; N, 6.38. Found: C, 70.97; H, 6.08; N, 6.29. 
 
Prepared using modified general procedure: Reaction was heated to reflux for 2 h. 
Purified by silica gel chromatography using 25% ethyl acetate/75% hexanes. 
5,7-Dibromo-2,3-dimethyl-3-(prop-2-en-1-yl)-3H-indole (5.61). Yellow oil (0.13 g, 81%); 
TLC Rf = 0.10 (10% ethyl acetate/90% hexanes); IR (neat) 3076, 2973, 2925, 2868, 1597 cm
-1; 
1H NMR (400 MHz, CDCl3)  7.63 (d, J = 1.6 Hz, 1H), 7.32 (d, J = 1.6 Hz, 1H), 5.21-5.11 (m, 
1H), 5.00-4.91 (m, 2H), 2.62-2.56 (m, 1H), 2.45-2.40 (m, 1H), 2.30 (s, 3H), 1.31 (s, 3H); 13C 
NMR (100 MHz, CDCl3)  188.6, 151.7, 146.7, 133.5, 131.4, 124.3, 119.1, 119.0, 114.3, 59.9, 
41.0, 21.7, 16.2; Anal. calcd for C13H13Br2N: C, 45.51; H, 3.82; N, 4.08. Found: C, 45.45; H, 
3.68; N, 3.94. 
 
Purified by silica gel chromatography using 10% ethyl acetate/90% toluene. 
Lit. ref. for characterization data: N. Kagawa, J. P. Malerich, V. H. Rawal. Org. Lett. 2008, 
10, 2381-2384.  
4a-(Prop-2-en-1-yl)-2,3,4,4a-tetrahydro-1H-carbazole (5.63). Yellow oil (84.0 mg, 67%); IR 
(neat) 2928, 2855, 1639, 1582 cm-1; 1H NMR (400 MHz, CDCl3)  7.61-7.59 (m, 1H), 7.36-7.30 
(m, 2H), 7.22-7.18 (m, 1H), 5.22-5.12 (m, 1H), 4.97-4.85 (m, 2H), 2.94-2.92 (m, 1H), 2.67-2.53 
(m, 3H), 2.39-2.36 (m, 1H), 2.25-2.19 (m, 1H), 1.90-1.78(m, 1H), 1.72-1.68 (m, 1H), 1.51-1.39 
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(m, 1H), 1.18 (td, J = 13.6, 4.4 Hz, 1H); 13C NMR (100 MHz, CDCl3)  188.8, 154.9, 144.6, 
132.1, 127.6, 124.7, 121.9, 120.1, 118.0, 57.7, 37.6, 37.0, 30.2, 28.8, 21.1. 
 
Prepared using modified general procedure: Reaction was heated to reflux for 8 h. 
Purified by silica gel chromatography using 2% ethyl acetate/98% dichloromethane. 
Lit. ref. for characterization data: Chen, J.; Cook, M. J. Org. Lett. 2013, 15, 1088-1091.  
11a-(Prop-2-en-1-yl)-7,8,9,10,11,11a-hexahydro-6H-cycloocta[b]indole (5.65). Yellow oil 
(0.17 g, 47%); TLC Rf = 0.40 (5% ethyl acetate/95% dichloromethane); IR (neat) 3075, 3007, 
2924, 2854, 1699, 1612 cm-1; 1H NMR (400 MHz, CDCl3)  7.45 (d, J = 8.0 Hz, 1H), 7.34-7.30 
(m, 1H), 7.23-7.18 (m, 2H), 5.17-5.07 (m, 1H), 4.89-4.81 (m, 2H), 2.85-2.79 (m, 1H), 2.66-2.52 
(m, 2H), 2.37-2.22 (m, 2H), 2.18-2.03 (m, 1H), 1.97-1.87 (m, 1H), 1.69-1.60 (m, 1H), 1.51-1.26 
(m, 4H), 1.06-0.84 (m, 2H); 13C NMR (100 MHz, CDCl3)  192.3, 155.1, 141.5, 132.2, 127.7, 
124.8, 121.9, 119.9, 117.9, 61.8, 42.5, 31.8, 30.5, 30.0, 25.7, 25.2, 23.7. 
 
Purified by silica gel chromatography using 35% ethyl acetate/65% hexanes. 
Lit. ref. for characterization data: Chen, J.; Cook, M. J. Org. Lett. 2013, 15, 1088-1091.  
Ethyl 9b-(prop-2-en-1-yl)-1,3,4,9b-tetrahydro-2H-pyrido[4,3-b]indole-2-carboxylate (5.67). 
Yellow oil (84.0 mg, 54%); TLC Rf = 0.49 (40% ethyl acetate/60% hexanes); IR (neat) 3077, 
2980, 2930, 2870, 1703, 1614, 1585 cm-1; 1H NMR (400 MHz, CDCl3)  7.63 (d, J = 7.6 Hz, 
1H), 7.41-7.36 (m, 2H), 7.26-7.22 (m, 1H), 5.18 (br s, 1H), 4.97-4.62 (m, 4H), 4.28-4.22 (m, 
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2H), 2.89-2.75 (m, 4H), 2.47-2.27 (m, 2H), 1.35 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, 
CDCl3)  184.8, 155.8, 155.3, 140.1, 131.5, 128.5, 125.2, 122.7, 120.5, 118.6, 62.0, 59.2, 52.6, 
45.6, 36.8, 30.6, 14.7. 
 
Prepared using modified general procedure: Reaction was heated to reflux for 3 h. 
Purified by silica gel chromatography using 30% ethyl acetate/70% hexanes. 
2-{2-[2-methyl-3-(prop-2-en-1-yl)-3H-indol-3-yl]ethyl}-1H-isoindole-1,3(2H)-dione (5.69). 
Clear yellow oil (48.0 mg, 52%); TLC Rf = 0.23 (50% ethyl acetate/50% hexanes); IR (neat) 
3076, 2978, 2931, 1771, 1713, 1577 cm-1; 1H NMR (400 MHz, CDCl3)  7.80-7.75 (m, 2H), 
7.70-7.66 (m, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.30 (td, J = 7.2, 1.2 Hz, 
1H), 7.22 (td, J = 7.2, 0.8 Hz, 1H), 5.19-5.09 (m, 1H), 4.96-4.86 (m, 2H), 3.09-2.96 (m, 2H), 
2.63 (dd, J = 13.6, 6.4 Hz, 1H), 2.43-2.35 (m, 5H), 2.19-2.12 (m, 1H); 13C NMR (100 MHz, 
CDCl3)  184.6, 167.8, 154.8, 140.0, 133.9, 132.0, 131.5, 128.2, 125.5, 123.2, 122.1, 120.1, 
118.6, 60.5, 41.2, 33.7, 33.3, 16.2; Anal. calcd for C22H20N2O2: C, 76.72; H, 5.85; N, 8.13. 
Found: C, 76.61; H, 5.89; N, 8.22. 
 
Prepared using modified general procedure: Reaction was heated to reflux for 18 h. 
Purified by silica gel chromatography using 5% ethyl acetate/95% dichloromethane. 
2--{2-[2-phenyl-3-(prop-2-en-1-yl)-3H-indol-3-yl]ethyl}-1H-isoindole-1,3(2H)-dione (5.71). 
Clear yellow oil (40.0 mg, 36%); TLC Rf = 0.25 (5% ethyl acetate/95% dichloromethane); IR 
(neat) 3061, 2977, 2929, 1772, 1714, 1613 cm-1; 1H NMR (400 MHz, CDCl3)  8.13-8.10 (m, 
2H), 7.68-7.60 (m, 5H), 7.46-7.42 (m, 3H), 7.36 (d, J = 7.6 Hz, 1H), 7.31 (td, J = 7.6, 1.2 Hz, 
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1H), 7.26-7.22 (m, 1H), 5.15-5.05 (m, 1H), 4.75-4.71 (m, 2H), 3.27-3.20 (m, 1H), 3.15-3.08 (m, 
1H), 2.86-2.77 (m, 3H), 2.64-2.57 (m, 1H); 13C NMR (100 MHz, CDCl3)  179.4, 167.7, 154.5, 
142.1, 133.7, 133.6, 131.9, 131.2, 130.7, 128.7, 128.3, 127.9, 126.0, 123.0, 121.5, 121.1, 118.7, 
60.8, 42.9, 35.5, 33.8; Anal. calcd for C27H22N2O2: C, 79.78; H, 5.46; N, 6.89. Found: C, 79.69; 
H, 5.21; N, 7.12. 
 
Prepared using modified general procedure: Reaction was stirred at rt for 18 h. 
Purified by silica gel chromatography using 1.5% methanol/% 98.5% ethyl acetate. 
N-{2-[(2,3-dimethyl-3H-indol-3-yl)methyl]phenyl}acetamide (5.73). Colorless oil (30 mg, 
30%); TLC Rf = 0.21 (2% methanol/98% ethyl acetate); IR (neat) 3281, 3042, 2964, 2926, 1663, 
1583, 1529 cm-1; 1H NMR (300 MHz, MeOH-d4)  7.37 (d, J = 7.5 Hz, 1H), 7.27 (td, J = 7.5, 1.2 
Hz, 2H), 7.17-7.10 (m, 2H), 7.02-6.93 (m, 2H), 6.78 (dd, J = 7.8, 1.2 Hz, 1H), 3.23 (d, J = 14.4 
Hz, 1H), 2.95 (d, J = 14.4 Hz, 1H), 2.30 (s, 3H), 1.98 (s, 3H), 1.36 (s, 3H); 13C NMR (75 MHz, 
MeOH-d4)  188.3, 170.4, 152.8, 143.2, 135.7, 130.9, 130.2, 127.6, 127.0, 125.8, 125.3, 125.2, 
122.7, 118.8, 58.0, 36.2, 21.8, 21.2, 14.7; Anal. calcd for C19H20N2O: C, 78.05; H, 6.90; N, 9.58. 
Found: C, 77.91; H, 6.69; N, 9.73 
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Chapter 6 – Synthesis of Small Molecule SH2-containing Inositol 5'-Phospohatase (SHIP) 
Inhibitors 
 
Abstract 
  The PI3K/Akt pathway is an important cell signaling pathway that is often aberrantly 
activated in cancer cells. A key feature of this pathway is the enzymatic modulation of the 
phosphorylation pattern on inositol phospholipids intercalated on the inside of the cell 
membrane. This phosphorylation pattern is used to activate and recruit signaling proteins to the 
plasma membrane, facilitating the transmission of signals from outside the cell to the nucleus. 
The SH2 domain-containing inositol-5’-phosphatases SHIP1 and SHIP2 are the key participants 
in this pathway, catalyzing the dephosphorylation of phosphates at the 5' position of the inositol. 
These dephosphorylation events play a critical role in downstream signaling pathways. Recent 
research has shown that inhibition or activation of SHIP using small molecules can modulate the 
concentration of key phosphoinositols at the plasma membrane, providing a means to influence 
signaling events in cells. Herein we have developed a new, stereoselective synthetic approach for 
the synthesis of two quinoline based small molecule SHIP inhibitors, which were discovered 
through high-throughput screening. Both of these molecules were synthesized on gram scales so 
that their biological activity could be further evaluated in mice. In addition to this the synthesis 
of tryptamine based small molecule SHIP inhibitor has also been accomplished. 
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6.1 Introduction 
6.1.1 The PI3K Signaling Pathway 
In eukaryotic cells, important information about the extracellular environment must pass 
from outside the cell through the plasma membrane to generate an appropriate response in the 
nucleus. This transfer of information is mediated by transmembrane receptors that then activate 
signaling cascades though complex network of enzymes and second messengers inside the cell. 
Phosphoinositides have become recognized as key participants in some of these signaling 
pathways, which are responsible for various cellular processes like cell growth, survival, cell 
death and cell differentiation.1 The position of phosphorylation on the inositol is a key 
recognition element in these pathways. Therefore phosphorylation and dephosphorylation are 
highly regulated, with many enzymes (like PI3K, PTEN, SHIP and INPP4) controlling these 
reactions (Figure 6.1).  
 
Figure 6.1. PI3K/Akt Signaling Pathway 
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PI3K refers to Phosphoinositide 3-kinase, which is responsible for phosphorylation at the 
3'-position of the phosphotidylinositol-4,5-bisphosphate (PI(4,5)P2, 1) to generate 
phosphotidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3, 2), a key second messenger.
1 The PI3K 
enzyme is initially activated by a nearby membrane bound receptor tyrosine kinase. The 
activation of PI3K results in the production of PI(3,4,5)P3, via phosphorylation of membrane 
bound PI(4,5)P2, rapidly increasing the concentration of the intracellular phosphoinositide.
2 
Phosphorylation to PI(3,4,5)P3 promotes downstream activation of Akt kinase activity by 
phosphorylation at threonine 308 of Akt (Figure 6.2). Akt is responsible for regulation of various 
cellular processes like cell growth, survival and cell death.3-5 Maintaining the correct 
concentration of PI(3,4,5)P3 is critical to regulate optimal activation of Akt pathway. Hence 
excess of PI(3,4,5)P3 needs to be hydrolyzed in order to prevent over activation of Akt pathway 
leading to cellular abnormalities. The phosphates on PI(3,4,5)P3 are hydrolyzed at two different 
positions on the inositol by two different enzymes. PTEN (Phosphatase and Tensin Homolog 
Protein) dephosphorylates PI(3,4,5)P3 back to the original isoform PI(4,5)P2 whereas SHIP (src 
homology 2 (SH2) – containing inositol 5’-phosphatase) is an enzyme which dephosphorylates 
PI(3,4,5)P3 to another isomeric bisphophate, phosphotidylinositol-3,4-bisphosphate (PI(3,4)P2, 3) 
differing from its earlier version in the position of phosphate on the inositol ring. Thus both 
PTEN and SHIP act as negative regulators of PI(3,4,5)P3 by dephosphorylating PI(3,4,5)P3 at a 
different position.  
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Figure 6.2. Enzymatic Modification of Inositols at Molecular Level 
 
6.1.2 Role of SHIP and PTEN in the PI3K Pathway 
Several cancer cell types have been shown to have a higher concentration of PI(3,4,5)P3 
than healthy cells, and hence maintaining a low PI(3,4,5)P3 concentration by inhibiting the PI3K 
pathway has become a popular strategy in cancer therapy.6-11 However such efforts are 
complicated with the need to selectively target the  isoform of PI3K (four isoforms are 
recognized, α, β, γ and δ).12-16 An alternative approach to lowering PI(3,4,5)P3 levels in cells is to 
upregulate the enzymes that hydrolyze PI(3,4,5)P3, specifically PTEN or SHIP. PTEN is a 
known tumor suppressor and it has been shown that PTEN knockout mice develop cancer and 
eventually it leads to their death.17 Hence up regulation of PTEN to maintain a low concentration 
of PI(3,4,5)P3 may lead to a plausible solution, but in cases where the PTEN gene is missing this 
up regulation would not be possible. 
The other enzyme that hydrolyzes PI(3,4,5)P3 is SHIP. Two major isoforms of SHIP 
exist, SHIP1 and SHIP2. Both the isoforms have a high degree of resemblance in amino acid 
sequence but differ considerably in their tissue distribution and specificity for recruitment, 
perhaps accounting for their different cellular functions.18-19 SHIP1 is primarily confined to 
blood and bone marrow cells in addition to being found in embryonic and mesenchymal stem 
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cells.20-21 SHIP2 is distributed ubiquitously in the rest of the body with especially higher levels of 
SHIP2 being found in heart, skeletal muscles and placenta.22 The difference in the two isoforms 
of SHIP may explain the different roles they play in physiology. SHIP1 knockout mice show 
several abnormal pathologies, such as progressive splenomegaly (enlargement of the spleen),19 
massive infiltration and consolidation of the lungs by macrophages23 and shortened life span. 
Experiments with SHIP1 knockout mice show that SHIP1 is critical to maintaining immune 
homeostasis. While these mice are viable, by the time the mice are 14 weeks old their chances of 
survival is only 40%.24  In contrast SHIP2 knockout mice did not show any reduced viability, 
however these mice showed a rapid loss in body weight.25 In addition SHIP2 knockout mice 
were highly resistant to weight gain despite being placed on a high calorie diet over a period of 
12 weeks. These mice did not develop hyperglycemia or hyperinsulinamia despite the poor diet, 
leading to the discovery that SHIP2 acts as a negative regulator of insulin signaling pathway.26 
Recent studies indicate that SHIP1/2 may, in some cases, facilitate tumor growth rather 
than act as tumor suppressors as has been shown for PTEN.18, 22, 24, 27-28 While SHIP acts to down 
regulate Akt by lowering the concentration of PI(3,4,5)P3, the enzyme may also cause a more 
potent activation of the Akt pathway (by stimulating phosphorylation of Akt at serine 473). In 
addition Irgm1 signaling is influenced by the concentration of the SHIP hydrolysis product 
PI(3,4)P2, which has also been shown to activate Akt.
29 This activation of Akt by PI(3,4)P2 is 
found to play a key role in malignant cells indicating the dual role that SHIP plays in the PI3K 
signaling pathway.18 Certain diseased cells like blood cancer cells show a high concentration of 
PI(3,4)P2 that is produced by SHIP1.
30-31 Hence inhibiting SHIP1 to maintain lower 
concentration of PI(3,4)P2 could lead to a treatment for blood cancer. SHIP1 also plays a key role 
in the immune system, specifically facilitating bone marrow graft rejection, and hence SHIP1 
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inhibition could facilitate mismatched bone marrow grafts.20, 32-35 Higher levels of SHIP2 are 
exhibited in breast cancer cells that is thought to promote the survival of these diseased cells.36-38 
Hence maintaining a lower concentration of PI(3,4)P2 by inhibiting SHIP1/2 may also lead to 
treatment of these disease states. Since both upregulation or down regulation of SHIP can 
provide a possible treatment, perturbing the PI3K signaling pathway using SHIP inhibitors and 
SHIP agonists has generated wide interest in the scientific community.39-42 Small molecules that 
selectively inhibit or upregulate SHIP1 and SHIP2 are desired to test the role of SHIP in these 
pathways. Intrigued by the possibility of modulating cell signaling with SHIP inhibitors, a high 
throughput screen was conducted using the National Cancer Institute (NCI) diversity set, which 
resulted in the identification of several lead compounds which showed SHIP inhibitory 
activity.18, 27 These hits included the steroid based inhibitor 3AC (6.5), the tryptamine based 
inhibitor 6.6 and two quinolines 6.7 and 6.8 as shown Figure 6.3. 
 
Figure 6.3. Lead Compounds from High Throughput Screening 
6.1.3 Background on SHIP1 Inhibition with 3AC 
 Previously findings on the activity of the steroidal selective SHIP1 inhibitor 3AC have 
already been reported.43 Preliminary in vitro studies found 3AC to be a selective SHIP1 inhibitor 
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with 50% inhibition at a concentration of 10 µM as determined by fluorescence polarization (FP) 
assay. Encouraged by these findings in vivo tumor studies using immunodeficient SCID mouse 
model were performed with 3AC. The mice were first challenged with OPM2 cells, which are an 
aggressive form of multiple myeloma (MM). After six hours the mice received their first 
injection of 3AC, followed by daily treatments for the next 7 days and then biweekly treatments 
for the ensuing 15 weeks (dosed at 60 µM). Evaluation of the blood samples (obtained after ~7 
weeks) from the 3AC treated mice showed a significant decrease in the circulating OPM2 cells 
in PBMC (peripheral blood mononuclear cell) compared to the vehicle mice (Figure 6.4, A). In 
addition to it the 3AC treated mice showed higher survival rate than the vehicle mice (Figure 6.4, 
B). A luciferin based detection method was utilized to monitor the growth of MM in vivo which 
confirmed that a few 3AC treated mice showed reduced growth of MM cells as compared to the 
vehicle treated mice (Figure 6.4, C). An examination of the tumor cells from mice that resisted 
treatment showed a significant up regulation of SHIP2, suggesting that SHIP1 inhibition may 
select for tumor cells with increased SHIP2 expression (Figure 6.4, C). From these results it was 
proposed that perhaps a pan-SHIP1/2 inhibitor may be a better approach for a cancer therapy, as 
the cancer cells will then be unable to compensate for the inhibition of SHIP1 by up regulation of 
SHIP2. 
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A) Box-and-whisker plots showing the mean, range and standard deviation for circulating MM 
cells B) Survival of 3AC and vehicle treatments groups that were challenged with MM cells 
(n=11/group). C) As before, NSG mice were challenged with 107 OPM2 cells stably expressing a 
luciferase transgene (12 mice/group). Five weeks after challenge and initiation of 3AC therapy or 
vehicle treatment the mice were injected with luciferin substrate. D) Western blot analysis of 
SHIP2 expression in MM tumors recovered from moribund vehicle (Veh)- and 3AC-treated 
mice. 
Figure 6.4. In Vivo SHIP1 Inhibition by 3AC43 
 
6.1.4 Quinolines for pan-SHIP1/2 Inhibition 
The search for pan-SHIP1/2 inhibitors led us to the two lead quinolines 6.7 and 6.8. 
These structures are similar to the antimalarial drug mefloquine, which was developed at the 
Walter Reed Army Hospital in the 1970s.44-45 Mefloquine (6.9) itself has also been found to be 
active against wide range of cancer cell lines like breast, blood, prostate, lymphoma, myeloma 
and colon cancer with an IC50 value between 10-20 µM.
46-47 These concentrations are much 
higher than the effective dose used to treat malaria. Another quinoline, vacquinol (6.10), was 
recently found to inhibit glioblastoma with an IC50 value of 3.14 µM, however around 15 µM 
concentration toxicity was observed.48 Quinolines 6.7 and 6.8 have also shown biofilm inhibition 
with an EC50 of 12 µM and 10.6 µM respectively.
49-51  
A) B) 
C) D) 
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Figure 6.5. Analogy to Antimalarial Drug Mefloquine 
 
6.1.5 Reported Racemic Synthesis of Lead Quinolines 
A racemic synthesis of these molecules has been reported in literature that does not form 
the aminoalcohol in a stereocontrolled manner.52-53 Synthesis of the quinoline 6.17 involved 
Doebner condensation of naphthylamine, pyruvic acid and benzaldehyde to provide the quinoline 
carboxylic acid 6.12 (Scheme 6.1). The acid 6.12 was then esterified to provide 6.13, which was 
then converted into the amylamine hydrobromide 6.15 via the β-ketoester 6.14a. Bromination 
provided the racemic α-bromo carbonyl compound 6.16. Intramolecular displacement of the 
bromide with the pendant amine and then reduction of the carbonyl group using Adam’s catalyst 
provided the racemic quinoline 6.17. 
247 
 
Scheme 6.1. Buchman’s Racemic Synthesis of Quinoline 6.1753 
 
 The reported racemic synthesis of the quinoline 6.26 involved a Pfitzinger reaction 
between the isatin 6.18 and the ketone 6.19 to provide the carboxylic acid 6.20 (Scheme 6.2). 
Addition of 2-pyridyl lithium to the carboxylic acid provided the racemic alcohol 6.23 that was 
then protected with an acetate providing 6.24. Hydrogenation of the pyridinium ring at high 
pressure over platinum oxide provided the quinoline precursor 6.25. Removal of the acetate 
group provided the quinoline 6.26 as a racemic mixture. Direct conversion of the intermediate 
6.22 to 6.26 by hydrogenation was also attempted, which provided only 4% of the desired 
product. 
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Scheme 6.2. Novotny’s Racemic Synthesis of Quinoline 6.2652 
 
In order to evaluate the biological properties of these quinolines towards SHIP1/2, a 
study was initiated to design a scalable synthesis of these quinolines and their analogs. In 
addition this synthesis would also verify the structure of these molecules. The stereochemistry of 
the amino alcohol was ambiguous from the samples provided by NCI. Careful examination of 
the 1H NMR of the compounds indicated that the compounds were single diastereomers. Based 
on the anti stereochemistry of the aminoalcohol in mefloquine it was assumed that the quinolines 
6.7 and 6.8 also possessed a similar anti stereochemistry. 
6.1.6 Synthesis of Tryptamine Based pan SHIP1/2 Inhibitor 
 Among the lead compounds found by HTS was the tryptamine based inhibitor 6.6. In 
addition to the synthesis of the quinoline compounds the synthesis of this tryptamine based 
inhibitor was also undertaken. Previous SAR studies on the tryptamine 6.6 provided the analog 
6.27 as a more potent inhibitor of SHIP2.54 Cancer cells treated with tryptamine 6.27 resulted in 
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decreased phosphorylation of Akt.38 A synthesis of 6.27 was therefore undertaken to further 
explore its biological properties. 
 
Figure 6.7. Tryptamine based SHIP Inhibitors 
 
6.2 Results and Discussion 
6.2.1 Retrosynthetic Analysis of Quinolines 6.7 and 6.8 
 Retrosynthetically the trans aminoalcohol was envisioned to be synthesized by 
stereospecific epoxide opening-cyclization of 6.29. Since its first report by Wainwright and co-
workers,55-56 this approach has seen wide application towards the synthesis of similar quinoline 
aminoalcohols.57-60 The epoxide 6.29 could be obtained from the trans alkene 6.30 which in turn 
will be accessed by the Horner-Wadsworth-Emmons (HWE) olefination of the phosphonate 6.32 
and the aldehyde 6.31. Similar alkenes have been reported to be synthesized with high selectivity 
under these olefination conditions.58 The phosphonate 6.32 may be prepared from the common 
quinoline scaffold 6.33 with a pendant carboxylic acid. 
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Scheme 6.3. Retrosynthetic Analysis of the Lead Quinolines 
 
6.2.2 Synthesis of Quinoline 6.7 
 The quinoline carboxylic acid 6.12 was synthesized following the reported protocol for 
Doebner condensation which provided 6.12 with a yield of 26% (Scheme 6.4).53 Even though 
this reaction provided a low yield, the ease of isolation of the product after completion of the 
reaction (pure product precipitates after the reaction is complete and may be isolated by 
filtration) made this transformation attractive. The carboxylic acid 6.12 was then reduced with 
BH3•THF to provide the alcohol 6.34 in 80% yield. The alcohol functionality was then converted 
to the chloride 6.35 with thionyl chloride. Subjecting the chloride 6.35 to Arbuzov conditions 
with trimethyl phosphite resulted in the formation of the phosphonate 6.36 in 87% yield. This 
reaction proceeded slowly and required three days and high temperature (110 °C) to proceed to 
completion. 
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Scheme 6.4. Synthesis of the Phosphonate 6.36 
 
The required aldehyde 6.38 for Horner-Wadsworth-Emmons olefination was obtained 
from 5-aminopentan-1-ol (6.37) over two steps (Scheme 6.5). The amine was first phthalimide 
protected followed by the oxidation of the alcohol to the aldehyde using TEMPO as a catalyst 
and trichloroisocyanuric acid (TCCA) as the stoichiometric oxidant as reported by De Luca et 
al.61 The oxidation proceeded to completion rapidly in 20 min to provide quantitative amount of 
the aldehyde 6.38. The product was not contaminated by any over oxidized carboxylic acid, 
however running the reaction for longer duration did result in some carboxylic acid formation. 
The aldehyde was then subjected to the HWE olefination with the phosphonate 6.36. Use of 
sodium hydride as a base provided varying yields of the olefin product. Incorporating Masamune 
and Roush’s modified HWE olefination conditions involving DBU as a base and lithium chloride 
as a Lewis acid62 provided the E alkene 6.39 in high yield and with high selectivity for the E 
alkene (>20:1). Epoxidation of the alkene using m-CPBA proceeded smoothly to provide the 
epoxide 6.40 with 61% yield. Removal of the phthalimide protecting group with hydrazine 
hydrate provided the free amine that underwent spontaneous addition to the epoxide to provide 
the anti aminoalcohol 6.41 in satisfactory yields. The amine was then converted into the 
corresponding hydrochloride salt to provide the target 6.7 in 60% yield. No protonation of the 
pyridinium ring was observed. The whole sequence was successfully scaled up to provide gram 
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quantities of the quinoline salt 6.7. Comparison of the synthesized sample with the sample 
obtained from NCI showed that they were identical, verifying the structure of the material 
originally obtained from the NCI. 
Scheme 6.5. Synthesis of the Quinoline 6.7 
 
  In order to evaluate the significance of the piperidinyl ring and the alcohol motif, the 
quinoline amine 6.44 was also synthesized from the chloride 6.35 via a classical Gabriel 
synthesis for amines. The chloride 6.35 was first converted into the phthalimide 6.42, which was 
then subjected to hydrazine to remove the phthalimide group to provide the free amine 6.43. The 
amine was then converted into the hydrochloride salt 6.44. 
Scheme 6.6. Synthesis of Quinoline Based Amine 6.44 
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6.2.3 Synthesis of Quinoline 6.8 
Even though a racemic synthesis of the quinoline 6.8 has been previously reported the 
sequence requires access to a high pressure reactor which can attain a pressure of 50 psi of 
hydrogen,52 which limits its availability, as special equipment is required to perform such 
transformations on large scale. In order to establish a more accessible route to 6.8 we chose to 
apply the established sequence for the quinoline 6.7 towards the synthesis of quinoline 6.8 
(Scheme 6.7). The first step involved chlorination of isatin (6.45) following a literature 
procedure involving TCCA in concentrated sulfuric acid to provide 5,7-dichloroisatin (6.18) in 
high yields.63 This reaction was further scaled up to 200 mmol without any loss of efficiency, 
however the reaction was found to be extremely exothermic and hence needed to be cooled to -
78 °C during addition of sulfuric acid to control the exotherm. In order to access the adamantyl 
substituent at the 2-position of the quinoline, a Pfitzinger reaction between 6.18 and the 
adamantyl methyl ketone (6.19) was envisioned as reported before.52 The ketone 6.19 was 
prepared from its carboxylic acid precursor using methyl lithium. Initially the Pfitzinger reaction 
was performed using 1.1 equiv of the ketone 6.19, which provided the quinoline 6.20 with a low 
yield of 20% and returned 50% of 6.19 unreacted. Using 2.0 equiv of the isatin 6.18 provided a 
higher yield of the product 6.20 (43%). Usually the Pfitzinger reaction proceeds in high yields 
with aryl ketones,64 the moderate yield in this case was attributed to the steric bulk of the ketone 
6.19. The carboxylic acid functionality was then reduced to provide the alcohol 6.47 with a 60% 
yield. The alcohol was then converted to the chloride 6.48 with a slightly lower yield (50%) than 
in the case of quinoline 6.7. The chloride was then converted into the phosphonate 6.49 with 
good yields. The phosphonate 6.49 was then subjected to the HWE olefination with the aldehyde 
6.38 to provide the E alkene 6.50 with similar efficiency as reported for the olefin 6.39. The 
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alkene 6.50 was converted into the epoxide 6.51 followed by removal of the phthalimide group 
that undergoes addition into the epoxide to provide the trans aminoalcohol 6.52. The amine was 
converted into the hydrochloride salt to provide the target quinoline 6.8. Comparison of the 
synthesized sample with the sample obtained from NCI showed that they were identical. 
Scheme 6.7. Synthesis of the Quinoline 6.8 
 
After completing the synthesis of the two quinolines 6.7 and 6.8 these lead compounds 
were tested for their biological activities using the Malachite Green assay. Some of the 
intermediates were also tested to gain useful insights into the SAR studies.  
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6.2.4 Malachite Green Assay and Results 
 The Malachite Green assay is an in vitro test to determine the free phosphate content 
based on the ion association of phosphomolybdate with the cationic Malachite Green dye. The 
formation of the green molybdophosphic acid complex over the multi-step sequence (Figure 6.9) 
is measured at 620 nm and is directly related to the free phosphate content. In this assay a 
truncated version of PI(3,4,5)P3 (6.2’) is utilized since the longer lipid chain of 6.2 had a 
tendency to form aggregates without a lipid bilayer present. 
 
Figure 6.8. PI(3,4,5)P3 and its Truncated Version 
To the PI(3,4,5)P3 analog, recombinant SHIP was added followed by the addition of the 
synthesized SHIP inhibitor and molybdic acid complex. The molybdate aggregates around any 
liberated free phosphates to form a complex, and stops the enzymatic reaction. Upon addition of 
the Malachite Green dye (yellow in color) to the solution the dye aggregates around the 
molybdate complex and changes its color to green. The greener solution implies formation of 
free phosphate hydrolyzed by SHIP thereby indicating poor inhibition of SHIP by the inhibitor. 
Yellow coloration is an indication of formation of fewer free phosphates thereby indicating 
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inhibition of the enzyme SHIP by the inhibitor. The amount of free phosphate can then be 
quantified using UV absorption. The strongly acidic nature of the assay (pH < 2) always results 
in some background hydrolysis of phosphates from inositols thereby lowering the sensitivity of 
this assay. 
 
Figure 6.9. Schematic Representation of Malachite Green Assay 
 The Malachite Green assay was performed according to the previously reported 
procedure.18 The lead quinoline 6.7 was found to have low solubility under the assay conditions 
and formed precipitates (Table 6.1, entry 1). Hence the citrate salt was synthesized which was 
found to be more soluble but provided only moderate inhibition (entry 2). The lead quinoline 6.8 
proved to be more potent particularly against SHIP2 (entry 3). The mefloquine salt showed 
significant inhibition of both SHIP1 and SHIP2 which may explain the previously reported 
antitumor activity (entry 4).46-47 Both quinine and quinidine sulfates were also tested, but these 
compounds showed no significant activity against SHIP1 or SHIP2 (entry 5 & 6). These 
examples provide evidence that the quinoline core with C-2 substitution may be required for 
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SHIP inhibition or the 5-methoxy substituent may be the reason for loss in activity. Next the 
carboxylic acid and alcohol intermediates of both the lead compounds were also tested to verify 
the need for the aminoalcohol motif (entries 7-11). None of the intermediates showed any 
activity stressing the need for the pendant amine. Interestingly the carboxylic acid 6.29 showed 
some selective inhibition of SHIP1. In order to validate the significance of the quinoline core the 
ephedrines 6.55 and 6.56 were tested, which showed close to no activity against SHIP1 or 
SHIP2. The need for the quinoline core and the pendant amine was clear from these results and 
hence the analog 6.44 was tested. Quinoline 6.44 showed significantly better inhibition than the 
lead quinoline 6.7 and its activity was comparable to that of the lead quinoline 6.8. These results 
indicate that the alcohol motif and the piperidine ring are not essential for SHIP inhibition and 
that the quinoline core and the pendant amine are critical for SHIP inhibition.  
Table 6.1. SHIP Inhibitory Activity of Quinolines 6.7 and 6.8 and Related Moleculesa 
 
Entry Compound 
SHIP1 
Inhibition 
SHIP2 
Inhibition 
1 6.7 N/Ab N/Ab 
2 6.41•citrate 38% 17% 
3 6.8 38% 73% 
4 mefloquine hydrochloride (6.9) 54% 54% 
5 quinine sulfate (6.53•0.5 H2SO4) 0% 8% 
6 quinidine sulfate (6.54•0.5 H2SO4) 19% 5% 
7 carboxylic acid 6.16 7%c 0%c 
8 carboxylic acid 6.29 44%c 0%c 
9 alcohol 6.34 2%c 18%c 
10 alcohol 6.47 0%c 14%c 
11 (1R, 2S)-(-)-ephedrine 6.55 0% 0% 
12 (1S, 2S)-(+)-pseudophedrine 6.56 2% 13% 
13 6.44 41% 66% 
 
aResults from the Malachite Green assay performed at 1mM concentration. bCompound 
precipitated during testing. cEvaluated at 500µM 
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6.2.5 Synthesis of the Tryptamine Based SHIP2 Inhibitor 
 In order to further evaluate the activity of 6.27 towards inhibition of SHIP we initiated a 
gram scale synthesis of the tryptamine 6.27. For installing the –SMe group at the 5-position of 
indole, a Fischer indole synthesis between the hydrazine salt 6.58 and the ketone 6.57 was 
envisioned. Subjecting 6.58 and 6.57 to Fischer indole synthesis provided the tryptamine 6.59 
with high yields. The indole nitrogen was N-alkylated using the benzyl chloride 6.60 and cesium 
carbonate as the base. The reaction was found to proceed to completion rapidly but provided 
only a moderate yield of the N-alkylated product 6.61. Subjecting the indole to longer reaction 
times resulted in rapid decomposition of the desired product. The phthalimide protecting group 
was then removed using hydrazine hydrate and the resulting amine was converted into the 
hydrochloride salt to provide the target 6.27. 
Scheme 6.8. Synthesis of the SHIP2 Inhibitor 6.27 
 
 
6.3 Conclusions and Future Work 
A new efficient and stereoselective route for the synthesis of the quinoline 6.7 and 6.8 
has been established. The sequence was successfully scaled up to provide gram quantities of the 
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inhibitors. The synthesized lead compounds and several other analogs were evaluated for their 
activities against SHIP1 and SHIP2 using the Malachite green assay. These SAR studies 
provided key insights to develop more potent SHIP1/2 inhibitors. Specifically, the piperidine 
ring and the free alcohol were of less significance while the free amine and quinoline core with a 
substituent at the 2-position are more critical for potency. The tryptamine based inhibitor 6.27 
was also synthesized on gram scale and its activities will be reported in due course.  
During our studies with 3AC and the quinolines, no reported crystal structure of SHIP1 
or SHIP2 was found in literature. Potter and co-workers recently published the crystal structure 
of the active site of SHIP2 with the known inhibitor, biphenyl 2,3’,4,5’,6-pentakisphosphate 
bound to the active site.65 With the crystal structure of SHIP2 now available, a model for SHIP1 
active site can be designed using the SHIP2 structure as a template. A more rational approach for 
designing the inhibitors is now possible by performing in silico docking, and these studies will 
be reported in the future. 
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6.4 Experimental 
General Information. All anhydrous reactions were run under a positive pressure of argon or 
nitrogen. All syringes, needles, and reaction flasks required for anhydrous reactions were dried in 
an oven and cooled under an argon atmosphere or in a desiccator. Dichloromethane, 
tetrahydrofuran, and diethyl ether were dried by passage through an alumina column following 
the method of Grubbs.1 Dimethylformamide was dried with 4Å molecular sieves and purified by 
vacuum distillation. All other reagents and solvents were purchased from commercial sources 
and used without further purification. 
Analysis and Purification. Analytical thin layer chromatography (TLC) was performed on pre-
coated, glass-backed plates (silica gel 60 F 254 ; 0.25 mm thickness). The TLC plates were 
visualized by UV illumination and by staining. Solvents for chromatography are listed as 
volume:volume ratios. Flash column chromatography was carried out on silica gel (40-63 µm). 
Melting points were recorded using an electrothermal melting point apparatus and are 
uncorrected. Elemental analyses were performed on an elemental analyzer with a thermal 
conductivity detector and 2 meter GC column maintained at 50 °C. 
Identity. Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were 
recorded at 300 or 400 MHz and 75 or 100 MHz respectively. The chemical shifts are given in 
parts per million (ppm) on the delta (δ) scale. Coupling constants are reported in hertz (Hz). The 
spectra were recorded in solutions of deuterated chloroform (CDCl3) with residual chloroform (δ 
7.26 ppm for 1H NMR, δ 77.23 for 13C NMR) as the internal reference or in solutions of 
deuterated dimethyl sulfoxide (DMSO-d6) with residual dimethyl sulfoxide (δ 2.50 ppm for 
1H 
NMR, δ 39.51 for 13C NMR) as the internal reference. Data are reported as follows: (s = singlet; 
d = doublet; t = triplet; q = quartet; p = pentet; sep = septet; dd = doublet of doublets; dt = 
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doublet of triplets; td = triplet of doublets; tt = triplet of triplets; qd = quartet of doublets; ddd = 
doublet of doublet of doublets; br s = broad singlet). Where applicable, the number of protons 
attached to the corresponding carbon atom was determined by DEPT-135 NMR. Infrared (IR) 
spectra were obtained from thin films deposited on KBr plates by evaporation of a solution of the 
compound in CH2Cl2 or as a solid in a KBr pellet. 
 
 
2-Phenylbenzo[h]quinoline-4-carboxylic acid (6.12).53 
1-Naphthylamine 6.11 (25.0 g, 175 mmol) was dissolved in 100 mL of ethanol. Benzaldehyde 
(17.8 mL, 18.6 g, 175 mmol) and pyruvic acid (12.2 mL, 15.4 g, 175 mmol) were added 
sequentially to the 1-naphthylamine solution at room temperature. The reaction was then 
refluxed open to air for 3 h. After cooling to room temperature, the mixture was vacuum filtered. 
The resulting solid was thoroughly washed with ethanol and dried under vacuum to yield 13.7 g 
(26%) of carboxylic acid 6.12 as a yellow solid. 
6.12. mp = 294-297 °C; TLC Rf = 0.11 (20% ethyl acetate / 80% hexanes); IR (KBr) 3061, 2623, 
1704, 1256, 868, 742, 687 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 9.42-9.39 (m, 1H), 8.58 (s, 
1H), 8.54 (d, J = 9.3 Hz, 1H), 8.48-8.44 (m, 2H), 8.11-8.04 (m, 2H), 7.87-7.79 (m, 2H), 7.66-
7.53 (m, 3H); 13C NMR (75 MHz, DMSO-d6) δ 167.9, 154.4, 146.3, 138.1, 138.0, 133.1, 130.8, 
129.9, 129.1, 128.9, 128.7, 128.0, 127.5, 127.2, 124.5, 122.3, 121.9, 118.9. Anal. Calcd for 
C20H13NO2: C, 80.25; H, 4.38; N, 4.68;. Found: C, 80.04; H, 4.39; N, 4.96. 
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(2-Phenylbenzo[h]quinolin-4-yl)methanol (6.34). 
Carboxylic acid 6.12 (5.00 g, 16.7 mmol) was suspended in 17 mL anhydrous THF under argon. 
After cooling the mixture to 0 °C, borane-tetrahydrofuran complex (1M in THF, 34.0 mL, 34.0 
mmol) was slowly added to the well-stirred mixture. After hydrogen gas evolution ceased, the 
reaction was allowed to warm to room temperature and stirred for 6 h. The mixture was then 
cooled to 0 °C and aqueous NaOH (3 M, 17 mL) was slowly added. The mixture was stirred at 
room temperature for 12 h, after which the THF was removed under vacuum. The resulting 
mixture was then extracted with ethyl acetate. The combined organic extracts were dried with 
MgSO4, filtered, and evaporated to an oil, which was diluted with 50 mL of methanol. The 
methanol was then removed under vacuum to yield 3.81 g (80%) of alcohol 6.34 as a white solid. 
6.34. mp = 140-144 °C; TLC Rf = 0.32 (20% ethyl acetate / 80% hexanes); IR (KBr) 3343, 3061, 
2899, 1591, 1377, 1020, 756, 693 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 9.41-9.38 (m, 1H), 
8.44-8.40 (m, 2H), 8.32 (s, 1H), 8.03-8.07 (m, 1H), 8.00-7.94 (m, 2H), 7.83-7.74 (m, 2H), 7.65-
7.59 (m, 2H), 7.56-7.50 (m, 1H), 5.72 (t, J = 5.5 Hz, 1H), 5.16 (d, J = 5.5 Hz, 2H); 13C NMR (75 
MHz, DMSO-d6) δ 154.4, 149.0, 145.0, 139.1, 133.2, 131.3, 129.5, 129.0, 128.3, 128.0, 127.13, 
127.09, 127.05, 124.4, 122.5, 121.1, 116.0, 60.3. Anal. Calcd. for C20H15NO: C, 84.19; H, 5.30; 
N, 4.91. Found: C, 84.06; H, 4.97; N, 5.09. 
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4-(Chloromethyl)-2-phenylbenzo[h]quinoline (6.35). 
Alcohol 6.34 (13.5 g, 47.4 mmol) was dissolved in 95 mL anhydrous dichloromethane. Neat 
thionyl chloride (4.82 mL, 7.90 g, 66.4 mmol) was slowly added to the solution at room 
temperature. The reaction was stirred at room temperature for 18 h and then carefully quenched 
with saturated aqueous NaHCO3. The reaction was diluted with an equal volume of water and 
vigorously stirred until all solids dissolved. The organic layer was separated, washed with brine, 
dried with Na2SO4, filtered, and evaporated under vacuum to yield 10.3 g (72%) of chloride 6.35 
as a tan solid. 
6.35. mp = 145-153 °C; TLC Rf = 0.80 (20% ethyl acetate / 80% hexanes); IR (KBr) 3062, 2942, 
1588, 1053, 752, 689 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.53-9.50 (m, 1H), 8.36-8.34 (m, 2H), 
8.06 (s, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.95-7.88 (m, 2H), 7.79-7.70 (m, 2H), 7.60-7.55 (m, 2H), 
7.52-7.48 (m, 1H), 5.10 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 155.4, 146.8, 142.5, 139.4, 
133.7, 132.2, 129.6, 129.0, 128.6, 128.3, 127.9, 127.6, 127.3, 125.3, 123.0, 120.4, 119.1, 43.1. 
Anal. Calcd. for C20H14ClN: C, 79.07; H, 4.65; N, 4.61. Found: C, 78.96; H, 4.50; N 4.83. 
 
Dimethyl ((2-phenylbenzo[h]quinolin-4-yl)methyl)phosphonate (6.36). 
Chloride 6.35 (1.97 g, 6.50 mmol) and trimethyl phosphite (13.7 g, 13.0 mL, 110 mmol) were 
combined in a flask with 6.5 mL toluene. The mixture was refluxed for 3 d. After cooling to 
room temperature, the mixture was concentrated under vacuum to a brown oil which was 
264 
 
triturated with diethyl ether. The resulting precipitate was vacuum filtered and washed with cold 
diethyl ether to yield 2.12 g (87%) of phosphonate 6.36 as a white solid. 
6.36. mp = 136-137 °C; TLC Rf = 0.43 (20% acetone / 80% dichloromethane); IR (KBr) 3061, 
2953, 2851, 1587, 1252, 1053, 804 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.54-9.51 (m, 1H), 8.37-
8.34 (m, 2H), 8.02-7.84 (m, 4H), 7.79-7.68 (m, 2H), 7.60-7.54 (m, 2H), 7.52-7.46 (m, 1H), 3.75 
(d, J = 22.5 Hz, 2H), 3.66 (d, J = 10.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 154.9 (d, J = 3.6 
Hz), 146.8 (d, J = 2.5 Hz), 139.5, 138.4 (d, J = 9.3 Hz), 133.7, 132.2, 129.5, 129.0, 128.5, 
127.79, 127.78, 127.6, 127.2, 125.3, 124.2 (d, J = 5.1 Hz), 121.2 (d, J = 1.5 Hz), 121.0 (d, J = 
6.5 Hz), 53.3 (d, J = 6.7 Hz), 30.3 (d, J = 138.2 Hz). Anal. Calcd for C22H20NO3P: C, 70.02; H, 
5.34; N, 3.71. Found C, 69.69; H, 5.42; N, 3.88. 
 
2-(5-Hydroxypentyl)isoindoline-1,3-dione (6.37A).66 
5-Amino-1-pentanol (18.7 g, 181 mmol) and phthalic anhydride (26.8 g, 181 mmol) were heated 
to reflux in 181 mL toluene with a Dean-Stark condenser attached for 24 hours. The mixture was 
cooled to room temperature, transferred to a separatory funnel using ethyl acetate, washed once 
with brine, dried with sodium sulfate, and concentrated under vacuum to provide 39.2 g (93%) 2-
(5-hydroxypentyl)isoindoline-1,3-dione as a white solid. 
6.37A. mp = 43-48 °C; TLC Rf = 0.29 (60% ethyl acetate / 40% hexanes); 
1H NMR (300 MHz, 
CDCl3) δ 7.87-7.80 (m, 2H), 7.74-7.67 (m, 2H), 3.70 (t, J = 7.1 Hz, 2H), 3.64 (t, J = 6.3 Hz, 2H), 
1.77-1.56 (m, 4H), 1.48-1.36 (m, 2H). 
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5-(1,3-Dioxoisoindolin-2-yl)pentanal (6.38).66 
2-(5-hydroxypentyl)isoindoline-1,3-dione (932 mg, 4.00 mmol) was dissolved in 13 mL 
anhydrous dichloromethane and cooled to 0°C while under argon. Trichloroisocyanuric acid (974 
mg, 4.20 mmol) and TEMPO (6 mg, 0.04 mmol) were then added. The mixture was stirred at 
room temperature for 20 minutes and then filtered through Celite. The resulting solution was 
washed with saturated sodium bicarbonate, 1M HCl, and brine, dried with sodium sulfate, and 
concentrated under vacuum to provide 850 mg (92%) aldehyde 6.38 as a yellow oil. 
6.38. TLC Rf = 0.70 (100% diethyl ether); 
1H NMR (300 MHz, CDCl3) δ 9.76 (t, J = 1.6 Hz, 
1H), 7.88-7.81 (m, 2H), 7.75-7.68 (m, 2H), 3.71 (t, J = 6.8 Hz, 2H), 2.51 (td, J = 7.4, 1.5 Hz, 
2H), 1.80-1.61 (m, 4H). 
 
(E)-2-(6-(2-Phenylbenzo[h]quinolin-4-yl)hex-5-en-1-yl)isoindoline-1,3-dione (6.39). 
Phosphonate 6.36 (377 mg, 1.00 mmol) and lithium chloride (63 mg, 1.50 mmol) were combined 
in a flask under argon and 5 mL of anhydrous THF was added followed by DBU (228 mg, 224 
μL, 1.50 mmol). Aldehyde 6.38 (347 mg, 1.50 mmol) was dissolved in 5 mL anhydrous THF 
under argon. The aldehyde solution was then transferred to the stirred phosphonate solution 
dropwise at room temperature. After stirring for 24 hours, the reaction was diluted with water 
and extracted with ethyl acetate. The combined organic extracts were dried with MgSO4, filtered, 
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and concentrated under vacuum. Purification by silica gel chromatography (20% ethyl acetate / 
80% hexanes) provided 330 mg (68%) of olefin 6.39 as a yellow solid. 
6.39. mp = 135-144 °C; TLC Rf = 0.67 (30% ethyl acetate / 70% hexanes); IR (KBr) 3059, 2934, 
2872, 1705, 1581, 1398, 1368, 1036, 721 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.52-9.50 (m, 1H), 
8.37-8.35 (m, 2H), 8.02 (s, 1H), 8.00 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.86-7.82 (m, 
2H), 7.80 (d, J = 9.1 Hz, 1H), 7.76-7.67 (m, 4H), 7.59-7.54 (m, 2H), 7.50-7.46 (m, 1H), 7.19 (d, 
J = 15.7 Hz, 1H), 6.53 (dt, J = 15.7, 6.9 Hz, 1H), 3.79 (t, J = 7.3 Hz, 2H), 2.47 (q, J = 7.1 Hz, 
2H), 1.85 (p, J = 7.5 Hz, 2H), 1.67 (p, J = 7.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 168.6, 
155.1, 146.6, 144.0, 140.1, 137.1, 134.0, 133.7, 132.21, 132.19, 129.2, 128.9, 128.1, 127.7, 
127.6, 127.1, 126.9, 126.1, 125.3, 123.3, 122.9, 121.2, 115.6, 37.9, 33.1, 28.3, 26.4. Anal. Calcd 
for C33H26N2O2: C, 82.13; H, 5.43; N, 5.81;. Found: C, 82.44; H, 5.13; N, 5.84. 
 
2-(4-(3-(2-Phenylbenzo[h]quinolin-4-yl)oxiran-2-yl)butyl)isoindoline-1,3-dione (6.40). 
Olefin 6.39 (4.76 g, 9.86 mmol) was dissolved in 62 mL of CHCl3. To this solution was added 3-
chloroperbenzoic acid (approx. 70%, 5.11 g, approx. 29.6 mmol). The mixture was refluxed for 
18 h. Excess peracid was consumed by vigorously stirring the reaction with 10% aq. Na2SO3. 
The mixture was poured into sat. aq. NaHCO3 and extracted with dichloromethane. The 
combined organic extracts were washed once with brine, dried with Na2SO4, and concentrated 
under vacuum. The crude solid was triturated with methanol and filtered to provide 3.00 g of 
epoxide 6.40 (61%) as a tan solid. 
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6.40. mp = 55-69 °C; TLC Rf = 0.61 (30% ethyl acetate / 70% hexanes); IR (KBr) 3059, 2933, 
2858, 1710, 1590, 1466, 720 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.51 (dd, J = 7.9, 0.8 Hz, 1H), 
8.37-8.34 (m, 2H), 7.95 (s, 1H), 7.93-7.89 (m, 2H), 7.88-7.83 (m, 2H), 7.80 (d, J = 9.0 Hz, 1H), 
7.78-7.69 (m, 4H), 7.58-7.52 (m, 2H), 7.50-7.45 (m, 1H), 4.36 (d, J = 1.9 Hz, 1H), 3.78 (t, J = 
7.2 Hz, 2H), 3.04-3.01 (m, 1H), 2.07-1.98 (m, 1H), 1.95-1.80 (m, 3H), 1.75-1.62 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 168.6, 155.7, 146.0, 144.0, 139.7, 134.2, 133.6, 132.3, 132.2, 129.5, 
129.0, 128.4, 127.93, 127.90, 127.7, 127.3, 125.4, 123.4, 123.2, 120.0, 114.2, 62.9, 55.9, 37.8, 
32.1, 28.6, 23.5. Anal. Calcd for C33H26N2O3: C, 79.50; H, 5.26; N, 5.62. Found: C, 79.46; H, 
5.28; N, 5.65. 
 
(2-Phenylbenzo[h]quinolin-4-yl)(piperidin-2-yl)methanol (6.41). 
Epoxide 6.40 (3.00 g, 6.00 mmol) was dissolved in a mixture of 30 mL ethanol and 30 mL THF. 
Hydrazine hydrate (600 μL, 12.4 mmol) was added and the reaction was refluxed for 2 hours. 
The reaction was concentrated under vacuum to provide a crude mixture of product and by-
products. Silica gel chromatography (90% dichloromethane / 9% methanol / 1% NH4OH) 
provided the free amine as a brown solid with some orange colored impurities. The mixture was 
suspended in 30 mL methanol and filtered to provide amine 6.41 (1.37 g ,62%) as a tan solid. 
6.41. mp = 175 °C (dec.); TLC Rf = 0.20 (90% dichloromethane / 9% methanol / 1% NH4OH); 
IR (KBr) 3286, 3060, 2932, 2851, 2744, 1590, 1443, 1382, 1107, 1048, 885, 700 cm-1; 1H NMR 
(300 MHz, DMSO-d6) δ 9.42- 9.38 (m, 1H), 8.41-8.38 (m, 2H), 8.30 (s, 1H), 8.16 (d, J = 9.3 Hz, 
1H), 8.06-8.03 (m, 1H), 7.95 (d, J = 9.2 Hz, 1H), 7.82-7.73 (m, 2H), 7.65-7.59 (m, 2H), 7.56-
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7.50 (m, 1H), 5.73 (br s, 1H), 5.34 (br s, 1H), 2.96-2.86 (m, 2H), 2.54-2.40 (m, 1H), 1.74-1.66 
(m, 1H), 1.59-1.51 (m, 1H), 1.48-1.40 (m, 1H), 1.34-1.14 (m, 3H); 13C NMR (100 MHz, DMSO-
d6) δ 153.8, 150.3, 145.3, 139.0, 133.0, 131.3, 129.4, 129.0, 128.3, 127.8, 127.0, 126.9, 124.5, 
122.8, 121.6, 116.9, 72.2, 61.4, 46.5, 26.7, 26.0, 24.1 (One signal in the aromatic region was not 
resolved). Anal. Calcd for C25H24N2O: C, 81.49; H, 6.57; N, 7.60. Found: C, 81.16; H, 6.24; N, 
7.83. 
 
2-(Hydroxy(2-phenylbenzo[h]quinolin-4-yl)methyl)piperidin-1-ium chloride (6.7).53 
Amine 6.41 (1.37 g, 3.72 mmol) was suspended in 100 mL diethyl ether and anhydrous 
hydrogen chloride (2M in diethyl ether, 4.0 mL, 8.0 mmol) was added. The resulting precipitate 
was collected by vacuum filtration, suspended in 100 mL ethanol, and filtered again to provide 
900 mg (60%) amine hydrochloride salt 6.7 as a white solid. 
6.7. mp = 258 °C (dec.); IR (KBr) 3280, 2936, 2854, 2710, 1589, 1377, 1106, 832, 698 cm-1; 1H 
NMR (300 MHz, DMSO-d6) δ 9.65 (d, J = 12.8 Hz, 1H), 9.43-9.37 (m, 1H), 8.39 (d, J = 10.4 
Hz, 3H), 8.32 (s, 1H), 8.24 (d, J = 9.6 Hz, 1H), 8.10-8.06 (m, 1H), 8.03 (d, J = 12.8 Hz, 1H), 
7.84-7.75 (m, 2H), 7.65-7.58 (m, 2H), 7.57-7.50 (m, 1H), 6.60 (d, J = 4.2 Hz, 1H), 5.90 (s, 1H), 
3.52-3.39 (m, 1H), 3.09-2.94 (m, 1H), 1.79-1.52 (m, 4H), 1.37-1.19 (m, 2H); 13C NMR (75 
MHz, DMSO-d6) δ 153.8, 147.3, 145.2, 138.7, 132.9, 131.0, 129.5, 128.9, 128.4, 127.8, 127.6, 
127.1, 126.9, 124.3, 121.7, 120.9, 116.3, 67.5, 58.7, 44.0, 21.6, 21.1, 20.8. Anal. Calcd for 
C25H25ClN2O: C, 74.15; H, 6.22; N, 6.92. Found: C, 74.19; H, 5.95; N, 6.82. 
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(2-Phenylbenzo[h]quinolin-4-yl)methanaminium chloride (6.44). 
Chloride 6.35 (304 mg, 1.00 mmol), phthalimide (177 mg, 1.20 mmol), and potassium carbonate 
(276 mg, 2.00 mmol) were combined with 10 mL DMF and heated to 80 °C for 24 hours. The 
mixture was cooled to room temperature and decanted to remove inorganic solids. The organic 
portion was diluted with 40 mL methanol to produce a precipitate, which was filtered, washed 
with methanol, and dried to provide 344 mg (83%) of quinolyl phthalimide 6.42 as a tan solid. 
6.42. mp = 215-218 °C; TLC Rf = 0.26 (20% ethyl acetate / 80% hexanes); IR (KBr) 2922, 2851, 
1714, 1642, 1391, 1105 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.52-9.50 (m, 1H), 8.31-8.25 (m, 
3H), 8.07 (s, 1H), 7.93-7.85 (m, 4H), 7.78-7.68 (m, 4H), 7.56-7.51 (m, 2H), 7.48-7.44 (m, 1H), 
5.42 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 168.2, 155.5, 146.9, 141.6, 139.8, 134.5, 133.7, 
132.3, 132.1, 129.5, 129.0, 128.5, 128.2, 127.9, 127.8, 127.2, 125.4, 123.8, 123.3, 120.7, 119.6, 
39.1. Anal. Calcd for C28H18N2O2: C, 81.14; H, 4.38; N, 6.76. Found: C, 80.79; H, 4.57; N, 6.76. 
 
The quinolyl phthalimide 6.42 (300 mg, 0.72 mmol) was suspended in 4 mL ethanol. Hydrazine 
hydrate (175 μL, 3.6 mmol) was added and the mixture was heated to reflux for 3 hours. The 
reaction was then cooled to room temperature and vacuum filtered. The resulting precipitate was 
washed with methanol and the combined filtrates were concentrated and purified by silica gel 
chromatography (5% methanol / 90% dichloromethane) to provide 184 mg of quinolyl amine 
6.43 (90%) as a white solid. 
6.43. mp = 121-123 °C; TLC Rf = 0.19 (5% methanol / 95% dichlormethane); IR (KBr) 3446, 
3058, 1625, 1591, 1553, 1499, 1381 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.53 (d, J = 8.2 Hz, 
270 
 
1H), 8.39-8.36 (m, 2H), 8.10 (s, 1H), 7.94-7.91 (m, 2H), 7.84 (d, J = 9.1 Hz, 1H), 7.78-7.68 (m, 
2H), 7.59-7.55 (m, 2H), 7.52-7.46 (m, 1H), 4.48 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 155.6, 
148.7, 146.4, 140.1, 133.7, 132.4, 129.4, 129.0, 128.3, 127.9, 127.7, 127.1, 125.4, 123.3, 120.4, 
116.8, 43.4 (One signal in the aromatic region was not resolved). Anal. Calcd for C20H16N2: C, 
84.48; H, 5.67; N, 9.85. Found: C, 84.44; H, 5.54; N, 9.61. 
 
The quinolyl amine 6.43 (128 mg, 0.45 mmol) was dissolved in 3 mL methanol and HCl in 
diethyl ether (2 M, 270 μL, 0.54 mmol) was added. The mixture was stirred for 5 minutes and 
concentrated in vacuo. The resulting oil was triturated with diethyl ether until a yellow 
precipitate formed. This was collected by vacuum filtration, washed with diethyl ether, and dried 
to provide 133 mg (92%) amine hydrochloride 6.44 as a yellow solid. 
6.44. mp = 178 °C (dec.); IR (KBr) 3429, 3080, 2911, 1625, 1513, 1377 cm-1; 1H NMR (300 
MHz, DMSO-d6) δ 9.42-9.38 (m, 1H), 8.80 (br s, 3H), 8.48-8.45 (m, 3H), 8.12-8.03 (m, 3H), 
7.90-7.76 (m, 2H), 7.66-7.52 (m, 3H), 4.74 (q, J = 5.7 Hz, 2H); 13C NMR (100 MHz, DMSO-d6) 
δ 154.2, 145.3, 140.9, 138.6, 133.2, 131.0, 129.8, 129.0, 128.6, 128.0, 127.8, 127.4, 127.2, 124.4, 
122.6, 120.9, 118.4, 38.7. Anal. Calcd for C20H17ClN2: C, 74.88; H, 5.34; N, 8.73. Found: C, 
74.49; H, 5.40; N, 8.61. 
 
5,7-Dichloroindoline-2,3-dione (6.45).63 
Isatin (14.7 g, 100 mmol) and trichloroisocyanuric acid (23.2 g, 100 mmol) were combined in a 
flask and cooled to -78°C with a dry ice-acetone bath. Concentrated sulfuric acid (75 mL) was 
added dropwise to the mixture via addition funnel. The mixture was allowed to slowly warm to 
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room temperature. After stirring for 3 days, the mixture was poured over ice and stirred until all 
the ice had melted. The precipitate was collected by vacuum filtration and washed twice with 
water. The orange-red solid was then washed with acetone until only a white solid (isocyanuric 
acid) remained. The filtrate was concentrated under vacuum to yield 19.8 g (92%) of 
dichloroisatin 6.45 as an orange-red solid. 
6.45. mp = 211-217 °C; TLC Rf = 0.65 (50% ethyl acetate / 50% hexanes); 
1H NMR (300 MHz, 
DMSO-d6) δ 11.59 (br s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H). 
 
1-(Adamantan-1-yl)ethanone (6.19).52 
1-Adamantanecarboxylic acid (7.20 g, 40.0 mmol) was dissolved in 40 mL of diethyl ether under 
argon. The mixture was maintained at approximately -5 °C with a NaCl-ice bath while methyl 
lithium (1.6M in diethyl ether, 52.5 mL, 84.0 mmol) was added dropwise with vigorous stirring. 
After complete addition, the cooling bath was removed and the slurry was allowed to stir for one 
hour at room temperature. The reaction was quenched and diluted by the addition of water and 
extracted with diethyl ether. The combined organic extracts were dried with MgSO4, filtered, 
concentrated under vacuum, and purified by silica gel chromatography (10% ethyl acetate / 90% 
hexanes) to yield 5.70 g (80%) of ketone 6.19 as a white solid. 
6.19. mp = 52-54 °C; TLC Rf = 0.43 (10% ethyl acetate / 90% hexanes); 
1H NMR (300 MHz, 
CDCl3) δ 2.09 (s, 3H), 2.04 (br s, 3H), 1.82-1.64 (m, 12H). 
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2-(Adamantan-1-yl)-6,8-dichloroquinoline-4-carboxylic acid (6.20).52 
Dichloroisatin 6.18 (33.8 g, 157 mmol, 2.0 equiv), ketone 6.19 (14.0 g, 78.7 mmol, 1.0 equiv), 
and potassium hydroxide (28.6 g, 501 mmol, 6.4 mmol) were combined with 78 mL ethanol and 
26 mL H2O and heated to reflux for 48 hours. The mixture was then allowed to cool to room 
temperature and concentrated under vacuum to leave a brown paste, which was taken up in H2O 
and diethyl ether. The organic layer was discarded and the aqueous layer was washed once more 
with diethyl ether. The aqueous layer was then acidified (pH 4 to 5) by the dropwise addition of 
concentrated HCl. The resulting precipitate was isolated by vacuum filtration and recrystallized 
from ethanol to provide 12.7 g (43%) of carboxylic acid 6.20 as a tan solid. 
6.20. mp = 152-157 °C; TLC Rf = 0.15 (30% ethyl acetate / 70% hexanes); IR (KBr) 3462, 2902, 
2848, 2651, 1703, 1591, 1268, 1193 cm-1; 1H NMR (300 MHz, DMSO-d6) δ 8.71 (s, 1H), 8.16-
8.12 (m, 2H), 2.68 (br s, 6H), 2.11 (br s, 3H), 1.79 (br s, 6H); 13C NMR (100 MHz, DMSO-d6) δ 
169.4, 166.9, 142.2, 136.1, 134.5, 131.1, 129.7, 124.6, 123.6, 120.8, 40.9, 36.0, 28.0 (One signal 
in the aliphatic region was not resolved). Anal. Calcd for C20H19Cl2NO2: C, 63.84; H, 5.09; N, 
3.72. Found: C, 64.18; H, 5.03; N, 3.87. 
 
2-(Adamantan-1-yl)-6,8-dichloroquinolin-4-yl)methanol (6.47). 
Carboxylic acid 6.20 (3.48 g, 9.26 mmol) was dissolved in 10 mL of anhydrous THF under 
argon. After cooling the mixture to 0°C, borane-tetrahydrofuran complex (1 M in THF, 18.5 mL, 
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18.5 mmol) was slowly added to the mixture. After hydrogen gas evolution ceased, the cooling 
bath was removed and the mixture was allowed to stir at room temperature overnight. The 
mixture was again cooled to 0°C and quenched with 20 mL 3M NaOH. The cooling bath was 
removed and, after stirring at room temperature for 6 hours, the mixture was extracted with 
diethyl ether. The combined organic extracts were dried with MgSO4, filtered, concentrated 
under vacuum, and purified by silica gel chromatography (30% ethyl acetate / 70% hexanes) to 
yield 2.00 g (60%) of alcohol 6.47 as a beige solid. 
6.47. mp = 190-198 °C; TLC Rf = 0.56 (30% ethyl acetate / 70% hexanes); IR (KBr) 3278, 2899, 
2845, 1596, 1448, 1081, 1060 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.83 (d, J = 2.3 Hz, 1H), 7.77 
(d, J = 2.2 Hz, 1H), 7.68 (s, 1H), 5.13 (dd, J = 5.7, 0.9 Hz, 2H), 2.16 (br s, 3H), 2.13 (br s, 6H), 
1.91 (t, J = 5.8 Hz, 1H), 1.83 (br s, 6H); 13C NMR (75 MHz, CDCl3) δ 170.1, 145.1, 142.5, 
135.9, 130.9, 129.7, 126.0, 121.1, 117.0, 62.3, 41.9, 40.6, 37.0, 28.9. Anal. Calcd. for 
C20H21Cl2NO: C, 66.30; H, 5.84; N, 3.87. Found: C, 66.44; H, 5.59; N, 3.69. 
 
2-(Adamantan-1-yl)-6,8-dichloro-4-(chloromethyl)quinoline (6.48). 
Alcohol 6.47 (8.36 g, 23.1 mmol) was dissolved in dichloromethane (250 mL). Thionyl chloride 
(2.52 mL 34.66 mmol) was then added. The mixture was stirred at 0 °C for 1 h and then 
quenched with sat. aq. NaHCO3. The organic layer was separated and the aqueous layer was 
extracted with dichloromethane. The combined organic extracts were dried over sodium sulfate, 
filtered, concentrated under vacuum, and purified by silica gel chromatography (1% ether / 99% 
hexanes) to provide 4.40 g (50%) of chloride 6.48 as a white solid. 
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6.48. mp = 155-158 °C; TLC Rf = 0.34 (100% hexanes); IR (KBr) 2900, 2847, 1672, 1597, 1450, 
721 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 2.2 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 7.58 
(s, 1H), 4.91 (s, 2H), 2.17 (br s, 3H), 2.12 (br s, 6H), 1.83 (br s, 6H); 13C NMR (75 MHz, CDCl3) 
δ 170.0, 142.9, 141.5, 136.2, 131.4, 130.1, 126.1, 121.3, 119.9, 42.8, 41.8, 40.6, 36.9 28.8. Anal. 
Calcd. for C20H20Cl3N: C, 63.09; H, 5.29; N, 3.68. Found: C, 63.28; H, 5.63; N, 3.57. 
 
Dimethyl ((2-(adamantan-1-yl)-6,8-dichloroquinolin-4-yl)methyl)phosphonate (6.49). 
Chloride 6.48 (1.20 g, 3.15 mmol) and trimethyl phosphite (6.27 mL, 53.2 mmol) were 
combined in a flask with 3.5 mL toluene under argon. The mixture was refluxed for 3 days, 
concentrated under vacuum, and purified by silica gel chromatography (40% ethyl acetate / 60% 
hexanes) to provide 1.06 g (74%) phosphonate 6.49 as a white solid. 
6.49. mp = 152-153 °C; TLC Rf = 0.33 (60% ethyl acetate / 40% hexanes); IR (KBr) 2952, 2902, 
2847, 1772, 1711, 1594, 1398, 1239, 1075, 1031, 856, 830 cm-1; 1H NMR (300 MHz, CDCl3) δ 
7.91 (d, J = 2.1 Hz, 1H), 7.78 (d, J = 2.1 Hz, 1H), 7.54 (d, J = 3.6 Hz, 1H), 3.66 (d, J = 11.1 Hz, 
6H), 3.55 (d, J = 22.5 Hz, 2H), 2.16 (br s, 3H), 2.11 (br s, 6H), 1.82 (br s, 6H); 13C NMR (75 
MHz, CDCl3) δ 169.4 (d, J = 3.9 Hz), 142.9 (d, J = 2.3 Hz), 137.5 (d, J = 9.2 Hz), 135.9, 131.0, 
129.8, 127.4 (d, J = 4.7 Hz), 122.0 (d, J = 1.3 Hz), 121.7 (d, J = 7.0 Hz), 53.3 (d, J = 6.9 Hz), 
41.8, 40.4, 36.9, 30.1 (d, J = 139.1 Hz), 28.8. Anal. Calcd. for C22H26Cl2NO3P: C, 58.16; H, 
5.77; N, 3.08. Found: C, 57.97; H, 5.57; N, 2.94. 
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2-((E)-6-(2-(Adamantan-1-yl)-6,8-dichloroquinolin-4-yl)hex-5-en-1-yl)isoindoline-1,3-dione 
(6.50). 
Phosphonate 6.49 (454 mg, 1.00 mmol) and lithium chloride (63 mg, 1.50 mmol) were combined 
in a flask under argon. Anhydrous THF (5 mL) was then added followed by DBU (152 mg, 149 
μL, 1.00 mmol). Aldehyde 6.38 (347 mg, 1.50 mmol) was dissolved in 5 mL anhydrous THF 
under argon in a separate flask. The aldehyde solution was then transferred to the stirred 
phosphonate solution dropwise at room temperature. After stirring for 24 hours, the reaction was 
diluted with H2O and extracted with ethyl acetate. The combined organic extracts were dried 
with MgSO4, filtered, and concentrated under vacuum. Purification by silica gel chromatography 
(10 % ethyl acetate / 90% hexanes) provided 402 mg of olefin 6.50 (68 %) as a white foam. 
6.50. mp = 63-69 °C; TLC Rf = 0.29 (5% ethyl acetate / 95% hexanes); IR (film) 2903, 2848, 
1771, 1712, 1396, 719 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 2.1 Hz, 1H), 7.86-7.83 
(m, 2H), 7.74-7.69 (m, 3H), 7.53 (s, 1H), 6.95 (d, J = 15.6 Hz, 1H), 6.40 (dt, J = 6.9, 15.6 Hz, 
1H), 3.77 (t, J = 6.9 Hz, 2H), 2.42 (q, J = 6.9 Hz, 2H), 2.19-2.10 (m, 9H), 1.86-1.76 (m, 8H), 
1.68-1.56 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 169.7, 168.6, 143.1, 142.8, 137.8, 135.6, 134.1, 
132.2, 130.3, 129.5, 126.4, 125.4, 123.4, 121.8, 115.8, 41.9, 40.4, 37.8, 37.0, 33.1, 28.9, 28.3, 
26.4. Anal. Calcd for C33H32Cl2N2O2: C, 70.84; H, 5.76; N, 5.01. Found: C, 70.57; H, 5.90; N, 
5.03. 
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2-(4-(3-(2-(Adamantan-1-yl)-6,8-dichloroquinolin-4-yl)oxiran-2-yl)butyl)isoindoline-1,3-
dione (6.51). 
Olefin 6.50 (3.27 g, 5.84 mmol) and 3-chloroperbenzoic acid (approx. 70%, 3.03 g, approx. 17.5 
mmol) were dissolved in 34 mL of chloroform. The mixture was refluxed for 15 hours. After 
cooling to room temperature, the reaction was quenched with 10% aqueous Na2SO3, diluted with 
dichloromethane, and then washed with saturated sodium bicarbonate and brine. The organic 
layer was dried with sodium sulfate, filtered, concentrated under vacuum and purified by silica 
gel chromatography (10% ethyl acetate / 90% hexanes) to provide 2.52 g (75%) epoxide 6.51 as 
a white foam. 
6.51. TLC Rf = 0.26 (30% ethyl acetate / 70% hexanes); IR (KBr) 2904, 2849, 1772, 1713, 1596, 
1397, 720 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.87-7.83 (m, 3H), 7.77 (d, J = 2.1 Hz, 1H), 7.74-
7.70 (m, 2H), 7.48 (s, 1H), 4.14 (d, J = 1.8 Hz, 1H), 3.76 (t, J = 7.1 Hz, 2H), 2.93-2.88 (m, 1H), 
2.14 (br s, 3H), 2.10-1.96 (m, 8H), 1.88-1.76 (m, 8H), 1.70-1.58 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 170.3, 168.6, 142.9, 142.2, 136.1, 134.1, 132.2, 131.0, 129.7, 126.4, 123.4, 120.6, 
114.9, 62.9, 55.5, 41.8, 40.6, 37.7, 36.9, 31.9, 28.9, 28.5, 23.4. Anal. Calcd for C33H32Cl2N2O3: 
C, 68.87; H, 5.60; N, 4.87. Found: C, 68.98; H, 5.84; N, 4.92. 
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(2-(Adamantan-1-yl)-6,8-dichloroquinolin-4-yl)(piperidin-2-yl)methanol (6.52). 
Epoxide 6.51 (2.50 g, 4.34 mmol) was dissolved in 15 mL ethanol. Hydrazine hydrate (632 µL, 
13.0 mmol) was added and the mixture was refluxed for 3 hours. After cooling to room 
temperature, the mixture was concentrated under vacuum and purified by silica gel 
chromatography (90% dichloromethane / 9% methanol / 1% NH4OH) to provide 983 mg of 
amine 6.52 (51%) as a beige solid. 
6.52. mp = 180 °C (dec.); TLC Rf = 0.29 (90% dichloromethane / 9% methanol / 1% NH4OH); 
IR (KBr) 3309, 3068, 2906, 2849, 2675, 1597, 1482, 1309, 1116, 869 cm-1; 1H NMR (300 MHz, 
DMSO-d6) δ 8.25 (d, J = 2.1 Hz, 1H), 7.99 (d, J = 2.1, 1H), 7.78 (s, 1H), 5.66 (s, 1H), 5.08 (s, 
1H), 2.88 (d, J = 14.4 Hz, 1H), 2.71-2.63 (m, 1H), 2.44-2.30 (m, 1H), 2.11 (br s, 3H), 2.05 (br s, 
6H), 1.78 (br s, 6H), 1.73-1.64 (m, 1H), 1.48-1.38 (m, 2H), 1.28-1.11 (m, 3H); 13C NMR (100 
MHz, DMSO-d6) δ 168.8, 149.1, 141.6, 134.5, 129.3, 128.9, 126.1, 122.4, 117.7, 72.4, 61.1, 
46.3, 41.2, 41.1, 36.2, 28.0, 26.2, 25.8, 23.9. Anal. Calcd for C25H30Cl2N2O: C, 67.41; H, 6.79; 
N, 6.29. Found: C, 67.55; H, 6.96; N, 6.26. 
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2-((2-(Adamantan-1-yl)-6,8-dichloroquinolin-4-yl)(hydroxy)methyl)piperidin-1-ium 
chloride (6.8).52 
Amine 6.52 (678 mg, 1.52 mmol) was suspended in diethyl ether and anhydrous hydrogen 
chloride (2M in diethyl ether, 1.6 mL, 3.2 mmol) was added. The resulting precipitate was 
collected by vacuum filtration, re-suspended in 25 mL diethyl ether with 25 mL of ethanol added 
and filtered again to provide 440 mg (60%) of 6.8 as a white solid. 
6.8. mp = 202 °C (dec.); IR (film) 3271, 2904, 2847, 1595, 1451, 1130 cm-1; 1H NMR (300 
MHz, DMSO-d6) δ 10.15 (d, J = 9.5 Hz, 1H), 8.52 (d, J = 2.1 Hz, 1H), 8.46-8.35 (m, 1H), 8.05 
(d, J = 2.1 Hz, 1H), 7.85 (s, 1H), 6.57 (d, J = 4.5 Hz, 1H), 5.85 (s, 1H), 3.31-3.20 (m, 2H), 2.94 
(q, J = 11.5 Hz, 1H), 2.12 (br s, 3H), 2.06 (br s, 6H), 1.78 (br s, 6H), 1.72-1.53 (m, 4H), 1.33-
1.12 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 168.8, 146.4, 141.6, 134.6, 130.4, 129.4, 125.2, 
121.9, 117.5, 67.6, 58.4, 44.1, 41.1, 39.8, 36.2, 28.0, 21.7, 21..0, 20.7. Anal. Calcd for 
C25H31Cl3N2O: C, 62.31; H, 6.48; N, 5.81. Found: C, 62.03 H, 6.36; N, 6.22. 
Malachite Green Phosphatase Release Assays 
Malachite Green Phosphatase Release Assays (Echelon-Inc.) were performed with 
recombinant human truncated SHIP1 (tSHIP1)6,7 or tSHIP2 (see below) as described previously.8  
Briefly, serial dilutions of the compounds were dissolved in appropriate solvent (e.g. DMSO) 
and added to recombinant human tSHIP1 or tSHIP2 diluted in enzyme reaction buffer (50 mM 
Hepes pH 7.4, 150mM NaCl, 1mM MgCl2, 0.25mM EDTA) in triplicate reactions in 96-well 
plates (22.5 µl/reaction). Reactions were incubated for 5 min at room temperature. 
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Phosphatidylinositol 3,4,5-trisphosphate diC8 (PI(3,4,5)P3diC8) (Echelon-Inc.) was added to 
each reaction at a final concentration of 100 µM and the reaction were carried out for 30 min at 
37 ˚C in a final volume of 25 µl/well. Final solvent concentration was ≤ 1%. Following 
incubation, 100 µL of Malachite Green Solution (Echelon-Inc.) was added to each well and 
plates were incubated at room temperature in the dark for 20 min. Plates were then read at 
620nm. 
Expression and purification of recombinant human truncated SHIP2 (tSHIP2). 
Human cDNA was obtained by random primed RT-PCR (Multiscribe Reverse 
Transcriptase, Invitrogen) on 100ng of total RNA extracted from human whole blood using 
QIAamp RNA blood Mini Kit (QIAGEN). Truncated SHIP2 (tSHIP2, nucleotides 199-3102, 
NM_001567.3) was amplified from cDNA with Phusion High-Fidelity DNA polymerase (New 
England Biolabs) in two fragments using forward and reverse primers 5’- 
ATAGGATCCTATGGCCCCCTCCTGGTA-3   or 5’- 
GCTCAATGCCTTTGACATCTCTCTGCG-3’, and 5’- 
TGCAGATGATGTGAGTTTCAGGGTAGGA-3 or 5’- 
GCGTAAGCTTGGCAGGGTTATTGAAGC-3’, respectively. The fragments were cloned into 
pSMART HC Amp (Lucigen) for assembly using the BamHI and HindIII restriction sites 
introduced by the primers and the natural NdeI site found in the INPPL1 sequence. The tSHIP2 
coding sequence was then subcloned using BamHI and HindIII sites into the pET24-TEV 
vector6,7 using standard cloning procedures, and verified by sequencing. Restriction and DNA 
modifying enzymes were from New England Biolabs, primers from Integrated DNA 
technologies and sequencing was performed by Molecular Cloning Labs.  E.coli BL21 DE3 
(EMD Millipore) were used for expression of pET24TEV-tSHIP2 by 20h stationary-phase 
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induction at 37˚C, 200rpm, in 1L LB Broth (Fisher) supplemented with 0.2% (w/v) D-Glucose 
(Sigma) and 50ug/ml kanamycin (Sigma) following 1:100 inoculation with starter culture. 
Protein was extracted form bacterial cell pellet using BugBuster HT (EMD Millipore), according 
to manufacturer’s recommendations. Protein was purified by FPLC using HisTrapHP 5ml 
column (GE) at a 5ml/min flow rate and 20 mM-1M imidazole gradient in Buffer A (20mM Tris 
pH 8.0, 300mM NaCl, 0.1mM β-ME). Fractions containing active protein by Malachite Green 
Phosphatase Release Assay (Echelon, see below) were pooled and dialyzed for 16h at 4˚C in 
Buffer A + 0.1% Triton-X100. Dialyzed protein was concentrated 10-fold with Amicon Ultra-0.5 
Ultracel 100 membrane (EMD Millipore).  Protein was aliquoted and stored in Buffer A 
containing 50% glycerol at -20 ˚C or -80 ˚C for longer-term storage. tSHIP2 protein expressed 
from this vector contains the pET-24b leader sequences, amino acids 18-985 of human SHIP2 
(INPPL1 NM_001567.3), TEV cleavage site and the 6-HIS-tag, resulting in a 1003 aa protein 
with a MW of 112kDa. 
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Appendix: 1H and 13C Spectra from Chapters 2-6 
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Racemic acetamide 3.24 from rearrangement of racemic 3.23  
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Acetamide 3.24 from rearrangement of (S)-3.23 under thermal conditions 
50% i-PrOH/heptane, 0.5 mL/min, Chiralcel OJ Column 
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Acetamide 3.24 from rearrangement of (S)-3.23 under Lewis acid catalyzed conditions 
50% i-PrOH/heptane, 0.5 mL/min, Chiralcel OJ Column 
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